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Studies have demonstrated the role of neuroinflammation in causing neurotoxicity and 
neuronal damage in neurodegenerative diseases and cerebral malaria (CM) patients. 
Zanthoxylum zanthoxyloides (Z. Z) is reputed for its anti-inflammatory activity. This 
study investigated the effect of Z.Z. and it’s bioactive, skimmianine (SK) on 
neuroinflammation in BV2 microglia cells stimulated with lipopolysaccharide (LPS) and 
synthetic hemozoin (sHZ). Cultured mouse microglia (BV2) cells were stimulated with 
LPS (100 ng/ml) and sHZ (400 µg/ml) following pre-treatment with Z. zanthoxyloides 
(4, 6 and 8 µg/ml) and skimmianine (10, 20, and 30 µM). Levels of nitric oxide (NO), 
PGE2, pro IL-1β, IL-1β, IL-6, TNFα and IL-10 were measured in cell culture 
supernatants. Protein expressions of iNOS, COX-2, NF-КB phospho-p65 subunit, 
phospho-IҡBα, total IҡBα, phospho-IKK, total IKK, caspase-1 and NLRP3 in extracts 
were investigated with western blotting. HEK293 cells were transfected with Cignal 
NF-κB (LUC) (CCS-013L) vector and reporter gene assays were used to investigate 
the effect of Z.Z and SK on luciferase activity of NF-КB in the nucleus. Isolation of SK 
was monitored with solid-phase-extraction (SPE), ELISA and HPLC. Structure 
elucidation of the isolated compound was determined by NMR analysis and mass 
spectrometry. Z.Z extract and SK reduced the levels of PGE2, IL-1β, IL-6, TNFα IL-1β, 
pro-IL-1β, caspase-1 protein and NLRP3 protein and increased the levels of IL-10 in 
BV2 cells stimulated with LPS and sHZ. Further experiments showed that Z. Z and SK 
decreased the expression of iNOS, COX-2 protein and inhibited NF-B and 
NLRP3signaling pathway in both LPS and sHZ-stimulated BV2 cells. These results 
suggest that Z.Z and SK inhibit neuroinflammation through NF-B and NLRP3 
signalling pathway in stimulated BV2 cells. This study suggests that bioactive 
compounds in Z. zanthoxyloides extract are potential phytochemical leads for treating 
neuroinflammation mediated neurodegenerative diseases and CM.  
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1 GENERAL INTRODUCTION 
1.1 Neuroinflammation and activation of microglia cells 
Neuroinflammation occurs when the cells of the central nervous system (CNS) 
including microglia and macroglia such as oligodendrocytes and astrocytes give an 
immunological response to infection, neurotoxins and injury, hence protecting the 
CNS. (baruaChen, Zhang, & Huang, 2016; Shabab, Khanabdali, Moghadamtousi, 
Kadir, & Mohan, 2017). Microglia cells are macrophages resident in the CNS and are 
about 10% of the cell population in CNS (Timmerman, Burm, & Bajramovic, 2018). 
Microglia cells are described to be in ‘M0 state’ as they act as surveillance in the CNS 
environment under homeostatic conditions and not in a resting state as previously 
reported (Butovsky et al., 2014; Timmerman et al., 2018). Reports have further 
demonstrated that there is a change in the phenotypic state of microglia cell when 
stimulated with inflammatory stimuli including lipopolysaccharide (LPS). In addition, 
microglia cells were described to transform morphologically from “M0” state (ramified) 
to “M1” state (amoeboid) when stimulated. In neuroinflammation, microglia cells are 
important as they have been demonstrated to be a major source of excessive 
secretion of pro-inflammatory cytokines and chemokines when activated with 
inflammatory stimuli. In addition, activated microglia cells secrete inflammatory 
cytokines such as TNFα, IL-1β, IL-6, and chemokines such as macrophage 
inflammatory protein-2 (MIP-2) and monocyte chemoattractant protein-1 (MCP-1). 
Moreover, reports have described the role of microglia cells including BV2 microglia 
cell line stimulated by LPS as experimental models to investigate the activity of 
potential compounds with anti-neuroinflammatory effect (Saijo & Glass, 2011; 
Stansley, Post, & Hensley, 2012). Thus, investigations on therapeutic drugs or 
medicinal plant that inhibits neuroinflammation mediated by activated microglia cells 
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is important in the treatment of neurodegenerative diseases such as parkinson’s 
disease (PD) and Alzheimer’s disease (AD). 
 Furthermore, increased production of pro-inflammatory cytokines (IL-1β, IL-6 and 
TNFα) have been observed in studies on incubation of monocytes and macrophages 
with hemozoin (Dunst, Kamena, & Matuschewski, 2017; Olivier, Van Den Ham, Shio, 
Kassa, & Fougeray, 2015; Perkins et al., 2011). Hemozoin is a malaria pigment that 
is derived from Plasmodium falciparum, a parasite that initiates the development of 
malaria in human through the bite of Anopheles mosquito (Ghazanfari, Mueller, & 
Heath, 2018; Hora, Kapoor, Thind, & Mishra, 2016). Moreover, studies done in 
cultured cells have also demonstrated a significant increase in production of nitric 
oxide (NO) in macrophage cells when stimulated with hemozoin (Jaramillo, Maritza, 
Godbout, & Olivier, 2005). These studies suggest the significant role of hemozoin in 
neuroinflammation. Therefore, inhibition of neuroinflammation induced by hemozoin is 
essential in reducing the increased level of pro-inflammatory cytokines and 
inflammatory mediators in stimulated microglia cells. 
1.1.1 Roles of pro -inflammatory mediators and inflammatory signalling 
pathways in neuroinflammation 
1.1.1.1 Tumor necrosis factor α (TNFα) 
Tumor necrosis factor-alpha (TNF-α) is a pro-inflammatory cytokine which increased 
level of its secretion from activated cells by inflammatory stimuli such as LPS plays a 
crucial role in neuroinflammation (Kempuraj et al., 2016; Y.-K.Kim, Na, Myint, & 
Leonard, 2016; J. A.Smith, A. Das, S. K. Ray, & N. L. J. B. r. b. Banik, 2012b). Microglia 
cells are the main source of cytokines released during chronic inflammation, especially 
in neurodegenerative diseases (Heneka, Kummer, & Latz, 2014; Kempuraj et al., 
2016; Y.-K. Kim et al., 2016). In AD, amyloid-beta (Aβ) was reported to activate 
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microglia cells to potentiate the release of pro-inflammatory cytokines including TNFα, 
which could lead to loss of neurons and tau hyperphosphorylation (Von Bernhardi, 
Tichauer, & Eugenín, 2010; W.-Y. Wang, Tan, Yu, & Tan, 2015). Furthermore, 
numerous studies have demonstrated the production of TNF-α in LPS from stimulated 
microglia cells and further described its inhibition to play a vital role in reducing 
neuroinflammation (Graeber, Li, & Rodriguez, 2011; Y.-C. Lu, Yeh, & Ohashi, 2008; 
Sheppard, Coleman, & Durrant, 2019). The role of TNFR1 expression in most cell 
types and activation of NF-κB signalling pathway have been described to be important 
as it leads to neuroinflammation (Kempuraj et al., 2016; Smith et al., 2012b). TNF-α 
binds to the TNFR1 to cause activation of adaptor protein called TNF receptor-
associated death domain (TRADD) (G. Olmos & J. Lladó, 2014; Shabab et al., 2017). 
Subsequently, the recruitment of receptor interacting protein (RIP) occurs to activate 
and phosphorylate IKK and IκB (Sedger & McDermott, 2014). This process leads to 
nuclear translocation of NF-κB to cause transcription of genes controlling the secretion 
of proinflammatory cytokines, COX-2 and iNOS which results to neuroinflammation. 
Research in the past has shown that excessive production of TNF-α from activated 
glia cells causes excitotoxicity and apoptosis (Shabab et al., 2017; Smith et al., 
2012b).  
In addition, studies have shown that TNF-α increases the level of glutamate in 
activated cells, a major excitatory neurotransmitter that causes excitotoxicity and also 
the secretion of TNF-α in excess (Olaniyan et al., 2016; Sedger & McDermott, 2014) 
However, excitotoxicity caused by glutamate release has been reported to be involved 
in the pathogenesis of neurodegenerative diseases including Parkinson’s disease, 
Multiple sclerosis and Alzheimer’s disease (Lull & Block, 2010; G. Olmos & J. J. M. o. 
i. Lladó, 2014). In addition, a previous study demonstrated that binding of TNF-α via 
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TNFR1 signalling pathway causes excitotoxicity by elevating the release of glutamate 
from microglia cells (Boeuf et al., 2012; H. Takeuchi et al., 2006). The role of excessive 
secretion of pro-inflammatory cytokines (TNF-α, IL-1β and IL-6) in macrophages 
induced by hemozoin has been demonstrated to be involved in the progression of 
neuroinflammation (Dunst et al., 2017; Gimenez et al., 2003). Therefore, inhibiting the 
elevated level of TNFα production in brain macrophages stimulated by inflammatory 
stimuli such as LPS is essential in reducing neuroinflammation in activated microglia 
cells. 
1.1.1.2  Interleukin-6 (IL-6) 
Previous research on increased level of IL-6 production has been associated with the 
pathology of neurodegenerative diseases including Parkinson’s diseases and 
Huntington’s disease (Kempuraj et al., 2016; Tanaka, Narazaki, & Kishimoto, 2014). 
An elevated  level of IL-6 was observed in brains of Alzheimer’s disease and was 
reported to potentiate neuronal loss in AD brain (Baune & T, 2015; McManus & 
Heneka, 2017). Studies on microglia cells induced by LPS have demonstrated that 
elevated level of IL-6 secretion from activated microglia cells which may be involved 
in the progression of neurodegenerative diseases (Y.-K. Kim et al., 2016; Smith et al., 
2012b; Tanaka et al., 2014). Moreover, previous studies have observed an increased 
level of IL-6 secreted in macrophages activated with hemozoin (Griffith, Sun, 
McIntosh, & Bucala, 2009). A different study on BV2 microglia cells induced by 
hemozoin observed a significant increase in the level of IL-6 secreted and described 
its inhibition as a therapeutic target in reducing neuroinflammation (Velagapudi, 
Kosoko, Olajide, & neurobiology, 2019). These studies shows the importance of 
excessive production of pro-inflammatory cytokines in hemozoin induced 
neuroinflammation. Therefore, the effect of elevated level of IL-6 in neuroinflammation 
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has made it an attractive cytokine to target by reducing its level of secretion from 
activated microglia cells.  
22 
 
1.1.1.3 Interleukin-10 (IL-10) 
Interleukin-10 is an anti-inflammatory cytokine produced in neural tissues and immune 
cells. It has a molecular weight of 18kDa and has 160 amino acid residues in its 
polypeptide chain (Wojdasiewicz, Poniatowski, & Szukiewicz, 2014). In stimulated 
immune cells, an increased level of IL-10 is produced as a response to reduce the pro-
inflammatory cytokine level of IL-6, IL-1β and TNF-α (Oliveira, Sakata, Issy, Gerola, & 
Salomão, 2011; Y. Sun et al., 2019). Furthermore, IL-10 secretion is blocked by 
elevated level of cytokines such as IL-13, IFNγ and IL-4 (Oliveira et al., 2011). This 
results in a low level of IL-10 production in neuroinflammation mediated by increase in 
pro-inflammatory cytokines. An in vivo study on IL-10 deficient mice observed a 
decline in cognitive function when injected with LPS in comparison to the wild type 
mice (Cameron, Brent, & Landreth, 2010). Furthermore, the reduced level of IL-10 
production has been found to be associated with pathology of neurodegenerative 
diseases and also described to be involved in the advancement of these diseases 
(Meng et al., 2018). Therefore, increasing the level of IL-10 cytokine may be an 
important strategy in reducing neuroinflammation by inhibiting activation of microglia 
cells. 
1.1.1.4 Nitric oxide  
Studies have shown the role of excessive production of nitric oxide in the pathogenesis 
of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, 
multiple sclerosis, and amyotrophic lateral sclerosis (Kempuraj et al., 2016; Shabab et 
al., 2017; Sharman et al., 2019; Tse, 2017). Investigations on activated microglia cells 
have established the synthesis of nitric oxide (NO) through the induction of nitric oxide 
synthase (NOS) (Hwang et al., 2017). Reports have shown that nitric oxide synthase 
occurs in three isoforms in the CNS: inducible NOS (iNOS), endothelial NOS (eNOS) 
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and neuronal NOS (nNOS) (Lind et al., 2017; Shabab et al., 2017; Yuste, Tarragon, 
Campuzano, & Ros-Bernal, 2015). Different from eNOS and nNOS, iNOS produces 
excessive amount of NO and are secreted when cells including microglia cell are 
induced by inflammatory stimuli such as LPS and TNF-α (Förstermann & Sessa, 
2012). Furthermore, iNOS has been demonstrated as a significant form of NOS 
because it is a main source of NO production in the brain (D. Kim et al., 2018). Also, 
reaction of NO with O2- further leads to generation of reactive nitrogen species (RNS) 
and reactive oxygen species (ROS), which causes neurotoxicity at increased levels 
(Asiimwe et al., 2016). Previous studies have also demonstrated an increased level of 
reactive nitrogen species (RNS) in neuroinflammation to cause apoptosis through 
nitrosative stress (Chen et al., 2016). Moreover, investigations done in vitro and in vivo 
have further showed upregulation of iNOS with elevated level of NO production in 
macrophages stimulated with ligand such as LPS and hemozoin (S. H. Lee et al., 
2016; Olivier et al., 2015; Velagapudi et al., 2019). These studies have demonstrated 
the role of excessive release of NO and increased expression of iNOS in 
neuroinflammation. Consequently, inhibiting level of NO and iNOS expression in 
activated microglia cells is essential in reducing neuroinflammation. 
1.1.1.5  Prostaglandin E2  
Prostaglandin E2 (PGE2) is derived from arachidonic acid has been reported to play 
an important role as a mediator in inflammatory processes (Stephenson, Nutma, van 
der Valk, & Amor, 2018). Cyclooxygenase-2 (COX-2) speeds up the conversion of 
arachidonic acid to PGH2 (Prostaglandin H2). This, in turn, gets converted by PGES 
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(Prostaglandin E synthase) to PGE2 (S.-H. Kim et al., 2019; Shabab et al., 2017). 
  
Figure 1-1: Prostaglandin E2 synthesis pathway 
Inflammatory stimuli including TNF-α hydrolyses the membrane phospholipids to secrete arachidonic 
acid. Thereafter, COX-2 converts arachidonic acid to PGH2, which in turn is converted to PGE2 (a pro-
inflammatory mediator) through prostaglandinE synthases. 
Previous studies have described an increased level of PGE2 and expression of COX-
2 protein in microglia cells stimulated with LPS (Ricciotti, FitzGerald, & biology, 2011; 
Sakai et al., 2017). This shows the importance of activated PGE2/ COX-2 pathway in 
microglia cells contributing to the progress of neuroinflammation. In rat model of AD, 
over-expression of COX-2 enzyme was observed in brain of rats and was 
demonstrated to be involved in causing progression of neuroinflammation and 
increase cognitive dysfunction (Sil & Ghosh, 2016). The importance of PGE2/ COX-2 
pathway has been reported as non-steroidal anti-inflammatory drugs including aspirin 
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causes an inhibition of this pathway to have effect such as anti-inflammatory and 
analgesic. 
Hence, the inhibition of excessive secretion of PGE2 through reducing the expression 
of COX-2 protein might reduce neuroinflammation, which is crucial in pathology of 
neurodegenerative diseases.  
1.1.1.6 NF-κB activation in neuroinflammation 
Nuclear factor kappa B cells (NF-κB) is a transcription factor which plays a crucial role 
in the immune system by controlling the expression of genes that encodes pro-
inflammatory cytokines, iNOS , COX-2 gene in addition to regulating cell proliferation, 
differentiation and survival (Biswas & Bagchi, 2016; Feng et al., 2017). NF-κB was 
discovered for over 30 years ago and has received a lot of attention due to its role in 
the pathology of numerous disorders (Zhang, Qian, Lenardo, & Baltimore, 2017). 
These include cardiovascular disorders (Gupta & Ashraf, 2018; Mangali et al., 2019), 
neurodegenerative diseases (Rather et al., 2018; Youssef, Ibrahim, Akashi, & 
Hossain, 2019), diabetes (Jayachandran, Vinayagam, Ambati, Xu, & Chung, 2018) 
and cancer (Patel, Horgan, McMillan, & Edwards, 2018; C. Xiao et al., 2018). 
There are five NF-κB genes in mammals, which are related structurally: RelA, RelB, 
c-Rel, NF-κB 1(p105, p50) and NF-κB 2 (p100, p52) (Hayden & Ghosh, 2011; 
Serasanambati & Chilakapati, 2016). These proteins share a common Rel homology 
domain, which they can form heterodimers and homodimers (Liu, Zhang, Joo, & Sun, 
2017). NF-κB dimers remain at resting state in the cytoplasm, because of its 
attachment to the inhibitory kappa-B (IκB) proteins (Biswas & Bagchi, 2016). Reports 
have demonstrated that NF-κB is activated by more than 150 powerful inducers 
including pro-inflammatory cytokines (TNF-α and  IL-1β), bacterial components 
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(lipopolysaccharide), viral components and oxidative stress (Herrington, Carmody, & 
Goodyear, 2016; Serasanambati & Chilakapati, 2016). 
Canonical and non-canonical pathways are the two main signalling pathways involved 
in NF-κB stimulation (Liu et al., 2017; Serasanambati & Chilakapati, 2016; S.-C. J. C. 
r. Sun, 2011). In canonical NF-κB pathway, receptors such as pattern recognition 
receptors (PRRs), TNF receptor, B-cell receptor and cytokine receptor bounds to by 
their respective ligands (Liu et al., 2017; Serasanambati & Chilakapati, 2016; H. 
Zhang, Sun, & bioscience, 2015). Binding of ligands to receptors leads to activation of 
TRAF6/ TAK1, which in turn activates the IΚΚ complex (Durand & Baldwin, 2017). 
Afterwards, phosphorylation of IκB by IΚΚ occurs, which leads to the degradation of 
IκB by proteasomes in the cytoplasm (Anchoori et al., 2010). Subsequently, there is 
nuclear translocation of NF-κB p65 subunit to cause transcription of inflammatory 
genes by binding of NF-κB to DNA of target genes (Underwood et al., 2013). Previous 
studies have demonstrated that NF-κB regulates the expression of iNOS, COX-2 and 
genes involved in the secretion of pro-inflammatory cytokines (Herrington et al., 2016). 
More investigations have shown that production of inflammatory mediators and pro-
inflammatory cytokines are dependent on NF-κB transcription (Hayden & Ghosh, 
2011; Liu et al., 2017). Observations from these studies confirms the importance of 
NF-κB transcription in neuroinflammation.  
Studies have identified three main ways which NF-κB signalling pathway are inhibited 
to prevent its activation. They are: inhibiting the kinases (IκB, IΚΚ) pathway in 
cytoplasm (Biswas & Bagchi, 2016; Herrington et al., 2016), blocking the ligand 
binding to receptor, which stops the signalling event at early stage (Molteni, Bosi, & 
Rossetti, 2018). In addition, inhibiting the binding of NF-κB to DNA prevents the  
transcription activity of NF-κB in the nucleus leading to a decrease in 
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neuroinflammation (Biswas & Bagchi, 2016; Herrington et al., 2016). These 
mechanisms of inhibition have been described to be essential target for inhibiting 
activated NF-κB signalling pathway, which is crucial in neuroinflammation and 
neurodegenerative diseases (Shabab et al., 2017).  
 
Figure 1-2: NF-κB pathway and inflammatory mediators 
Ligands such as LPS and TNF-α binds to receptors to cause a conformational change and activates 
the IΚΚ complex. Subsequently, phosphorylation of IκB by IΚΚ occurs, which leads to the degradation 
of IκB by proteasomes in the cytoplasm. Afterwards, nuclear translocation of NF-κB p65 subunit occurs 
and causes transcription of inflammatory genes by binding of NF-κB to DNA of target genes. This event 
leads to secretion of pro-inflammatory factors.The family of IκB proteins includes IκBα, IκB β, 
IκBε, IκBζ, BCL-3 (B cell lymphoma 3) and IκBNS (Courtois, 2018; Durand & Baldwin, 
2017). Studies have identified IκBα as the most abundant in its family and more 
importantly as they mainly controls the NF-κB dimers (p65 and p50) by inhibiting NF-
κB until phosphorylation of IκBα occurs in the cytoplasm (Prescott & Cook, 2018; 
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Serasanambati & Chilakapati, 2016). Reports have shown that IκBα phosphorylation 
is done by a kinase called IΚΚ (IκB kinase)(Durand & Baldwin, 2017). IKK is made of three 
subgroups namely: IΚΚα (IΚΚ1), IΚΚβ (IΚΚ2), IΚΚγ (NEMO- NF-κB essential 
modulator). IΚΚα and IΚΚβ are kinases that function as a catalyst while IΚΚγ has a 
regulatory function(Christian, Smith, & Carmody, 2016). Moreover, attenuating the 
level of IB and IKK phosphorylation have been demonstrated as unique targets for 
pharmacological inhibition of NF-κB signalling pathway (Feng et al., 2017; Li et al., 
2018; B. Wang et al., 2018). An example of IKKβ inhibitor is β-carboline, which acts 
as an analog of ATP and binds to ATP site on IKK molecule to cause inhibition (Wu, 
Clausen, Nielsen, & therapeutics, 2015). In addition, some IKK inhibitors such as 
BMS-345541 act by having allosteric effect because the more selective in inhibiting 
IKKβ over IΚΚα (Nadia Lampiasi & Giovanna Montana, 2016). This mechanism of 
action contributes to the reason some therapeutic agents could not target IKK 
phosphorylation. Furthermore, sulfasalazine, an inhibitor of IκB blocks NF-κB 
activation by preventing degradation of IκB in the cytoplasm (Wahl, Liptay, Adler, & 
Schmid, 1998; Y.-R. Wang et al., 2016). 
1.1.1.7  Role of NLRP3 inflammasome in inflammation  
Inflammasomes are protein complexes that were first identified and described in 2002 
(Martinon, Burns, & Tschopp, 2002; Shao, Xu, Han, Su, & Liu, 2015). They include 
NLRP1, NLRP2, NLRP3, dsDNA (double stranded DNA), NLRC4 and AIM2 (absent 
in melanoma 2) (Shao, Cao, & Liu, 2018; Shao et al., 2015). Reports have shown that 
NLRP3 inflammasome is made up of NLRP3 protein, procaspase-1 and an adapter 
protein called ASC (apoptosis-associated speck-like protein) (Martinon et al., 2002; E. 
Ozaki, Campbell, & Doyle, 2015; Shao et al., 2018). NLRP3 inflammasome have been 
demonstrated to be activated by stimuli such as uric acid and hemozoin. (Eigenbrod 
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& Dalpke, 2015; Shao et al., 2018). Subsequently, there is assembly of NLRP3, 
procaspase-1 and an ASC into a complex. This complex then catalyses the conversion 
of procaspase-1 into an active caspase-1, leading to secretion of mature IL-1β from 
pro IL-1β.  
In addition, activation of NLRP3 inflammasome have been shown to be involved in the 
secretion of IL-1β and IL-18 cytokines, which leads to pyroptotic cell death because of 
elevated, level these pro-inflammatory cytokines (Gaidt & Hornung, 2017; Shi, Gao, & 
Shao, 2017). In addition, previous studies have shown that activated NLRP3 
Inflammasome controls the secretion of IL-1β in immune and inflammatory cells, which 
includes monocytes, dendritic cells and macrophages (S Jahan et al., 2017).  
 
Figure 1-3: NLRP3 inflammasome pathway 
Activation of NLRP3 inflammasome by DAMPS (Damage-associated molecular pattern such as uric 
acid and heparin sulfate) or PAMPs (pathogen-associated molecular pattern molecules such as LPS) 
causes the conversion of pro-caspase-1 to active caspase-1. Subsequently, there is maturation of Pro-
IL-1 β to IL-1 β and this leads to secretion of IL-1 β, a pro-inflammatory cytokine. 
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IL-1β is one of the important pro-inflammatory cytokine produced in response to 
inflammation, pathogen and injury (Wojdasiewicz et al., 2014). IL-1 β has a predicted 
molecular weight ranging between 31-33 kDa. Pro IL-1 β is an inactive form of IL-1 β, 
it is converted by an enzyme called caspase-1 to IL-1 β and released as cytokines 
outside the cell (Dinarello, 2013; Piccioli & Rubartelli, 2013). Investigations have 
further shown that secretion of IL-1β are mainly from macrophages and monocytes of 
the innate immune system as well as endothelial cells and fibroblast that are non-
immune cells (Dinarello, 2013; Piccioli & Rubartelli, 2013).Pathogen associated 
molecular patterns (PAMPs) act on the pattern recognition receptor (IL-1RI) in 
macrophages to secrete pro-IL-1β, hence regulating gene expression pathway 
(Lopez-Castejon & Brough, 2011; Piccioli & Rubartelli, 2013; O. Takeuchi & Akira, 
2010; Wojdasiewicz et al., 2014). Investigations on overproduction of IL-1β in activated 
microglia cells have been suggested to contribute to the progression of neurotoxicity 
and neuroinflammation (Mendiola & Cardona, 2017). In addition, previous studies 
have observed excessive release IL-1β in neuroinflammation in LPS stimulated BV2 
microglia cells (Matt, Lawson, & Johnson, 2016; Mendonca, Taka, Bauer, Cobourne-
Duval, & Soliman, 2017). Similarly, more investigations have demonstrated over-
production of IL-1β from macrophages and human monocytes stimulated with 
hemozoin, a malaria pigment (White, Turner, Medana, Dondorp, & Day, 2010). These 
studies indicate the involvement of IL-1β in the advancement of neuroinflammation, 
an important factor in the pathogenesis of neurodegenerative diseases. Therefore, 
targeting elevated level of IL-1β in neuroinflammation through inhibition of NLRP3/ 
caspase-1 activation and pro-IL-1 β is crucial in reducing the degree of IL-1β secretion 




1.2 Neuroinflammation in neurodegenerative diseases  
The effect of neuroinflammation in neurodegenerative diseases including Parkinson’s 
disease (PD), multiple sclerosis, Huntington’s disease, amyotrophic lateral sclerosis 
(ALS) and Alzheimer’s disease (AD) have been described to be an important factor 
that exacerbate the progression of these diseases (Chen et al., 2016; McManus & 
Heneka, 2017). However, the involvement of activated microglia cells are observed 
from postmortem examination done on patients with neurodegenerative diseases 
followed by damage and loss of neurons as the disease progresses (Bolós, Marta, 
Perea, & Avila, 2017; Ransohoff, 2016). In addition, secretion of pro-inflammatory 
cytokines (TNFα, IL-1β and IL-6), inflammatory mediators such as iNOS, COX-2 and 
reactive oxygen species (ROS) as a result of microglia cell activation have been 
demonstrated to cause neuroinflammation, exacerbating neurodegeneration (Park, 





Figure 1-4: Neuroinflammation in neurodegenerative diseases 
Activation of microglia cells by stimuli such as LPS causes the release of pro-inflammatory factors 
leading to neuroinflammation. Thereafter, prolonged neuroinflammation causes damage and loss to the 




Reports have shown an accumulation of amyloid beta (Aβ) plaque to be present in AD 
patient’s brain using postmortem analysis (Kempuraj et al., 2016). Previous studies 
have demonstrated that Aβ deposit in the brain of AD patients triggers the activation 
of microglia cells to cause the excessive secretion of pro-inflammatory (McManus & 
Heneka, 2017) cytokines, which contributes to the progression of the disease. 
Furthermore, the activation of microglia cells by Aβ aggregates are described to be 
recognized by toll-like receptors (TLRs) in microglia cells (Sharman et al., 2019). An 
in vitro study demonstrated that the induction of microglia cells by Aβ resulted in 
secretion of reactive oxygen species (ROS) and reactive nitrogen species (RNS), 
causing neurotoxicity (Von Bernhardi, Eugenín-von Bernhardi, & Eugenín, 2015). 
These neurotoxic mediators were suggested to increase the progression of 
neurodegenerative diseases (W. J. Huang, Zhang, & Chen, 2016). The response of 
microglia cells to Aβ plaque by toll-like receptors are suggested to cause induction of 
neuroinflammation in AD (Sadigh-Eteghad et al., 2015). The use of anti-inflammatory 
therapy, nonsteroidal anti-inflammatory drugs (NSAIDs) such as acetic acid, oxicam 
and inhibitor of COX-2 enzyme have been shown to reduce the risk of AD progression 
(Rubio-Perez, Miguel, & Morillas-Ruiz, 2012). Conversely, due to the complexity in the 
association of AD pathology and innate immunity, NSAIDs do not show its use 
clinically in AD patient (Du, Wang, & Geng, 2018). Reports demonstrated that NSAIDS 
could not inhibit the neuroinflammation involved in the pathology of AD but rather it 
reduced the symptoms of the disease (Gao, Yu, Chen, & Zhou, 2016).   
Studies have demonstrated the presence of activated microglia cells, increased level 
of iNOS, COX-2 and pro-inflammatory cytokines in the substantia nigra and striatum 
of Parkinson’s disease patient (Chao, Yinxia, Wong, & Tan, 2014; De Virgilio et al., 
2016; Halliday & Stevens, 2011; Tiwari & Pal, 2017). The loss of neuron in the basal 
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ganglia is associated with motor symptoms such as posture unsteadiness, stiffness, 
tremor, and slow movement (bradykinesia) in patient with PD (De Virgilio et al., 2016; 
Tiwari & Pal, 2017). Previous investigations on in vivo studies of CNS disorders 
including PD have further described that neuroinflammation increases the progression 
of neuronal damage. In neuroinflammation, increase in level of pro-inflammatory 
cytokines including TNF-α as a result of activated microglia cells have been shown to 
cause disruption of blood brain barrier (BBB) in neurodegenerative diseases. Increase 
in BBB permeability further contributes to the progression of neurodegenerative 
diseases by allowing the passage of cytokines and neurotoxic molecules. Moreover, 
previous investigations on cerebrospinal fluid of patients with PD have shown an 
elevated level of inflammatory mediators including reactive oxygen species (ROS), 
reactive nitrogen species (RNS) and TNF-α. In addition, post mortem examination on 
the tissue of patients with amyotrophic lateral sclerosis (ALS) revealed the presence 
of activated microglia cells (Frakes et al., 2014; Philips & Robberecht, 2011). An in 
vivo study on transgenic mice suggested that activation of microglia cells is involved 
in the death of motor neurons (Philips & Rothstein, 2015). These observations suggest 
the role of pro-inflammatory cytokines and inflammatory mediators causing 
neuroinflammation and neurotoxicity in neurodegenerative diseases. Drugs such as 
levodopa are available in the treatment of PD but are limited in their action as they 
only treat symptoms which includes slow movement but not inflammation involved in 
the pathology of PD (LeWitt, 2015; Poewe et al., 2017). The outcome of the failed 
clinical trial of NSAIDs led to investigations for the search of drugs with anti-




Numerous research has identified the inhibitory activity of some medicinal plant on 
inflammation in both animal models and cell culture studies(Shakya, 2016; Tomlinson 
& Akerele, 2015). Investigations on medicinal plants with anti-inflammatory properties 
have shown to be promising in the treatment of neurodegenerative diseases (X.-S. 
Wang et al., 2017).  In vitro studies on Curcumin longa are suggested to have a 
possible role in the treatment of AD by reducing inflammation induced by amyloid-beta 
(Aβ) (Hamaguchi, Ono, Yamada, & therapeutics, 2010). A report in a different study 
demonstrated that Coriandum sativum improved memory performance due to its anti-
inflammatory activities and indicated to be a potential treatment in AD (Mani & Parle, 
2009). Moreover, previous in vivo studies on oxalis corniculata showed its anti-
inflammatory and anti-oxidant activity in Parkinson’s disease model (Aruna, Rajeswari, 
& Sankar, 2016). Therefore, these studies suggest the importance of medicinal plant 
with anti-inflammatory activities. These medicinal plants could be a major source of 
drugs that could offer a potential treatment in reducing neuroinflammation in 
neurodegenerative diseases. 
1.2.1 Gap in Knowledge 
To date, investigations to determine the effect of Zanthoxylum zanthoxyloides extract 
and isolated bioactive compounds from this extract on neuroinflammation are 
unknown.  
1.2.2 Aim and objectives of this study 
This study was aimed to investigate whether Zanthoxylum zanthoxyloides extract 
and isolated bioactive compounds could modulate LPS-induced neuroinflammation 
in BV-2 microglia cells. In addition, there was a separate investigation on the effect 
of Zanthoxylum zanthoxyloides extract and isolated bioactive compounds on 
neuroinflammation stimulated by hemozoin in BV-2 microglia cells. 
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Hence, this research will categorically achieve the following objectives: 
1. To investigate the inhibitory activity of Z. zanthoxyloides extract in LPS and 
hemozoin-induced neuroinflammation in BV-2 microglia. 
2. To identify bioactive compounds in Z. zanthoxyloides extract  
3. To evaluate the inhibitory activity of isolated bioactive compounds from this 






2 Chapter 2- Background information on medicinal 
plants in drug discovery 
Medicinal plants have become an area of research interest in the past till date (Malviya 
& Malviya, 2017; Medhi, Deka, & Bhau, 2013). This is because of their wide use in 
traditional medicine and drug discovery (Patiño, Prieto, & Cuca, 2012). In drug 
discovery, medicinal plants are useful in the search of bioactive compounds as they 
are a rich source of numerous secondary metabolites. Morphine from opium poppy 
(Norn, Kruse, & Kruse, 2005), Vinblastine and Vincristine  from Catharanthus roseus 
(Priyadarshini & Keerthi, 2012), Artemisinin from Artemisia annua (Miller & Su, 2011), 
Digoxin from Digitalis lanata (Chauhan, Ruby, & Dwivedi, 2012) are as a result of drug 
discovery from medicinal plants (Patiño et al., 2012; Shakya, 2016; Singh, 2015). 
The genus Zanthoxylum of the family Rutaceae is very important because of its wide 
range of uses in medicine and industry (Medhi et al., 2013; Patiño et al., 2012). 
Zanthoxylum is derived from a Greek word Xanthoxylum, which means ‘’yellow 
wood’’(Patiño et al., 2012). It is made up of about 549 species which are majorly 
located in America (Mexico, Brazil, Argentina and Puerto Rico) (Groppo & Pirani, 
2017), Asia (China, India, Vietnam and Malaysia) (Zhu, Huang, Ji, Su, & Zhou, 2016) 
and Africa (Kenya, Zimbabwe, Cameroon, Senegal, Rwanda and Nigeria) (Adesina, 
2005; Tine, Diop, et al., 2017). Zanthoxylum species that are known especially in 
Africa are about thirty-five in numbers (Tine, Diop, et al., 2017). They include 
Zanthoxylum gillettii (Sinan, Zengin, Bene, & Mahomoodally, 2019), Zanthoxylum 
rubescens (Penali, Mulholland, Tano, Cheplogoi, & Randrianarivelojosia, 2007), 
Zanthoxylum bouetense (Pan, 2010), Zanthoxylum tessmannii (Tankeo et al., 2015) 




2.1 Zanthoxylum zanthoxyloides 
Zanthoxylum zanthoxyloides (Z. zanthoxyloides), a popular specie of Zanthoxylum 
genus is a spiny tree that is about 6- 12 meters tall (Iwu, 2014; Nwankwo, Chioma, 
Ofem, Amara, & Chijioke, 2017).  In West Africa, the different parts of Z. 
zanthoxyloides tree such as the leaves, fruits, stem bark and root are popularly used 
in traditional medicine for the treatment of diseases which includes malaria (Gansané 
et al., 2010), toothache (Orafidiya, Akinkunmi, Oginni, & Oluwamakin, 2010) and sickle 
cell disease (Folashade & Omoregie, 2013; Kouri, 2004; Ouattara et al., 2009). In 
Nigeria, the root parts of Z. zanthoxyloides are used as chewing stick due to its 
antimicrobial and antibacterial activities against oral microbiota (Adesina, 2005; 
Kénou, Christel & Djossa, & Assogbadjo, 2018; Medhi et al., 2013; Orafidiya et al., 
2010). 
Studies have identified the use of methanolic extract of Zanthoxylum zanthoxyloides 
in the treatment of malaria (Gansané et al., 2010; Kassim et al., 2005; Odugbemi, 
Akinsulire, Aibinu, & Fabeku, 2007; Traoré et al., 2015; Wangensteen, An, 
Christopher, Diallo, & Karl, 2017). An in vitro study which used a  multi-resistant strain 
of Plasmodium falciparum revealed that Z. zanthoxyloides extract has anti-plasmodial 
activity with an IC50 of 1.2µg/ml, hence supporting its wide use in treatment of malaria 
(Gansané et al., 2010). In addition, previous studies have shown the anti-inflammatory 
activity of methanolic extract of Zanthoxylum zanthoxyloides root (Fogang et al., 2012; 
Prempeh & Mensah-Attipoe, 2008, 2009). The study showed an inhibition of 
carrageenan-induced paw inflammation in rats and xylene-induced pinna inflammation 










Table 2.1: Synonyms, trivial and local names of Zanthoxylum zanthoxyloides  
Synonyms of Zanthoxylum 
zanthoxyloides 
Fagara zanthoxyloides  
 







Rapeko (Moore language from Burkina 
Faso)  
Guene gui deg (Wolof language from 
Gambia, Senegal and Mauritania) 
 






2.1.1 Compounds isolated from Zanthoxylum zanthoxyloides  
Z. zanthoxyloides extract has been shown to contain secondary metabolites such as 
flavonoid (Azando et al., 2011; Ogunbolude et al., 2014a), alkaloid (Dupont et al., 
2005; Michael, 2017; Wouatsa et al., 2013), aliphatic and aromatic amides (Adesina, 
1986; Patiño et al., 2012). It also contains lignans (Adesina, 2005; Azando et al., 2011; 
Patiño, Prieto, & Cuca, 2008) and coumarins (Cho et al., 2012; Negi, Bisht, Bh, Singh, 








Parts of Z. zanthoxyloides   References 
Roots  Stem      Fruits  
Flavonoids 
 
   (Ogunbolude et al., 
2014b; Tine, Yang, et 
al., 2017) 
Neohesperidin + + +                    ‘’ 
Hesperidin + + +                     ,, 
Quercetin + + +                     ,, 
Neodiosmin                         ,, 
Lignans                          ,, 
Sesamin +   (Chaaib et al., 2003) 
Asarinin +   (Adesina, 2005) 
Coumarins     
Bergapten  + + (Adesina, 2005; Patiño 
et al., 2012) 
Imperatonin  +  (Adesina, 2005; Patiño 




+   (Patiño et al., 2012; 





  + (Adesina, 2005; Tine, 





Parts of Z. zanthoxyloides   References 




  + (Adesina, 2005; Tine, 
Renucci, Costa, Wélé, 
& Paolini, 2017) 
Tripterpenes     
Squalene +   (Adesina, 2005; Mbaze 
et al., 2007; Rasooli, 
2012) 
Lupeol +  + (Misra, Wouatsa, 
Kumar, Kumar, & 
Tchoumbougnang, 
2013; Rasooli, 2012) 
Campesterol +   (Adesina, 2005; 
Rasooli, 2012) 
β-Amyrin +   (Adesina, 2005; 
Rasooli, 2012) 




+ +  (Adesina, 2005; Patiño 





Parts of Z. zanthoxyloides   References 
Roots  Stem      Fruits  
Pellitorine  
 
+   (Adesina, 2005; Patiño 




+   (Adesina, 2005; Patiño 






  + (Adesina, 2005; Patiño 




    
 Fagaronine + +  (Adesina, 2005; Patiño 
et al., 2012) 
 Chelerythrine +   (Adesina, 2005; Patiño 
et al., 2012) 
 Fagaridine  +  (Adesina, 2005; Patiño 





+   (Adesina, 2005; Patiño 
et al., 2012; Wang-
sheng et al., 2017) 
 Buesgenine   
 
+   (Adesina, 2005; Patiño 
et al., 2012; Wang-





Parts of Z. zanthoxyloides   References 
Roots  Stem      Fruits  
Aporphine 
alkaloids 
    
Berberine  +   (Adesina, 2005; Patiño 
et al., 2012) 
Tembetarine  +   (Adesina, 2005; Patiño 
et al., 2012) 
Magnoflorine  +   (Adesina, 2005; Patiño 




+   (Patiño et al., 2012; 




    
Dictamnine  +   (Patiño et al., 2012; 
Wangensteen et al., 
2017) 
Skimmianine  +   (Adesina, 2005; Patiño 
et al., 2012) 
Fagarine  +   (Adesina, 2005; Patiño 
et al., 2012) 
Acronycine  +  + (Adesina, 2005; Patiño 











































   
 
 
   
 
 
Figure 2-2 continued 





Fagaronine Chelerythrine Fagaridine 







   
 
 
























2.2 Methodology  
2.2.1 Collection of plant  
Zanthoxylum zanthoxyloides roots were collected from the botanical garden of 
University of Ibadan, Nigeria in the month of June 2015. Mr D.P.O. Esimekhuai (a 
taxonomist) in the Department of Botany, University of Ibadan, Nigeria, authenticated 
the plant. A voucher specimen coded UIH 22474 was deposited in the University 
Herbarium.  
2.2.2 Soxhlet extraction  
Soxhlet extraction is a common technique in isolation of compounds that is useful in 
extraction of solid samples in a solvent, based on the polarity and phytochemical 
components in the plant (Azwanida, 2015; De Castro & Priego-Capote, 2010). Soxhlet 
extraction in hexane and dichloromethane (DCM) are necessary to remove the non-
polar and semi-polar components in plants while extraction in methanol is important 
to obtain polar components from plants. This method requires putting of powdered 
sample of the extract in a filter paper made of cellulose and this is placed in the thimble 
chamber of the Soxhlet apparatus (Azwanida, 2015). In this study, solvents including 
hexane, dichloromethane (DCM) and methanol needed for the extraction were put in 
a round-bottom flask. The extraction solvent is heated, and the vapour condenses into 
the thimble chamber (where the extract is placed) and drips back into the bottom flask. 
This cycle is repeated until the extraction process is completed.  
The powdered plant material of Z. zanthoxyloides root was extracted using a 
Soxhlet extractor as shown in  
Figure 2-3. The root sample was extracted in 800 ml each of n-hexane, 
dichloromethane and methanol sequentially. These extraction solvents were heated 
up between 50-60°C using an ElectrothermalTM (Fisher Scientific, Loughborough, 
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Uk). The extraction process was cycled ten times for each solvent. The methanolic 
extracts was dried using a Cole palmer rotary evaporator (Stone UK).and then stored 
at 4°C for pharmacological assays. In this study, methanolic extract of Zanthoxylum 
zanthoxyloides was continued with and used for pharmacological assays because it 
has been reported in numerous in vivo studies to have anti-inflammatory activities 










2.2.3 Cell culture 
2.2.3.1 Culture of BV2 microglia cells 
BV2 mouse microglia cell line ICLCATL03001 was purchased from Interlab Cell Line 
Collection (Banca Biologica e Cell Factory, Italy) and cultured in Roswell Park 
Memorial Institute (RPMI) 1640 medium (Life Technologies) supplemented with 10% 
fetal bovine serum (Sigma), 1mM sodium pyruvate (Sigma), 100U/ml Penicillin and 
100mg/ml Streptomycin (Sigma). Once the cells became confluent, cells were sub-
cultured at 1:10 using trypsin/EDTA solution (Sigma) to detach adhered cells to the 
flask, as BV2 cells are semi-adherent cells. The cells were later maintained at 37o C 
in 5% CO2 incubator after subculture. Cells were seeded in plates at a concentration 
of 2 x 105 cells/ ml, before experiments were carried out. Subsequently, the plated 
cells were being incubated until they reached confluence before experiments. 
2.2.3.2 Culture of HEK 293 cells 
Human Embryonic Kidney (HEK) cells (European collection of cell cultures) are 
adherent cells and they were cultured in MEM medium (ThermoFisher Scientific, UK). 
MEM medium was supplemented with 2mM l-glutamine (Sigma), 10% FBS (Sigma), 
100U/ml Penicillin and 100mg/ml Streptomycin (Sigma). The cells were later 
maintained at 37o C in 5% CO2 incubator. Cells were sub-cultured at 1:3 with 
trypsin/EDTA solution (Sigma), when they became confluence.  
2.2.4 Sample preparation  
Methanolic extract of Zanthoxylum zanthoxyloides extract was prepared in DMSO 
(Sigma, UK). Primary stock concentration was prepared and stored in -80°C. A stock 
concentration of 2, 3 and 6 mg/ml was prepared to reach a final or working 
concentration of 4, 6 and 8µg/ml of Zanthoxylum zanthoxyloides used for 
experiments. 1 mg/ml of lipopolysaccharide (LPS) (Sigma, UK) made from 
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Salmonella enterica serotype typhimurium was used in preparing a stock 
concentration of 100 µg/ml and kept in 4°C. BV2 cells were treated with methanolic 
extract of Zanthoxylum zanthoxyloides (4, 6 and 8µg/ml) for 30 minutes and 
stimulated with LPS at 100 ng/ml for time required by different experiments. In a 
different investigation, hemozoin (5 mg) (InvivoGen, USA) was dissolved in 1 ml of 
sterile PBS to make 5mg/ml. This mixture was then sonicated (Grant XUBA 1) to 
obtain a homogenous suspension. A working concentration of 400 µg/ml was used 
from the stock in experiments. BV2 microglia cells were treated with methanolic 
extract of Z. zanthoxyloides (4, 6 and 8 µg/ml) for 30 minutes and stimulated with 
hemozoin at 400 µg/ml for the time needed by each experiment. 
2.2.5 Griess assay (Measurement of nitrite production) 
Nitric oxide (NO) is an important mediator for regulating chronic inflammation in the 
central nervous system (CNS). Nitrite (NO2-) production level was measured in the cell 
culture supernatant as an indicator of NO production because NO2- is non-volatile and 
stable (Green et al., 1982; Tse, 2017; Tsikas, 2007). The principle of Griess reaction 
relies on two main steps: the reaction of sulphanilic acid with acidified NO2- containing 
sample to form diazonium ion and addition of N-(1-naphthyl) ethylenediamine to form 
chromophoric azo dye, which absorbs light at a wavelength of 540 nm. Cultured BV2 
cells were seeded at density of 2 x 105 cells/ ml (1mL/well) in a 24-well plate and 
incubated until it reached confluence. At confluence, BV2 cells were treated with Z. 
zanthoxyloides (4, 6 and 8 µg/ml) and stimulated with LPS (100 ng/ml) for 24 hours. 
In a separate study, there was incubation of BV2 cells with Z. zanthoxyloides (4, 6 and 
8 µg/ml) for 30 minutes, followed by stimulation with hemozoin (400 µg/ml) for 24 
hours. Subsequently, cell culture supernatants were collected and centrifuged at 1500 
rpm for 5 minutes. Nitrite concentration in the cell culture supernatant was measured 
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using the Griess assay kit (Promega, UK). Briefly, 50 µl of sulphanilamide was added 
to 50 µl of cell culture supernatants in a 96 well plate. The plate was then incubated in 
the dark for 10 minutes at room temperature. Afterwards, 50 µl of NED solution (N-1-
napthylethylenediamine) was added and incubated in the dark for 10 minutes at room 
temperature. Absorbance was read at a wavelength of 540nm in a microplate reader 
(Infinite F50, Tecan). 
2.2.6 Determination of TNFα, IL-6, IL-1β, IL-10 and Pro-IL-1β by Enzyme 
linked immunosorbent assay (ELISA)  
ELISA is a plate-based assay technique that is designed for detecting and quantifying 
antigens in cell supernatants (Konstantinou, 2017; Lequin, 2005). Sandwich ELISA 
was used for this experiment because it is a very sensitive assay for detection of 
antigens in cell culture supernatant. Sandwich ELISA measures the antigens in a 
sample between two layers of antibodies: capture and detection antibodies. TNFα, IL-
6 and IL-1β are pro-inflammatory cytokines that mediate chronic inflammation and 
elevated levels of their secretion in activated microglia cells have been shown to be 
involved in neuroinflammation (Becher & Spath, 2017). IL-10 is an anti-inflammatory 
cytokine as increased level of IL-10 has been reported to reduce the level of pro-
inflammatory cytokines in LPS stimulated macrophage (Castillo, Patricia, & Kolls, 
2016; Couper, Blount, & Riley, 2008). Pro IL-1β is a pro-form of IL-1β, a potent pro-
inflammatory cytokine produced by cells of the innate immune system in response to 
pathogens. BV2 cells were seeded in 24-well plates at a concentration of 2x105 
cells/ml (1 mL/well) and incubated at 37oC until they reached confluence. BV2 cells 
were treated with Z. zanthoxyloides (4, 6 and 8 μg/ml) for 30 min and then stimulated 
with LPS (100 ng/ml) for 24 hours. In a different investigation, BV2 microglia cells were 
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incubated with Z. zanthoxyloides (4, 6 and 8 μg/ml) for 30 min and then stimulated 
with hemozoin (400 μg/ml) for 24 hours. 
In both studies, levels of TNFα, IL-6, IL-1β and IL-10 in cell supernatants were 
measured with a Biolegend, ELISA kit, UK while Pro IL-1β was measured with an 
Invitrogen ELISA kit.  
 
Figure 2-4: Sandwich ELISA  
 
ELISA kits and samples were brought to room temperature from storage before the 
experiments. Microplates were coated with monoclonal capture antibody of cytokines 
to be detected overnight at 4ºC fridge. The microplates were then washed with 1x 
wash buffer for four times to remove unbound antibodies. Subsequently, blocking 
buffer (assay diluent) was added to each well for 1 hour to cover the non-specific 
binding sites in the plates. Samples and standards were added to the appropriate wells 
and incubated at room temperature for 2 hours with shaking. Afterwards, the wells 
were washed for four times and 100µl of detection antibody was added to bind 
specifically to the target antigen. This was incubated for an hour further with shaking 
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at room temperature. Following incubation, the wells were washed four times and 100 
µl of Avidin-HRP (horseradish peroxidase) was added to each wells for 30 minutes 
with shaking at room temperature. The addition of this enzyme was to amplify the 
signal that can be detected (colorimetric) by acting on the substrate to develop a 
colour. Subsequently, the plate was washed five times at the end of the incubation 
and 100µl of TMB (3, 3’,5, 5’-Tetramethylbenzidine) substrate was added to each well. 
This was incubated at room temperature in the dark for 15 to 30 minutes. Lastly, the 
blue colour that developed after adding TMB substrate was stopped by adding 100µl 
of stop solution to each well. Absorbance was read at 450nm using a plate reader 
(Infinite F50, Tecan). 
2.2.7 Caspase-1 Glo® inflammasome assay  
Caspase-1 is part of the cysteine aspartic acid-specific protease (caspase) family 
(Kanneganti, 2018; Sollberger, Strittmatter, Garstkiewicz, Sand, & Beer, 2014). It is 
important for cytokine maturation (from pro-IL1β to IL-1β and pro-IL18 to IL-18) when 
induced by inflammatory stimuli (Flores et al., 2018; Sollberger et al., 2014). The 
Caspase-1 Glo® inflammasome assay is a bioluminescent method which selectively 
measures caspase-1 activity in cells. This principle is based on the binding of caspase 
1 to a luminogenic substrate, Z-WEHD-aminoluciferin. This leads to a cell lysis which 
produces light, a luminescent signal that is proportional to caspase-1 activity in the 
cells. BV2 cells were seeded in a white, opaque 96 well plates (2x105/cells/ml) for 






Figure 2-5: Reaction of Caspase-Glo® 1 inflammasome assay  
 
Light 




BV2 cells were treated with Zanthoxylum zanthoxyloides (4, 6 and 8μg/ml) for 30 min 
and stimulated with hemozoin (400μg/ml) for 24 hours. Caspase-1 activity was 
measured using the Caspase-1 Glo® inflammasome assay kit (Promega, USA). The 
reagents in the assay kit were allowed to equilibrate to room temperature prior to the 
experiment. 100µl of prepared Caspase-Glo® 1 Reagent was added to the wells in 
the 96 well plate. This process was then followed by incubation at room temperature 
for 60 minutes to stabilize the luminescent signal. At the end of the incubation, 
luminescence was read with FLUOstar OPTIM reader (BMG LABTECH). 
2.2.8 Prostaglandin E2 production using Enzyme Immunoassay (EIA) 
Prostaglandin E2 (PGE2) is an abundant metabolite of arachidonic acid and a mediator 
of inflammation (S.-H. Kim et al., 2019; Shabab et al., 2017). It is catalysed by 
cyclooxygenase-2, an enzyme that converts arachidonic acid to prostaglandins 
(Shabab et al., 2017). Prostaglandin E2 level in the cell culture supernatants was 
measured by DetectX® PGE2 Multi-Format ELISA kit (Arbor assays, USA). Enzyme 
immunoassay detects the PGE2 amount in a sample by the binding of antigen to an 
antibody. BV2 cells were seeded in 24-well plates (2x105/1 ml/well) and incubated at 
37oC until they become confluent. BV2 cells were treated with Zanthoxylum 
zanthoxyloides (4, 6 and 8 μg/ml) for 30 min and then stimulated with LPS (100 ng/ml) 
for 24 hours. Separately, microglia BV2 cells were treated with Z. zanthoxyloides (4, 6 
and 8 μg/ml) for 30 min and then activated with hemozoin (400 μg/ml) for 24 hours. At 
the end of the incubation, cell culture supernatants were centrifuged and collected into 
an Eppendorf tube. The kits and samples were brought to room temperature from 
storage prior to experiment. 100µl of samples and prepared standards were added to 
the plates pre-coated with goat anti-mouse IgG. Subsequently, 25µl of PGE2 conjugate 
and PGE2 antibody was added. Then, this was incubated at room temperature for 2 
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hours with shaking at 250rpm. The wells were washed for four times after the 
incubation step to remove unbound proteins. Thereafter, 100 µl of TMB (3, 3’, 5, 5’-
Tetramethylbenzidine) substrate was added to each well and incubated for 30 minutes 
at room temperature without shaking. The incubation was stopped by a stop solution 
(1M of hydrochloric acid). Absorbance was measured in a plate reader (Infinite F50, 
Tecan) at wavelength of 450nm. 
2.2.9 Extraction of cytoplasmic lysates from cultured BV2 cells 
Protein extraction is an important step to isolate proteins from cultured cells, and an 
initial step in analytical techniques including western blotting. Cultured BV2 cells were 
washed with cold 1x PBS at the end of cell stimulation. Then, 25µl of RIPA (Radio 
immunoprecipitation assay buffer) lysis buffer (Cell signalling, UK), which contains 
2Mm PMSF (Phenylmethylsulfonyl fluoride) was added to the wells and incubated on 
ice for 15 minutes. Thereafter, wells containing cells were scraped and the lysates 
were collected in an Eppendorf tube on ice. Then, the lysates were collected in 
epperndorf tubes and placed in a cold centrifuge for 15 minutes at 13500 rpm. 
Afterwards, the lysates were collected in new epperndorf tubes and stored in -80°C 
freezer until is needed. 
2.2.10 Extraction of nuclear extracts from cultured BV2 cells 
Nuclear extraction was done using Episeeker Nuclear Extraction Kit (Abcam, UK). At 
the end of BV2 cells incubation, these were placed on ice and washed with cold 1x 
PBS. Thereafter, 20µl of pre-extraction buffer (ENE1 buffer) (made up of protease 
inhibitor) and DTT were added to the cells for 10 minutes while incubated on ice. The 
cells were then centrifuged at 13000 rpm for 1 minute at 4°C. Then, 10µl nuclear 
extraction buffer (ENE 2 buffer) was added to the pellets and put on ice for 15 minutes 
with intermittent vortexing every 5 minutes. Subsequently, the samples were 
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centrifuged for 15 minutes at 13500 rpm at 4°C. Lastly, the nuclear extract was 
transferred to a new eppendorf tube and stored at -80°C. 
2.2.11 Measurement of protein concentration 
Concentration of protein in the cytoplasmic and nuclear cell extracts were measured 
using Pierce Coomassie (Bradford) protein assay kit (Thermo Scientific, UK). This 
assay is based on reaction between the coomassie dye and protein in an acidic 
environment which leads to development of colour change (colorimetric reaction) that 
can be read (Bradford, 1976; Grintzalis, Georgiou, & Schneider, 2015; Noble & Bailey, 
2009). In this assay, the cytoplasmic and nuclear lysates were diluted 1:15 in 
deionised water. Then, 5µl of the lysates and BSA (bovine serum albumin) standards 
(125- 2000µg/ml) were added to wells in 96 well plate in duplicates. Thereafter, 
coomassie reagent (250µl) was added to all the wells and incubated at room 
temperature for 10 minutes. The absorbance was in a microplate reader (Infinite F50, 
Tecan) at a wavelength of 540nm.  
2.2.12 Western blotting 
Western blotting is a technique that detects presence of a target protein in a cell. 
It mainly involves separation of protein mixtures according to their molecular 
weight and specific detection of target protein by appropriate antibodies (Mahmood 
& Yang, 2012). Firstly, 5 μl of LDS (lithium dodecyl sulphate) (Life Technologies) and 
2 μl of sample reducing agent (Life Technology) were added to 25 μg of protein (as 
described in section 2.2.9, 2.2.10 and 2.2.11). These steps are required to denature 
proteins, which breaks down the disulphide bonds between the tertiary structures of 
proteins. Denaturing of protein unfolds the tertiary structure of protein into linear forms, 
which helps to migrate proteins easily onto the Bis-Tris gel during electrophoresis. 
Then, lysates were heated with dry bath (Fisher Scientific) in LDS and sample 
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reducing agent at 70°C for 10 minutes to speed up the protein denaturing process. 
Thereafter, gel electrophoresis was performed which involves loading of samples into 
wells of a pre- cast polyacrylamide gels (made up of Bis-Tris gel 4-12%) (Life 
Technologies) and adding of NuPAGE® Antioxidant (ThermoFisher, UK) to the 
running buffer (Life Technologies) in a gel tank. Electrophoresis was important to 
separate the protein of interest from other proteins in the sample according to their 
molecular weight and this was ran at a constant voltage of 200V for 35 minutes. 
Subsequently, the separated protein was transferred from the gel onto a polyvinylidine 
fluoride (PVDF) membranes (Thermoscientific, UK) for 2 hours at 25V. This transfer 
process was required to immobilize proteins on a support membrane (PVDF) which is 
important for immuno-detection of target protein. PVDF membrane was used in this 
experiment because of its high affinity for protein binding and also the membrane can 
be stripped and re-probed for another target protein. Membranes were blocked at 
room temperature for 1 hour using Odyssey blocking buffer (LICOR Biosciences) so 
as to prevent the binding of non-specific proteins and thus increasing the specificity of 
target protein. Following the blocking step, the membrane was incubated with primary 
antibodies overnight at 4oC to bind to the target protein. On the next day, the 
membranes were washed thrice with 1x TBS-T (Tris-buffered saline and tween 20) 
(Chem Cruz TM) for 5 minutes each. Then, the membrane was incubated with 
secondary antibody (Alexa Fluor 680 goat anti-rabbit; 1:10000) (Invitrogen) in the dark 
for 1 hour at room temperature. After the incubation, the membrane was washed thrice 
with 1x TBS-T. The protein detection was scanned using LICOR Odssey imager. 




Table 2.3: List of antibodies used in western blot experiments 
 Antibody 
 
Source Type Dilution Predicted 
molecular 
weight (kDa) 


















































































2.2.13  NF-B p65 transcription factor assay 
NF-B is a transcription factor that regulates gene expression and plays an important 
role in inflammation and immune responses (Liu et al., 2017). The excessive release 
of pro-inflammatory cytokines in neuroinflammation and neurodegenerative disorders 
has been associated with the activation of NF-КB transcription factor in stimulated 
microglia cells (E.-J. Lee et al., 2017; Ramaswami & Hayden, 2015). Hence, inhibiting 
the binding of DNA to NFB in the nucleus is fundamental in reducing 
neuroinflammation. NF-B transcription factor assay is an electrophoretic mobility shift 
assay (EMSA) that uses ELISA technique to study NF-B to DNA binding in the 
nucleus (Serasanambati & Chilakapati, 2016). NF-B p65 transcription factor kit 
(TransAM® NF-B transcription factor Active Motif, Belgium) was used in this assay 
as it is sensitive, non- radioactive and can be measured quantitatively (E.-J. Lee et al., 
2017; Ramaswami & Hayden, 2015). This kit has 96-well plate that contains 
oligonucleotide NF-КB binding site (‘5-GGGACTTTCC-3’) which has been immobilised 
in the wells of the plate. Figure describes the method showing the activated NF-B 
p65 in the nuclear extract binding to the oligonucleotide containing binding site and 
addition of primary and secondary antibody for the detection of activated NF-B 
transcription factor. Afterwards, absorbance was read at 450 nm of wavelength after 





Figure 2-6: Diagram showing NFκB transcription factor assay principle (ELISA format) 
In this study, effect of Z. zanthoxyloides on DNA binding activity of NF-κB in BV2 cells 
were carried out using an ELISA based TransAM® NF-кB transcription factor EMSA 
kit (Active Motif, Belgium). Cultured BV2 cells were treated with Zanthoxylum 
zanthoxyloides (4, 6 and 8 μg/ml) for 30 minutes prior to stimulation with LPS (100 
ng/ml) for 1 hour. Differently, pre-treatment of cultured BV2 cells with Zanthoxylum 
zanthoxyloides (4, 6 and 8 μg/ml) for 30 minutes and stimulation with hemozoin (400 
μg/ml) for an hour were also investigated. At the end of 1-hour incubation, nuclear 
extracts were collected in epperndorf tubes. Subsequently, 30 µl of complete binding 
buffer was added to the wells so as to increase the affinity between the activated NF-
κB in nuclear extracts and the binding site (containing DNA oligonucleotide which has 
been immobilised). Then, 20 µg of nuclear lysates samples were added to the 
appropriate wells. Subsequently, the samples were incubated for 1 hour with shaking 
(100 rpm) at room temperature. The wells of the plate containing the samples were 
then washed for three times to remove the unbound proteins which results in 
background reduction and also increase the signal of the binding reaction. Thereafter, 
100 µl of NF-κB p65 antibody (primary antibody at 1:1000 dilution factor) was added 
for 1 hour with shaking at room temperature. The addition of the primary antibody was 
important to detect the targeted NF-B p65 in the nuclear lysates. At the end of the 
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incubation, the washing step was repeated and 100 µl/ well of anti -rabbit HRP-
conjugated antibody (secondary antibody at 1:1000) was added for 1 hour at room 
temperature. Addition of secondary antibody was essential because it increases the 
sensitivity of NF-B p65 detection by binding to its primary antibody. The washing step 
was repeated again after secondary antibody incubation. Furthermore, 100 µl /well of 
developing solution (TMB substrate) were added and incubated for 15 minutes in the 
dark. Addition of TMB substrate is important for detection of activated NF-B p65 
because it reacts with the HRP linked with the secondary antibody to form blue 
coloured products for colorimetric measurement. Reaction with TMB substrate was 
stopped by adding100 µl/ well of stop solution (H2SO4 solution). Absorbance was 
measured in a plate reader (Infinite F50, Tecan) at wavelength of 450nm. 
2.2.14 Immunofluorescence 
The use of immunofluorescence technique has been described to be important in 
detection and expression of target proteins in cells (Donaldson & G, 2015). In IMF 
assay, antibodies are labelled with fluorescent dyes to visualise the antigen-antibody 
reaction under a fluorescent microscope. The technique can be a direct or an indirect 
antigen-antibody reaction. The indirect antigen-antibody reaction involves two 
antibodies: the primary antibody, which attaches directly to the target molecule and 
secondary antibody labelled with a florescent dye (fluorophore) to detect the primary 
antibody for visualising the target protein. In addition, counterstaining with (DAPI 4’, 6 
diamidino- 2-phenylindole dichydrochloride) in immunofluorescence is an essential 
process that stains the nucleus for assessing the cell structure and determine the cell 
numbers. In this technique, cultured BV2 cells were seeded out in 24-well plates 
(2x105/1 ml/well) until they were confluent. Cultured microglia BV2 cells were pre-
treated with Z. zanthoxyloides (4, 6 and 8 μg/ml) for 30 minutes and further stimulated 
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with LPS (100 ng/ml) for 1 hour. In a separate experiment, BV2 microglia cells were 
incubated with Z. zanthoxyloides (4, 6 and 8 μg/ml) for 30 minutes and induced with 
hemozoin (400 μg/ml) for 60 minutes. At the end of 1 hour incubation, BV2 cells were 
brought out from the incubator, placed on ice and fixed with ice-cold methanol (100%) 
for 15 minutes in -20oC freezer. Fixation with methanol was required to immobilize 
antigens in cells for staining and visualization, preserve the intracellular structure and 
also permeabilize the cells for antibody-antigen binding in detecting the target protein. 
Subsequently, PBS was used in washing the cells after each incubation step to remove 
unbound antibodies which can cause poor signal to background ratio. Afterwards, the 
cells were incubated for an hour with blocking solution (5% BSA solution and 10% 
horse serum in TBS-T (1x)) at room temperature to prevent non-specific binding of 
antibodies to antigens that may interfere with the detection of protein of interest. Then, 
cells were incubated overnight at 4oC with primary antibody, Total-NFҡB-p65 (Santa 
Cruz Biotechnology) diluted in 1:100. Following the overnight incubation, washing step 
was repeated and cells were incubated for further 2 hours with secondary antibody 
(Alexa Flour 488- conjugated donkey anti-rabbit IgG, Life Technologies) in the dark at 
dilution ratio of 1 to100. Lastly, cells were counterstained with 50nm of DAPI 
(Invitrogen) for 5 minutes. Fluorescent cell images were acquired using a fluorescent 
microscope, EVOS® Floid cell imaging (Life Technologies). 
2.2.15  Reporter gene assay 
Studies have reported that the binding of NF-κB to its binding site causes transcription 
of genes that controls the production of pro-inflammatory cytokines and inflammatory 
mediators in neuroinflammation. (Damoiseaux & Hasson, 2018). The reporter gene 
assay is important to study expression of target genes at the stage of transcription in 
the nucleus. Moreover, reporter gene assay specifically analyses the functional activity 
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of transcription factors in causing transcription of target genes. Cignal NFκB (LUC) 
(CCS-013L) (Cignal® SA Biosciences) vector used in this study depends on 
technology of dual luciferase (firefly and renilla) reporter enzymes to provide a 
sensitive, reproducible results and minimise experimental variables. Firefly luciferase 
acts as experimental reporter by observing modifications in expressions of target 
genes while renilla luciferase acts as control reporter to minimise variable factors such 
as cell number differences and transfection efficiency (Branchini et al., 2018; Clément 
et al., 2015). Dual-Glo® luciferase assay gives an advantage to analyse both firefly 
and renilla luciferase activity in the same sample (Branchini et al., 2018; Clément, 
Salone, & Rederstorff, 2015). Figure.2-7 shows the firefly luciferase reaction which 
involves oxidation of luciferin to oxyluciferin, catalysed by firefly luciferase in the 
presence of oxygen, magnesium and adenosine triphosphate (ATP). This reaction 
results in production of light that is measurable as luminescent intensity. Differently, 
renilla luciferase enzyme converts coelenterazine into coelenteramide in presence of 
oxygen to emit light. 
Figure.2-7: Firefly luciferase reaction with substrate (Luciferin) to produce light  
 
   
Luciferin  Oxyluciferin + CO2 + AMP + PPi + LIGHT 
 









Figure 2-8: Schematic diagram of dual reporter assay 
The Cignal NFκB (LUC) (CCS-013L) (Cignal® SA Biosciences) vector was used in 
this study to investigate the effect of Z. zanthoxyloides on NF-κB mediated 
transcriptional activity in HEK293 cells with the use of Dual-Glo® luciferase assay 
(Promega, UK). Cultured HEK293 cells were grown in a T-75 flask containing 
complete MEM medium (ThermoFisher, UK) with 5% FBS as supplement. Afterwards, 
the cells were sub-cultured when they reached confluence at a ratio 1:3 Subsequently, 
HEK293 cells were seeded out at a concentration of 4 × 105 cells/mL in a solid-white 
96-well plate and re-suspended in Opti-MEM reduced serum medium (Gibco) with 5% 
FBS twenty-four hours before transfection. HEK293 cells were then transfected with 
Cignal NFκB (LUC) (CCS-013L) vector (1ng DNA/ μl) in addition to lipofectamineTM 
2000 transfection reagent (ThermoFisher, UK) and subsequently incubated for 16 
hours in 5% CO2 incubator at 37ºC. Thereafter, the media was changed to Opti-MEM® 
(without 5% FBS) and incubated for additional 8 hours after transfection with NF-κB 
vector. In order to elucidate effect of Z. zanthoxyloides extract on NF-κB driven gene 
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expression, transfected HEK293 cells were pre-incubated with Z. zanthoxyloides for 
30 minutes and stimulated with TNF-α (1 ng/mL) for 8 hours. Afterwards, NF-kB-
mediated gene expression was measured with Dual-Glo luciferase assay kit 
(Promega, UK) at the end of the 6 hours stimulation. 75µl of Dual-Glo® luciferase 
assay reagent was added to each well and incubated for 10 minutes at room 
temperature to measure firefly (experimental reporter) luminescence. After the 
incubation, 75µl of Dual-Glo® stop &Glo® Reagent was added to the wells to measure 
renilla (control reporter) luminescence. Luminescent intensity were measured using 
FLUOstar OPTIMA reader (BMG LABTECH). 
2.2.16 MTT assay for cell viability  
Cell viability assays measures the ratio of live to dead cells in a cell population (Riss 
et al., 2016; Van Meerloo, Kaspers, & Cloos, 2011). 3-(4, 5-dimethylthiazol-2-yl)-2, 5- 
diphenyl tetrazolium bromide (MTT) assay is a viability assay that causes reduction by 
mitochondrial reductase, converting yellow tetrazolium salt to insoluble crystalline 
purple formazan product to indicate viable cells (Bahuguna, Ashutosh, Khan, Bajpai, 
& Kang, 2017; Riss et al., 2016; Van Meerloo et al., 2011). MTT assay was done to 
ensure that concentrations of Z. zanthoxyloides used in this study was not decreasing 
the viability of BV2 cells after treatment and the result obtained were not as a result of 
toxicity of the extract. Viability of BV2 cells were determined on stimulation of BV2 
cells with LPS (100 ng/ml) or in a separate experiment with hemozoin (400 μg/ml) after 




Figure 2-9: Principle of MTT assay 
Cultured BV2 cells were seeded in 96 well plates (2x105/cells/ml) and incubated at 
37oC until they become confluent. BV2 cells were stimulated with Z. zanthoxyloides 
(4, 6 and 8μg/ml) for 30 min and then stimulated with LPS (100 ng/ml)/ hemozoin 
(400μg/ml) for 24 hours. Twenty-four hours after stimulation, culture medium was 
replaced with MTT solution (5mg/ml) (Sigma) and incubated for 4 hours. MTT solution 
(150 ul) was replaced with DMSO and mixed thoroughly on a plate shaker to dissolve 










2.2.17 Statistical analysis 
All experiments were performed independently at least three times. Data are 
expressed as mean ±SEM. Statistical analysis was performed using one-way analysis 
of variance (ANOVA) with post-hoc Student-Newman-Keuls test. ANOVA compared 
the mean values between independent groups to determine the statistical difference. 
As required for each experiment, data were converted to percentage in relative to 
untreated control, hemozoin control, LPS control or TNFα control. Statistical analysis 
was performed using Graph pad prism software version 5. Statistical difference of p 
value less than 0.05 (p<0.05) were considered significant. Moreover, level of 
significance in experiments were shown as ααα p<0.001 in comparison with the 
untreated cells while * p<0.05, **p<0.01, ***p<0.001 were compared with the LPS or 




2.3 `Results  
2.3.1 Methanolic extract of Zanthoxylum zanthoxyloides decreased TNFα, 
IL-1β, IL-6 and elevated IL-10 production in LPS activated BV2 
microglia 
In neuroinflammation, prolonged exposure of LPS to microglia cells have been 
reported to secrete excessive pro-inflammatory cytokines (TNFα, IL-1β, IL-6), reactive 
nitrogen and oxygen species (Becher & Spath, 2017; Molteni, Gemma, & Rossetti, 
2016). The effect of Z. zanthoxyloides extract on important pro-inflammatory cytokines 
were examined to investigate the anti-neuroinflammatory activity of this extract on 
elevated levels of secreted TNFα, IL-1β, IL-6 in LPS stimulated BV2 microglia cells. 
Result in Figure 2-10 shows that BV2 cells activated with LPS (100 ng/ml) caused a 
significant increase (p<0.001) in the level of TNFα (~14.3-fold increase) elevation in 
comparison to untreated cells. Conversely, pre-treatment with Z. zanthoxyloides at 4 
and 6 µg/ml significantly reduced (p<0.05) the production of TNFα (~1.3-fold and ~1.5-
fold respectively) when compared to LPS control while a further decrease (p<0.01) 
was observed at 8 µg/ml of this extract (~2-fold reduction) in comparison to LPS 
stimulated cells. In addition, there was a marked increase (p<0.001) in the level of IL-
1β (~10-fold increase) in BV2 cells activated with LPS relative to unstimulated BV2 
cells. The outcome of this investigation showed that Z. zanthoxyloides at 4 µg/ml 
significantly decreased (p<0.01) the secretion of IL-1β (23% reduction) when 
compared to BV2 cells stimulated with LPS. Pre-treatment with 6 and 8 µg/ml of Z. 
zanthoxyloides further inhibited the secretion of IL-1β (65% and 33% decrease) 
respectively, when compared to LPS control. Similarly, the effect of Z. zanthoxyloides 
on IL-6 production were also determined. The extract at 4 µg/ml reduced (p<0.01) the 
production of IL-6 (66.5%) while at 6 and 8 µg/ml, there was a further decrease 
(p<0.001) (44% and 32%) respectively. 
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A reduced level of IL-10 (an anti-inflammatory cytokine) production has been detected 
during neuroinflammation caused by excessive release of pro-inflammatory cytokines 
in stimulated microglia cells (Meng et al., 2018). The effect of Z. zanthoxyloides extract 
on level of IL-10 production in LPS activated BV2 microglia cells were also 
investigated. Result in Figure 2-10d shows a significant decrease (p<0.001) in the 
level of IL-10 produced (~2.9-fold reduction) in BV2 cells treated with LPS in 
comparison to the untreated cells. On the other hand, pre-treatment with Z. 
zanthoxyloides (4, 6 and 8 μg/ml) significantly increased (p<0.001) the level of IL-10 








Figure 2-10: Zanthoxylum zanthoxyloides reduced TNFα, IL-1β, IL-6 and increased IL-
10 production in BV2 microglia cells stimulated with LPS 
Cultured BV2 cells were treated in presence or absence of Z. zanthoxyloides (4, 6 and 8 µg/ml) and 
stimulated with LPS (100 ng/ml) for 24 hours. At the end of the incubation period, cell culture 
supernatants were collected and cytokine levels of (a) TNFα, (b) IL-1β and (c) IL-6 (d) IL-10 were 
analysed using ELISA technique. Data are expressed as mean ± SEM for 3 separate experiments. 
Analysis was done using one-way ANOVA with post-hoc Student Newman-Keuls test (multiple 
comparisons ααα p<0.001 in comparison with the untreated cells and *p<0.05 **p<0.01, ***p<0.001) in 
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2.3.2  Methanolic extract of Zanthoxylum zanthoxyloides inhibited nitrite 
production through suppression of iNOS protein in LPS-activated 
BV2 microglia 
Reports have associated the excessive release of nitric oxide (NO) mediated by 
inducible nitric synthase (iNOS) with neuroinflammation in stimulated microglia cells 
by stimuli such as LPS. (Dawson & Dawson, 2018; Yuste et al., 2015). Effect of Z. 
zanthoxyloides on the production of NO and expression of iNOS protein were 
investigated in this study. Result showed a significant increase (p<0.001) in the levels 
of NO (~4-fold increase) in BV2 cells stimulated with LPS when compared to untreated 
cells. However, Z. zanthoxyloides at 4, 6 and 8 µg/ml significantly inhibited (p<0.001) 
the production of NO production (~1.9-fold, ~2.3-fold and ~3.2-fold respectively) in a 
concentration- dependent manner in comparison to LPS stimulated BV2 cells 
Following the results on the inhibitory action of Z. zanthoxyloides on NO, western blot 
experiment was done to further investigate the effect of this extract on expression of 
iNOS. A significant elevation in the expression of iNOS protein was detected on 
stimulation with LPS (100 ng/ml) in comparison to unstimulated cells. Result revealed 
a marked reduction (p<0.001) in the expression of iNOS protein by Z. zanthoxyloides 
at 4 (~1.3-fold), 6 (~1.8-fold) and 8 µg/m l (~2.2-fold) in BV2 cells stimulated with LPS 
when compared to cells stimulated with LPS alone. These results suggest that Z. 
zanthoxyloides (4, 6 and 8 µg/ml) reduced NO production through suppressing the 








Figure 2-11: Zanthoxylum zanthoxyloides inhibited nitric oxide (NO) release (a) and 
inducible nitric oxide (iNOS) protein expression (b) in BV2 cells stimulated with LPS 
Cultured BV2 cells were treated with or without Zanthoxylum zanthoxyloides (4, 6 and 8 μg/ml) and 
stimulated with LPS (100 ng/ml) for 24 hours. Thereafter, cell culture supernatants and cytoplasmic 
extract were collected and evaluated for production of NO and protein expression of iNOS.  
Zanthoxylum zanthoxyloides reduced nitric oxide (NO) release (A) through inhibiting inducible nitric 
oxide (iNOS) protein expression (B) in BV2 cells stimulated with LPS. Data are expressed as mean 
±SEM for 3 separate experiments. Analysis was done using one-way ANOVA with post-hoc Student 
Newman-Keuls test (ααα p<0.001 in comparison with the untreated cells and (***p<0.001) in comparison 
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2.3.3 Methanolic extract of Zanthoxylum zanthoxyloides suppressed PGE2 
production by inhibiting COX-2 protein expression in LPS activated 
BV2 microglia 
The excessive secretion of PGE2 mediated by COX-2 have been described to 
contribute significantly to brain inflammation in neurodegenerative disorders (Sil & 
Ghosh, 2016; Weiwer, 2018). Therefore, inhibition of COX-2 gene in reducing the 
release of PGE2 mediator is important for attenuating neuroinflammation in activated 
microglia cells. Investigations on the effect of Z. zanthoxyloides on the secretion of 
PGE2and expression of COX-2 protein were elucidated. Result showed a marked 
increase (p<0.001) in the levels of PGE2 (~4.4-fold increase) in cells treated with LPS 
when compared to BV2 cells that are untreated. Conversely, the level of PGE2 was 
reduced at 6 (~1.3-fold decrease) and 8 μg/ml (~1.6-fold reduction) of this extract in 
LPS stimulated BV2 cells when compared to LPS activated cells only. Z. 
zanthoxyloides at 4 μg/ml did not significantly decrease the production of PGE2 in 
relation to LPS control. Subsequently, to understand whether the inhibitory action of 
the extract on PGE2 were mediated by COX-2, the effect of Z. zanthoxyloides on 
protein expression of COX-2 was investigated. Results in Figure 2-12 shows a 
significant elevation (p<0.001) in the level of COX-2 expression (~2.7-fold increase) in 
LPS stimulated BV2 cells in relation to BV2 cells that were unstimulated. However, Z. 
zanthoxyloides at 4 μg/ml significantly reduced (p<0.01) the expression of COX-2 
(78.6%) while at 6 and 8ug/ml of the extract, there was a further marked reduction 
(p<0.001) (58.4% and 42.6%) respectively, in LPS stimulated BV2 cells in relation to 







Figure 2-12: Zanthoxylum zanthoxyloides suppressed PGE2 production and COX-2 
protein expression in LPS activated BV2 microglia 
Cultured BV2 cells were treated with or without Z. zanthoxyloides (4, 6 and 8 μg/ml) and stimulated with 
LPS (100 ng/ml) for 24 hours. Z. zanthoxyloides suppressed PGE2 production (a) and COX-2 protein 
expression (b) in BV2 microglia. Data are expressed as mean ±SEM for 3 separate experiments 
Analysis of data was done on 3 separate experiments using one-way ANOVA with post-hoc Student 
Newman-Keuls test (multiple comparisons ααα p<0.001 in comparison with the untreated cells and 
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2.3.4 Methanolic extract of Zanthoxylum zanthoxyloides inhibited 
neuroinflammation through NFκB signaling pathway  
The significant role of NFκB in controlling the secretion of pro-inflammatory cytokines 
and expression of inflammatory mediators such as iNOS and COX-2 have been 
reported in activated microglia cells (Biswas & Bagchi, 2016; El-Bakoush & Olajide, 
2018; J. A. Smith, A. Das, S. K. Ray, & N. L. Banik, 2012a). Following results on the 
inhibitory effect of Z. zanthoxyloides on production of TNFα, IL-1β, IL-6 and protein 
expression of iNOS and COX-2, investigation on the effect of this extract on NFκB 
signalling pathway were further elucidated. Dual-Glo® luciferase assay was used in 
studying the effect of Z. zanthoxyloides on NF-κB mediated gene transcription. Result 
in Figure 2-13a displays a significant increase (p<0.001) in the activation of NF-κB 
dependent gene transcription increase on activation of transfected HEK293 cells with 
TNFα when compared to untreated cells. However, pre-treatment with Z. 
zanthoxyloides at 4 µg/ml resulted in reduction (p<0.05) of NF-ΚB mediated luciferase 
reporter gene expression (~1.24-fold decrease) in relation to HEK293 cells stimulated 
with TNFα. A further marked inhibition of NF-κB mediated gene transcription was 
observed on pre-treatment with Z. zanthoxyloides at 6 µg/ml (~1.5-fold reduction, 
p<0.01) and 8 µg/ml (~2.4-fold decrease, p<0.001). 
Following the translocation of activated NF-ΚB into the nucleus, NF-ΚB binds to the 
promoter region of DNA for transcription of genes such as iNOS which are involved in 
inflammation. Hence, inhibiting the binding of NF-ΚB to DNA is crucial in blocking NF-
ΚB from initiating gene transcription. Effect of Z. zanthoxyloides on DNA-binding 
activity of NF-ΚB were determined in BV2 microglia stimulated by LPS. Result in Figure 
2-13b reveals a significant elevation (p<0.001) in the DNA binding of NF-ΚB (~2.7-fold 
increase) in relation to unstimulated BV2 cells. Conversely, there was a marked 
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reduction (p<0.001) in DNA binding of NF-ΚB on pre-treatment with Z. zanthoxyloides 
at 6 (~1.4-fold rise) and 8 µg/ml (~1.6-fold increase) in LPS –stimulated BV2 cells 
when compared to LPS stimulated BV2 cells alone. There was no significant reduction 
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Figure 2-13: Zanthoxylum zanthoxyloides inhibited neuroinflammation through NFκB 
signaling pathway  
(a) Z. zanthoxyloides concentration dependently inhibited activity of NFκB in transfected HEK293 cells 
induced by TNFα. Transfected HEK293 cells were stimulated with TNFα (1ng/ml) in presence or 
absence of Z. zanthoxyloides (4, 6 and 8 μg/ml) for 6 hours. (b) Z. zanthoxyloides at 6 and 8 μg/ml 
decreased DNA binding activity of NFκB in LPS stimulated BV2 microglia cells. Subsequently, 
luminescence was measured. Nuclear cell lysates were added to wells pre-coated with NFκB 
oligonucleotide, followed by addition of NFκB p65 antibody and secondary antibody. Thereafter, 
absorbance was measured on a microplate reader. Analysis of data was done on 3 separate 
experiments using one-way ANOVA with post-hoc Student Newman-Keuls test (multiple comparisons 
ααα p<0.001 in comparison with the untreated cells and *p<0.05**p<0.01, ***p<0.001) in comparison with 
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Furthermore, its effect on phosphorylation of IKKα protein were elucidated. Result from 
this study in Figure 2-14a presents a significant increase (p<0.001) in the level of IKKα 
phosphorylation by ~3.4-fold in LPS-induced BV2 microglia but pre-treatment with Z. 
zanthoxyloides (4, 6 and 8 μg/ml) did not cause a reduction in IKK phosphorylation 
when compared to BV2 cells treated with LPS. Moreover, western blot experiments 
were done to investigate the effect of Z. zanthoxyloides extract on the expression of 
IκB and NFκB -p65 subunit in BV2 cells stimulated with LPS. As expected, western 
blot result in Figure 2-14b significantly increased (p<0.001) the phosphorylation of IκB 
by ~3-fold when compared to untreated cells. However, there was a marked reduction 
(p<0.001) in the level of IκB phosphorylation on pre-treatment with Z. zanthoxyloides 
at 4 (~1.2-fold), 6 (~1.6-fold) and 8 μg/ml (~2.4-fold) in LPS-stimulated BV2 cells when 
compared to LPS control. Furthermore, there was a significant degradation (p<0.001) 
of total IκBα by 30% in BV2 cells stimulated with LPS when compared to untreated 
cells. In contrast, Z. zanthoxyloides at 6 and 8 μg/ml in Figure 2-14c significantly 
inhibited the degraded total IκB and increased it by 14.3% (p<0.01) and 29.5% 
(p<0.001) respectively when compared to LPS control while there was no significant 
increase in the level of total IκBα at 4 μg/ml of Z. zanthoxyloides. Furthermore, effect 
of Z. zanthoxyloides on translocated NFκB p65 subunit in the nucleus were 
investigated. Result in Figure 2-14d shows a marked increase (p<0.001) in 
phosphorylation of p65 by ~2.8-fold on stimulation of BV2 cells with LPS in comparison 
to the unstimulated cells. However, a significant inhibition (p<0.001) was observed in 
the level of phosphorylated p65 on treatment of BV2 cells with Z. zanthoxyloides at 4 
(~1.2-fold), 6 (~1.7-fold) and 8 μg/ml (~2.4-fold) in LPS-stimulated BV2 cells in relation 
to LPS control. Afterwards, immunofluorescence assay similarly showed a reduced 
expression of activated p65 subunit when treated with Z. zanthoxyloides (4, 6 and 8 
μg/ml) in LPS activated microglia.  
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Figure 2-14: Effect of Zanthoxylum zanthoxyloides on phosphorylated IKK, IкB and 
nuclear translocation of NF-КB p65 in BV2 cells activated with LPS 
Zanthoxylum zanthoxyloides did not significantly reduce phosphorylation of IKK. In contrast, 
Zanthoxylum zanthoxyloides significantly inhibited (B) phosphorylation of IкB, (C) degradation of IKB 
and (D) translocation of NF-КB p65 subunit in LPS activated BV2 cells. Cultured BV2 cells were 
stimulated with LPS (100ng/ml) in the presence or absence of Zanthoxylum zanthoxyloides (4, 6 and 
8μg/ml) for 1 hour. At the end of the incubation, cytoplasmic or nuclear extract was collected and 
western blot was performed to analyse p65 subunit and IҡB protein expression. Analysis was done 
using one-way ANOVA with post hoc Student Newman–Keuls test (multiple comparisons, ααα p<0.001 
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Figure 2-15: Effect of Zanthoxylum zanthoxyloides on p65 NF-кB protein expression 
in LPS activated microglia 
Immunofluorescence assay was done to further confirm the western blot result on NF-КB p65 subunit. 
Zanthoxylum zanthoxyloides (4, 6 and 8 μg/ml) decreased the expression of NF-КB p65 in LPS induced 
BV2 cells. Activated microglia cells were labelled with NF-КB p65 antibody and counterstained with 




2.3.5 Methanolic extract of Zanthoxylum zanthoxyloides did not reduce 
viability of LPS stimulated BV2 microglia cells 
MTT assay was on done to assess the viability of LPS –induced BV2 microglia cells 
on pre-treatment with Z. zanthoxyloides at 4, 6 and 8 μg/ml. Results showed that there 
was no significant difference in viability of cells treated with Z. zanthoxyloides (4, 6 
and 8 μg/ml) in LPS activated BV2 microglia cells when compared with control 
(untreated) cells. 
 
Figure 2-16: Z. zanthoxyloides did not affect BV2 cell viability 
The viability of cultured BV2 cells pre-treated with Z. zanthoxyloides (4, 6 and 8 µg/ml) was not affected. 
BV2 cells were stimulated with LPS (100 ng/ml) in the presence or absence of Z. zanthoxyloides (4, 6 
and 8 µg/ml) for 24 h. At the end of the incubation period, MTT assay was used to assess the viability 
of BV2 cells. All values are expressed as mean ± SEM for 3 separate experiments. Statistical analysis 
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2.3.6 Methanolic extract of Zanthoxylum zanthoxyloides reduced TNFα and 
IL-6 secretion and increased IL-10 in hemozoin-induced BV2 cells 
Increase in secretion of pro-inflammatory cytokines (IL-6 and TNFα) and inflammatory 
mediators such as iNOS have been observed in studies on incubation of monocytes 
and macrophages with hemozoin, which results in neuroinflammation (Dunst et al., 
2017; Olivier et al., 2015; Perkins et al., 2011). Therefore, inhibiting the level of 
excessive secretion of pro-inflammatory cytokines and inflammatory mediators may 
reduce neuroinflammation induced by hemozoin. Anti-inflammatory activity of Z. 
zanthoxyloides have been demonstrated in vivo to reduce inflammation induced by 
carrageenan and xylene (Prempeh & Mensah-Attipoe, 2008, 2009). However, studies 
to reveal the effect of Z. zanthoxyloides on neuroinflammation induced by synthetic 
hemozoin in BV2 microglia cells remains unknown. In subsequent studies, the effect 
of Z. zanthoxyloides on hemozoin-induced neuroinflammation stimulated with 
hemozoin in BV2 microglia cells were elucidated. 
Effect of Z. zanthoxyloides on the degree of TNFα, IL-6 and IL-10 production in 
hemozoin induced BV2 cells were investigated in this study. The outcome of this study 
in Figure 2-17 displays a marked elevation (p<0.001) in the levels of TNFα (~2.6-fold 
increase) and IL-6 (~6.7-fold increase) when compared to unstimulated BV2 cells. 
However, pre-treatment with Z. zanthoxyloides at 4 and 6 µg/ml in hemozoin induced 
BV2 cells significantly reduced (p<0.01) the level of TNFα (~1.5-fold and ~1.9-fold, 
respectively) respectively in comparison to hemozoin-stimulated cells. A further 
significant decrease (p<0.001) was observed on pre-treatment with 8 μg/ml of this 
extract (~2.6-fold reduction) in hemozoin-induced BV2 cells when compared to 
hemozoin-induced cells only. In addition, in hemozoin-induced BV2 cells, result also 
showed that Z. zanthoxyloides at 6 and 8 µg/ml significantly diminished the release of 
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IL-6 (55.2% and 33.5% respectively) relative to hemozoin stimulated cells. Z. 
zanthoxyloides (4 µg/ml) did not significantly reduce IL-6 secreted in hemozoin-
induced BV2 cells. 
Moreover, the effect of Z. zanthoxyloides on IL-10 production in BV2 cells activated 
with hemozoin were examined. Following stimulation of BV2 cells with hemozoin, there 
was a significant inhibition (p<0.001) in the production of IL-10 (34% reduction) when 
compared to untreated cells. However, Z. zanthoxyloides at 4, 6 and 8 μg/ml markedly 
elevated (p<0.001) the degree of IL-10 production (53%, 74% and 91.7% respectively) 






 Figure 2-17: Zanthoxylum zanthoxyloides reduced TNFα, IL-6 and increased IL-10 
release in hemozoin-activated BV2 microglia 
Z. zanthoxyloides markedly reduced (a) TNFα and (b) IL-6 and increased (c) IL-10 production in 
hemozoin induced BV2 cells. Cultured BV2 cells were treated with or without Z. zanthoxyloides (4, 6 
and 8µg/ml) and stimulated with hemozoin (400µg/ml) for 24 hours. At the end of the incubation period, 
cell culture supernatants were collected for ELISA measurements. Data are expressed as mean ±SEM 
for 3 distinct experiments. Analysis was done using one-way ANOVA with post-hoc Student Newman-
Keuls test (multiple comparisons. ααα p<0.001 in comparison with the untreated cells and **p<0.01, 
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2.3.7 Methanolic extract of Zanthoxylum zanthoxyloides inhibited nitrite 
production through suppression of iNOS protein in hemozoin-
stimulated BV2 microglia 
Excessive accumulation of NO in activated microglia cells have been demonstrated to 
cause neurotoxicity which may contribute to the progression of neurodegenerative 
diseases (Yuste et al., 2015). In addition, investigation showing stimulation of BV2 
microglia cells with synthetic hemozoin resulted in a significant increase in levels of 
NO mediated by increased expression of iNOS protein (Velagapudi et al., 2019). 
Hence, inhibiting released NO and expressed iNOS enzyme could reduce 
neuroinflammation in neurodegenerative diseases. The effect of Z. zanthoxyloides on 
secretion of NO and expression of iNOS were determined. 
Result in Figure 2-18 shows a significant elevation (p<0.001) in the levels of NO 
released (~4.2-fold increase) in hemozoin stimulated BV2 cells in comparison to 
unstimulated cells. Z. zanthoxyloides at 4, 6 and 8 µg/ml markedly decreased) NO 
production (77.9%, 63.3% and 46% respectively) in hemozoin activated cells. 
Furthermore, western blot experiment was done to investigate the effect of Z. 
zanthoxyloides on protein expression of iNOS. Z. zanthoxyloides 4, 6 and 8 µg/ml 
significantly inhibited (p<0.001) expressed iNOS protein (73%, 55% and 41% 







Figure 2-18: Effect of Zanthoxylum zanthoxyloides on nitric oxide (NO) release and 
inducible nitric oxide synthase (iNOS) protein expression in BV2 cells stimulated with 
hemozoin 
Zanthoxylum zanthoxyloides inhibited NO production (A) in hemozoin induced BV2 microglia. Further 
investigation using immunoblotting showed that Zanthoxylum zanthoxyloides (4, 6 and 8μg/ml) 
produced significant suppression of iNOS protein expression (B). BV2 Cells were treated with or without 
Zanthoxylum zanthoxyloides (4, 6 and 8ug/ml) and stimulated with hemozoin (400µg/ml) for 24 hours. 
Data are expressed as mean ±SEM for 3 passages. Analysis was done using one-way ANOVA with 
post-hoc Student (multiple comparisons ααα p<0.001 in comparison with the untreated cells and **p<0.01 
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2.3.8 Methanolic extract of Zanthoxylum zanthoxyloides suppressed PGE2 
production by inhibiting COX-2 protein expression in hemozoin 
induced BV2 microglia 
The role of excessive secretion of PGE2 catalysed by COX-2 enzyme have been 
reported to be involved in neuroinflammation (S.-H. Kim et al., 2019; Ricciotti et al., 
2011). Hence, the inhibition of PGE2 and COX-2 protein might reduce 
neuroinflammation induced by hemozoin. Results in Figure 2-19 shows the effect of 
Z. zanthoxyloides on released PGE2 and expression of COX-2 in hemozoin induced 
BV2 cells. A significant increase (p<0.001) in the secretion of PGE2 (~9.8-fold 
increase) was detected in cells stimulated with hemozoin in comparison to untreated 
cells. However, pre-treatment with Z. zanthoxyloides at 4 and 6 μg/ml markedly 
suppressed (p<0.01) the elevated level of PGE2 (~1.3-fold and ~1.5-fold reduction 
respectively) in hemozoin-stimulated BV2 cells relative to hemozoin-stimulated cells. 
Moreover, a decrease was observed at 8 μg/ml of this extract (~1.9-fold). Thereafter, 
western blot experiments on expression of COX-2 was investigated to further explain 
the mechanism of PGE2 secretion in hemozoin-induced BV2 cells. There was a 
significant increase (p<0.001) in the level of COX-2 protein (~3.7-fold) in hemozoin-
stimulated BV2 cells when compared to unstimulated BV2 cells. On the other hand, Z. 
zanthoxyloides (4, 6 and 8 μg/ml) caused a marked and concentration-dependent 
decrease in COX-2 expression (71.7%, 49.8% and 30.4% respectively) in comparison 







Figure 2-19: Zanthoxylum zanthoxyloides suppressed PGE2 production by inhibiting 
COX-2 protein expression in BV2 cells stimulated with hemozoin 
BV2 Cells were treated with or without Zanthoxylum zanthoxyloides (4, 6 and 8ug/ml) and stimulated 
with hemozoin (400μg/ml) for 24 hours. Zanthoxylum zanthoxyloides (4, 6 and 8μg/ml) significantly 
reduced PGE2 production (A). Also, results in (B) show marked reduction of COX-2 protein in hemozoin 
induced cells. Data are expressed as mean ±SEM for 3 passages. Analysis was done using one-way 
ANOVA with post-hoc Student (multiple comparisons ααα p<0.001 in comparison with the untreated cells 
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2.3.9 Methanolic extract of Z. zanthoxyloides inhibit neuroinflammation 
via NF-κB signaling pathway in hemozoin-activated BV2 microglia 
The significant role of NF-κB in regulating the expression of cytokines and chemokines 
in cells induced by hemozoin have been demonstrated in a previous study to 
investigate the mechanism of hemozoin action in murine macrophages (Jaramillo et 
al., 2005). Furthermore, NF-κB p65 subunit binds to the DNA binding site in the 
nucleus after translocation to cause transcription of genes such as iNOS and COX-2 
(Inukai, Kock, Bulyk, & development, 2017). Therefore, reducing the binding of NF-κB 
to DNA is essential to inhibit the transcriptional activity of NF-κB which secretes pro-
inflammatory cytokines and inflammatory mediators. In this study, the effect of Z. 
zanthoxyloides on DNA binding activity of NF-κB in hemozoin stimulated BV2 cells 
were investigated. Result in Figure 2-20a display a significant elevation (p<0.001) in 
the DNA binding activity of NF-ΚB (~2.1-fold increase) on stimulation of BV2 cells with 
hemozoin (400 μg/ml) in comparison to untreated cells. On the other hand, Z. 
zanthoxyloides at 6 and 8 µg/ml, markedly decreased the DNA binding activity of NF-
ΚB (~1.3-fold and ~1.7-fold reduction respectively) while at 4 µg/ml of this extract, there 
was no significant difference when compared to BV2 cells stimulated with hemozoin.  
Subsequently, western blots experiments were done to elucidate the effect of Z. 
zanthoxyloides on the expression of IκB and NF-κB -p65 subunit in BV2 cells 
stimulated with hemozoin. Results shows a marked increase (p<0.001) in the level of 
p-IκB-α (~3-fold increase) in hemozoin treated cells when compared to untreated 
BV2cells. However, pre-treatment with Z. zanthoxyloides at 4 μg/ml significantly 
inhibited (p<0.01) phosphorylation of p-IκB- α (~1.2-fold reduction) in hemozoin-
induced BV2 cells in relation to cells stimulated with hemozoin only. A further marked 
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inhibition (p<0.001) was detected at 6 (~1.3-fold) and 8 μg/ml (~2.3-fold) of Z. 
zanthoxyloides extract. 
A significant decrease (p<0.001) was observed in the level of total IκB-α (63.9%) in 
BV2 cells stimulated with hemozoin when compared to untreated cells. Furthermore, 
Z. zanthoxyloides at 4, and 6 μg/ml markedly elevated (p<0.01) the degraded total 
IκB-α (74.2% and 80.6% increase respectively) in hemozoin-stimulated BV2 cells 
when compared to hemozoin control. Furthermore, 8 μg/ml of this extract markedly 
restored (p<0.001) the level of total IκB-α (97% increase). 
Thereafter, pre-treatment of Z. zanthoxyloides on nuclear translocation of NF-κB -p65 
subunit in BV2 cells activated with hemozoin was investigated. Following stimulation 
of BV2 cells with hemozoin, there was a significant increase (p<0.001) in 
phosphorylation of p65 (~3.1-fold increase) in comparison to unstimulated cells. In 
contrast to this, Z. zanthoxyloides at 4 μg/ml markedly reduced (p<0.05) the degree of 
p-p65 (~1-fold decrease) while there was a further significant inhibition (p<0.001) at 6 
(~1.6-fold reduction) and 8 μg/ml (~2.5-fold) of this extract in comparison to hemozoin 
stimulated cells. These results were further confirmed by immunofluorescence assay 
showing a reduced expression of NFκB -p65 when pre-treated with Z. zanthoxyloides 






   
    
  
Figure 2-20: Zanthoxylum zanthoxyloides inhibits neuroinflammation via NFκB 
signalling pathway in hemozoin activated BV2 microglia 
A) Z. zanthoxyloides at 6 and 8 μg/ml decreased DNA binding activity of NFκB in hemozoin stimulated 
BV2 microglia cells. (B) Zanthoxylum zanthoxyloides markedly reduced (B) phosphorylation of IкB, (C) 
degradation of IKB and (D) translocation of NF-КB p65 subunit in hemozoin induced BV2 cells. 
Cultured BV2 cells were stimulated with hemozoin (400μg/ml) in the presence or absence of 
Zanthoxylum zanthoxyloides (4, 6 and 8μg/ml) for 1 hour. At the end of the incubation, cytoplasmic or 
nuclear extract was collected and western blot was done to measure the level of p65 subunit and IҡB 
protein expression. Analysis of data was done on 3 separate experiments using one-way ANOVA with 
post-hoc Student Newman-Keuls test (multiple comparisons ααα p<0.001 in comparison with the 
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Figure 2-21: Effect of Zanthoxylum zanthoxyloides on p65 NF-кB protein expression 
in hemozoin induced BV2 microglia 
Zanthoxylum zanthoxyloides (4, 6 and 8 μg/ml) decreased the expression of NF-КB p65 in hemozoin 
induced BV2 cells. Activated BV2 microglia cells were labelled with NF-КB p65 antibody and 
counterstained with DAPI. Images were acquired using EVOS® Floid ® cell imaging and analysed 




2.3.10 Methanolic extract of Zanthoxylum zanthoxyloides reduced pro-IL-1β 
and IL-1β secreted by inhibiting NLRP3 protein and caspase-1 activity 
in hemozoin induced BV2 microglia 
The role of activated NLRP3 inflammasome and caspase-1 by pathogens such as 
hemozoin has been reported to be involved in the maturation of pro-IL-1β to active IL-
1β, hence controlling the secretion of IL-1β (Jo, Kim, Shin, & Sasakawa, 2015; 
Primiano et al., 2016). Increase in release of IL-1β from activated microglia cells have 
been demonstrated to be involved in advancement of neuroinflammation (Jason et al., 
2001; Oyegue-Liabagui et al., 2017). Hence, decreasing the level of pro-IL-1β and IL-
1β production through inhibiting activated caspase-1 and NLRP3 protein is essential 
in reducing neuroinflammation in stimulated microglia cells. In Figure 2-22 a and b, 
results present a marked increase (p<0.001) in the levels of pro-IL-1β (~2-fold) and IL-
1β (~2.9-fold) in BV2 cells induced by hemozoin when compared to unstimulated cells. 
Contrarily, Z. zanthoxyloides at 4, 6 and 8 μg/ml significantly reduced (p<0.001) 
elevated level of pro-IL-1β (~1.4-fold, ~1.6-fold and ~1.9-fold decrease respectively) 
when compared to hemozoin treated cells. Based on this result, there was a further 
investigation on the effect of Z. zanthoxyloides on IL-1β, the mature form of pro-IL-1β 
cytokine. Z. zanthoxyloides at 4 μg/ml significantly decreased (p<0.05) the level of 
secreted IL-1β (~1.2-fold while at 6 and 8 μg/ml of this extract, there was a further 
inhibition (p<0.01) in secretion IL-1β (~1.3-fold and ~1.5-fold decrease respectively) 
when compared to cells induced with hemozoin.  
Furthermore, Figure 2-22 c and d show a significant increase (p<0.001) in caspase-1 
activity (~6.8-fold increase) measured by caspase-1 inflammasome and expression of 
NLRP3 protein (~2.9-fold increase) were observed on stimulation of BV2 cells with 
synthetic hemozoin in comparison with untreated cells. However, the elevated level of 
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caspase-1 activity was significantly inhibited (p<0.001) by Z. zanthoxyloides at 4 (~1.1-
fold), 6 (~1.4-fold) and 8 μg/ml (~1.7-fold) when compared to BV2 cells induced by 
hemozoin. This result was supported by western blot experiments showing that Z. 
zanthoxyloides (4, 6 and 8 μg/ml) decreased expression of activated caspase-1 in 
hemozoin induced BV2 cells. Moreover, western blot experiment result shows that Z. 
zanthoxyloides at 4 μg/ml markedly reduced (p<0.05) the level of NLRP3 protein 
expression (~1.1-fold) and a further decrease (p<0.001) was detected at 6 μg/ml (~1.6-
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Figure 2-22: Zanthoxylum zanthoxyloides suppressed the levels of IL-1β and pro-IL-
1β secretion by inhibiting NLRP3 protein and caspase-1 activity in hemozoin activated 
BV2 microglia 
Zanthoxylum zanthoxyloides (4, 6 and 8 µg/ml) significantly inhibited (a) pro-IL-1β and (b) IL-1 β 
production (c) caspase-1 activation measured by caspase-1 Glo inflammasome assay in hemozoin 
induced BV2 microglia (d) expression of caspase-1 by immunoblotting experiment and (e) expression 
of NLRP3 protein. BV2 cells were stimulated with hemozoin (400 μg/ml) in the presence or absence of 
Z. zanthoxyloides (4, 6 and 8 μg/ml) for 24 hours. At the end of the incubation period, supernatants 
were collected for ELISA measurements. For western blot experiment, cytoplasmic extract was 
collected at the end of 24 hours’ incubation and western blot was performed to measure protein 
expression of caspase-1 and NLRP3 protein. Data were expressed as mean ±SEM for 3 separate 
experiments. Analysis was done using one-way ANOVA with post-hoc Student Newman-Keuls test 
(multiple comparisons. ααα p<0.001 in comparison with the untreated cells and * p<0.05, **p<0.01, 
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2.3.11 Methanolic extract of Zanthoxylum zanthoxyloides did not decrease 
viability of BV2 cells induced by hemozoin 
MTT assay was used in investigating the viability of BV2 cells pre-treated with Z. 
zanthoxyloides (4, 6 and 8μg/ml) and stimulated with hemozoin for 24 hours. Results 
showed no significant reduction in viability of cells in comparison to untreated BV2 
cells. 
 
Figure 2-23: Z. zanthoxyloides did not decrease the viability of hemozoin induced BV2 
microglia 
Pre-treatment with Z. zanthoxyloides did not decrease the viability of BV2 microglia stimulated with 
hemozoin. Cells were stimulated with hemozoin (400 μg/ml) in the presence or absence of Z. 
zanthoxyloides (4, 6 and 8 μg/ml) for 24 h. At the end of the incubation period, MTT assay was done to 
investigate viability of BV2 cells. All values are expressed as mean ± SEM for 3 independent 
experiments. Analysis was done statistically using one-way ANOVA with post-hoc Student Newman-
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Neuroinflammation occurs as a response of immune cells to stimuli such as LPS which 
activates toll like receptors to cause excessive secretion of pro-inflammatory cytokines 
and mediators (Cherry, Olschowka, & O’Banion, 2014; Lehnardt, 2010). Excessive 
production of pro-inflammatory cytokines in neuroinflammation has been shown to 
cause neurotoxicity which increases the progression of neurodegenerative diseases 
(Smith et al., 2012a; Wojdasiewicz et al., 2014). The inhibition of pro-inflammatory 
cytokines has been suggested to be a therapeutic strategy in reducing 
neuroinflammation, a contributing factor to the pathology of neurodegenerative 
diseases (El-Bakoush & Olajide, 2018; Rubio-Perez et al., 2012; Schain, Kreisl, & 
reports, 2017).The role of medicinal plants have been demonstrated in several studies 
to be significant in brain inflammation and development of anti-inflammatory drugs 
(Tomlinson & Akerele, 2015). 
In the current study, a significant increase in the level of pro-inflammatory cytokines 
(TNFα, IL-1β and IL-6) and reduced level of IL-10 was observed on stimulation of BV2 
microglia cells with LPS. However, methanolic extract of Z. zanthoxyloides significantly 
decreased the level of pro-inflammatory cytokines and elevated the IL-10 level in BV2 
cells stimulated with LPS This suggest that Z. zanthoxyloides extract inhibited 
neuroinflammation by reducing the secretion of pro-inflammatory cytokines (TNFα, IL-
1β and IL-6) and elevating the production of anti-inflammatory cytokine (IL-10) to 
attenuate neuroinflammatory response. Zanthoxylum acanthopodium, a closely 
related species in Zanthoxylum genus was reported to reduce the level of pro-
inflammatory cytokines (IL-6 and TNFα), inflammatory mediators (iNOS and COX-2) 
in LPS induced macrophage cells (Yanti, Nuriasari, & Juliana, 2011). Moreover, an in 
vivo study on LPS induced mice has demonstrated that Zanthoxylum alatum 
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significantly reduced the production of pro-inflammatory cytokines (IL-1β, IL-6, IL-2 
and TNFα) and increased the level of IL-10, hence suggesting its anti-inflammatory 
effect (Barua et al., 2018). Observations from these previous studies demonstrates 
the inhibitory effect of species in Zanthoxylum genus on cytokines in both in vivo and 
in monocytes. This further support the results from this current study done in BV2 
microglia cells. These studies indicate the anti-inflammatory activity of species of 
Zanthoxylum genus in different models of inflammation. 
Furthermore, the effect of Z. zanthoxyloides on NO production and expression of iNOS 
were investigated. Result from this study showed that Z. zanthoxyloides markedly 
suppressed the release of NO production by inhibiting the expression of iNOS enzyme 
in LPS induced BV2 cells. This result shows a first indication that Z. zanthoxyloides 
could inhibit neuroinflammation by reducing the secretion of NO through reducing 
expression of iNOS enzyme. In addition, observation from this current study confirms 
the role of excessive release of nitric oxide (NO) mediated by iNOS (inducible nitric 
oxide synthase) in neuroinflammation and in pathology of neurodegenerative diseases 
which has been investigated previously (Asiimwe et al., 2016; Yuste et al., 2015). 
Moreover, Z. zanthoxyloides evidently reduced the level of secreted PGE2 and the 
protein expression of COX-2. Similarly, a previous in vivo study reported the inhibitory 
effect of Z. zanthoxyloides on PGE2 concentration in rat induced with carrageenan 
(Prempeh & Mensah-Attipoe, 2008). This observation suggests the anti-inflammatory 
activity of Z. zanthoxyloides extract in peripheral inflammatory cells and this current 
study provides first evidence that this extract could inhibit neuroinflammation through 
PGE2/ COX-2 pathway in BV2 microglia activated with LPS. 
Numerous studies have established the role of NF-κB in regulating the gene 
expression of COX-2, iNOS and genes that encodes pro-inflammatory cytokines which 
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releases IL-6, TNFα, NO and PGE2 (Weiwer, 2018; Yu, Lao, & Zheng, 2016). In 
addition, binding of NF-κB to the promoter site in DNA of target genes is important for 
transcription of inflammatory genes such as COX-2 (Ang & Wernig, 2018). Moreover, 
investigations have shown an association between activated NF-κB signalling 
pathway and neurodegenerative diseases including PD and AD (Baune & T, 2015). 
Hence, inhibiting the activation of NF-κB in neuroinflammation is important in reducing 
the secretion of pro-inflammatory cytokines and inflammatory mediators. In this study, 
the effect of Z. zanthoxyloides on NF-κB signalling pathway were elucidated. Result 
showed that Z. zanthoxyloides significantly inhibited the transcriptional activity of NF-
κB by decreasing NF-κB mediated luciferase activity in transfected HEK293 cells 
stimulated by TNFα. The outcome of this study implies that Z. zanthoxyloides may 
have inhibitory effect on activated NF-κB signalling pathway. Moreover, there was a 
reduction in the binding activity of NF-κB to DNA by Z. zanthoxyloides in LPS –
stimulated BV2 cells. This result suggests that the anti-inflammatory activity of Z. 
zanthoxyloides on IL-6, IL-1β, TNFα, NO, PGE2, iNOS and COX-2 may be due to the 
inhibitory effect of this extract on NF-κB signalling pathway.  
NF-κB p65 and p50 are heterodimer subunits in NF-κB family members, are 
demonstrated to play an important role in transcription of inflammatory genes 
(Christian et al., 2016). In resting cells, NF-κB is bound to IκB and remain inactive until 
inflammatory stimuli such as LPS activate the cells. This leads to the phosphorylation 
of IKK, which in turn phosphorylates IκB and subsequent degradation of IκB. This 
event leads to the translocation of NF-κB to the nucleus which then binds to DNA of 
inflammatory genes for the purpose of transcription. Consequently, the effect of Z. 
zanthoxyloides on phosphorylation of p65 in LPS-stimulated BV2 microglia cells were 
elucidated. Result shows that Z. zanthoxyloides inhibited p65 phosphorylation in a 
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concentration dependent manner. Observation from these results suggest that Z. 
zanthoxyloides reduce neuroinflammation by exerting its inhibitory effect on NF-κB 
signalling pathway in BV2 microglia cells. Following these results, studies of Z. 
zanthoxyloides on kinases that are upstream in NF-κB signalling pathway were 
investigated. Contrarily, Z. zanthoxyloides did not inhibit the phosphorylation of IKK in 
BV2 cells stimulated with LPS. Taking into account that most IKK inhibitors have been 
reported to act by competing with ATP molecule on binding to sites on IKK to exert 
their action (Nadia Lampiasi & Giovanna Montana, 2016). This may cause interference 
reducing the activity of IKK inhibitors. In addition to this, some IKK inhibitors also act 
by having allosteric effect on IKK (Tian et al., 2015). For example, an IKK inhibitor can 
significantly reduce IKKβ phosphorylation and not inhibit IKKα. This may also 
contribute to the insignificant inhibition of IKKα phosphorylation by Z. zanthoxyloides 
extract in LPS stimulated BV2 microglia cells. Furthermore, result from this study 
shows inhibition of NF-κB signalling pathway by reducing the expression of 
phosphorylated p-IκBα and depletion of IκBα. Taken together, observations from these 
results suggest that Z. zanthoxyloides extract inhibit neuroinflammation through 
targeting IκBα/NF-κB signalling pathway in LPS-stimulated BV2 microglia cells. This 
current study provides first indication on the inhibitory effect of Z. zanthoxyloides on 
neuroinflammation through NF-κB signalling pathway in LPS-stimulated BV2 microglia 
cells. The inhibitory action of Z. zanthoxyloides in this study is important and might be 
helpful in treatment of neuroinflammation mediated neurodegenerative diseases. 
Investigations have identified the role of neuroinflammation induced by hemozoin to 
be significant in pathologies such as cerebral malaria (Wassmer & Grau, 2017). 
Furthermore, previous studies have shown elevated level of of pro-inflammatory 
cytokines (IL-1β, IL-6 and TNFα) secretion on stimulation of monocytes and 
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macrophages with hemozoin (Dunst et al., 2017; Olivier et al., 2015; Perkins et al., 
2011; Velagapudi et al., 2019). Therefore, inhibition of neuroinflammation by reducing 
the level of pro-inflammatory cytokines and inflammatory mediators in hemozoin-
stimulated cells could be a potential therapeutic target for neuroinflammatory 
disorders. The effect of Z. zanthoxyloides on IL-6 and TNFα were investigated in this 
study. The outcome of this experiment showed an increase in the level of IL-6 and 
TNFα in BV2 cells induced by synthetic hemozoin. In addition, the increased level of 
TNFα and IL-6 were significantly decreased on pre-treatment with Z. zanthoxyloides 
in hemozoin activated BV2 cells. Moreover, a reduced level of IL-10 was detected on 
stimulation of BV2 cells with hemozoin. Z. zanthoxyloides increased the level of IL-10, 
suggesting the anti-inflammatory activity of this extract. The outcome of these 
investigations is significant and suggest that Z. zanthoxyloides can attenuate 
neuroinflammatory response by hemozoin to inhibit pro-inflammatory cytokines and 
increasing anti-inflammatory cytokines in brain macrophage cells. Observations from 
this current study proposes a new mechanism that Z. zanthoxyloides extract could 
reduce hemozoin-induced neuroinflammation in BV2 microglia cell line. 
Excessive release of NO have been suggested to contribute to the development of 
neuroinflammation in malaria (Dunst et al., 2017). In this current study, a significant 
increase in level of NO mediated by iNOS was observed in BV2 cells stimulated with 
hemozoin. In addition, Z. zanthoxyloides suppressed the level of PGE2 secreted 
through inhibition of COX-2 expression in BV2 cells induced by hemozoin. These 
results suggest the effect of Z. zanthoxyloides on PGE2 and NO production through 
suppression of iNOS and COX-2 proteins, respectively. These results provide first 
proof of anti-inflammatory activity of Z. zanthoxyloides on neuroinflammation through 
reducing the production of NO and PGE2 with their mediators. 
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Research in the past have demonstrated the activation of NF-κB by hemozoin through 
toll-like receptor 2 (TLR-2) and toll like receptor-9 (TLR-9) (Coban et al., 2006; Kawai 
& Akira, 2011; Polimeni et al., 2012). The activation of NF-κB through TLR2 and TLR9 
receptors have been shown to be important in immune responses to infections which 
includes P.falciparum, a malaria parasite (Wagner, 2010). These studies suggest the 
involvement of activated TLRs and NF-κB signalling pathway in neuroinflammation 
induced by hemozoin. Hence, attenuation of hemozoin-induced neuroinflammation 
through inhibition of activated NF-κB pathway may help target neuroinflammatory 
related disorders. The current investigation explored the effect of Z. zanthoxyloides on 
NF-κB signalling pathway in order to elucidate the mechanism of action of this extract 
in hemozoin induced BV2 cells. In this study, an increased level of DNA binding activity 
of NF-κB, phospho-p65 and phosphorylation of IκB were observed in hemozoin 
induced BV2microglia cells. These results suggest that hemozoin was able to activate 
NF-κB signalling pathway in BV2 cells microglia. A similar result was reported 
revealing an increase in the phosphorylation of NF-κB p65 subunit and DNA binding 
activity of NF-κB in hemozoin-stimulated BV2 microglia cells (Velagapudi et al., 2019).  
Z. zanthoxyloides significantly inhibited the DNA binding activity of NFκB, 
phosphorylation of NF-κB p65 subunit, phosphorylation of p-IκBα and degradation of 
IκBα in BV2 cells activated with hemozoin. These results indicate that Z. 
zanthoxyloides could inhibit neuroinflammation through blocking of IκBα/NF-κB 
pathway in hemozoin-induced BV2 microglia cells. In addition, the outcome of this 
investigation further indicates that Z. zanthoxyloides could reduce the binding of NF-
κB to DNA, resulting in inhibition of gene transcription involved in inflammation such 
as iNOS and COX-2.  This is the first study suggesting the general effect of Z. 
zanthoxyloides on NFκB signalling pathway in hemozoin-stimulated BV2 microglia 
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cells. Therefore, the inhibitory role of Z. zanthoxyloides on hemozoin-induced 
neuroinflammation though NFκB signalling pathway is important as it may be a 
potential therapeutic strategy in treatment of neuroinflammatory disorders such as CM. 
Previous studies have demonstrated that hemozoin induces the release of IL-1β 
cytokine from pro-1β by activating NLRP3 inflammasome with further increased 
caspase-1 activity in macrophage cells and in BV2 microglia cells (Ozaki, Ema, & 
Campbell, 2015; Shio et al., 2009; Velagapudi et al., 2019). Observations from these 
studies suggest the role of hemozoin on inflammation through NLRP3 inflammasome 
pathway in peripheral blood cells and in the brain’s resident macrophage cells. In this 
current research, similar increase in levels of NLRP3 with caspase-1 activity, pro-IL-
1β and IL-1β cytokine were observed on stimulation of BV2 cells with hemozoin in 
comparison to untreated BV2 cells.  Z. zanthoxyloides inhibited the expression of 
NLRP3 protein with subsequent reduction of caspase-1 activity (using both caspase-
1 inflammasome assay and western blot experiments as detection technique) in 
hemozoin-stimulated BV2 microglia cells. In addition, Z. zanthoxyloides elevated level 
of pro-IL-1β and IL-1β. These results provide the first proof showing the inhibitory 
action of Z. zanthoxyloides on NLRP3 inflammasome and caspase-1 activity in BV2 
cells activated with hemozoin. Results from these investigations suggest that Z. 
zanthoxyloides reduced hemozoin-induced neuroinflammation through NLRP3 
pathway and this is significant as it may be a promising therapeutic agent in treatment 
of neuroinflammation in severe complications of malaria infections.  
In summary, investigations on methanolic extract of Z. zanthoxyloides in this current 
study have been demonstrated to inhibit neuroinflammation by targeting NFκB and 
NLRP3 signalling pathway in BV2 cells induced by LPS or hemozoin in a separate 
study. The observations from these investigations have presented the first evidence 
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of anti-neuroinflammatory effect of methanolic extract of Z. zanthoxyloides in BV2 
microglia cells. .  
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3 CHAPTER 3- Bioassay guided isolation of bioactive 
compounds from Z. zanthoxyloides and their anti-
neuroinflammatory activities  
3.1 Background of this chapter 
Medicinal plants have been shown in several studies to be a primary source of 
discovering new drugs and the process includes isolation of bioactive compounds and 
phytochemical studies such as Mayer’s test to detect the presence of alkaloids in a 
mixture (Shakya, 2016; Tomlinson & Akerele, 2015). Subsequently, the identification 
and elucidation of compound structure are investigated and pharmacological activities 
of the known compound are then determined (Atanasov et al., 2015; Latif & Sarker, 
2012). In addition, isolated compounds from medicinal plants have been described to 
provide background information which includes size, molecular weight and functional 
groups which is necessary in synthesising more compounds chemically (Nothias et 
al., 2018). In order to isolate compounds from medicinal plants, bioassay guided 
fractionation is considered as first stage in drug discovery to detect the presence of 
compounds with biological activity in an extract during isolation process (Malviya & 
Malviya, 2017; Waksmundzka-Hajnos & Sherma, 2010). The process of compound 
Isolation are continuously repeated until a pure bioactive compound is derived from 
plants extract (Kabera, Semana, Mussa, & He, 2014). Examples of drugs isolated from 
plants includes: the isolation of aspirin, an anti-inflammatory drug from bark of Salix 
alba tree (Rainsford, 2013), isolation of quinine, an anti-malaria drug from the bark of 
Cinchona succirubra (Thanacoody, 2016) and isolation of paclitaxel (anti-cancer drug) 
from Taxus brevifolia tree (Priyadarshini & Keerthi, 2012). In addition, studies have 
also reported the isolation of artemisinin from Artemisia annua which is used in malaria 
treatment (Miller & Su, 2011). Moreover, isolation of galanthamine from Huperzia 
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serrata have been reported for its benefit in treatment of early phase of Alzheimer’s 
disease (Zhan et al., 2016). Consequently, isolation of compounds from medicinal 




3.2 Isolation of bioactive compounds from Z. zanthoxyloides 
3.2.1 Solid phase extraction 
Solid phase extraction (SPE) is a process that separates compounds between two 
phases.(Płotka-Wasylka, Justyna, Szczepańska, de la Guardia, & Namieśnik, 2016) 
In SPE technique, the compounds to be extracted are separated between a liquid and 
solid phase. SPE was used to further fractionate methanolic extract of Z. 
zanthoxyloides that was initially obtained through soxhlet extraction process (as 
described in 2.2.2). A commercially available SPE catridge was used for 
fractionation of the Z. zanthoxyloides extract (Reid & Sarker, 2012). Two grams (2 
g) of the methanolic extract was used for solid phase extraction using a Strata C-18 
cartridge 20g (Phenomenex, California, USA). The cartridge was previously washed 
with 50 mL of MeOH and followed by running 100 mL of water. Thereafter, the extract 
was dissolved in 10ml of 10% methanol (MeOH) in water. The cartridge was eluted 
with a gradient of methanol to water (MeOH-H2O) mixture obtaining four fractions (F1, 
20:80; F2, 50:50; F3, 80:20 and F4, 100:0). This procedure resulted in 200ml each of 
the fraction. The fractions were dried using a rotary evaporator and a freeze-dryer. 
Afterwards, fractions were kept in the 4o C fridge for further experiments. 
3.2.2 Analytical and Preparative HPLC 
The role of high performance liquid chromatography (HPLC) has been shown as an 
important technique in the process of isolation because of its use in separation and 
identification of different components in plants extract (Thammana, 2016). Results 
from HPLC technique is represented on a graph called chromatogram, which shows 
peaks representing the presence of compounds in a sample. Analytical and 
preparative HPLC are useful to separate, quantify, detect and isolate natural products 
or mixture of compounds. The use of prep-HPLC technique has been shown to 
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separate wide classes of compounds from crude extract in large quantities (Latif & 
Sarker, 2012). In addition, solvents used in HPLC have the ability to dissolve the 
sample, having high purity, transparent and not interfering with compound of interest 
and have low viscosity (Huang, Tung-Yung, Chi, & Chien, 2018; Latif & Sarker, 2012). 
Analytical HPLC was used in this experiment to screen the presence of secondary 
metabolites in the fractions while prep HPLC was used in purifying and isolating the 
compound. Twenty-six (26) mg of fraction 3 (the bioactive fraction in Z. zanthoxyloides 
extract) was purified on an Agilent 1260 infinity HPLC system equipped with an Agilent 
1260 DAD and an Ace-5 C18 column (150 × 21.2 mm, 5 µm particle size, Hichrom 
Ltd). Preparative HPLC was performed using a gradient of mobile phase A (water 
with 0.1% trifluoroacetic acid) and mobile phase B (methanol with 0.1% trifluoroacetic 
acid) with the following time schedule: 30% B, 0–35 min; 100% B, 35-37min; 100 % 
B, 37-39 min; 30% B, 39-42 min. The flow rate was maintained at 10.0 mL/min and 
UV absorbance was recorded. Furthermore, Figure 3-8 shows the prep-HPLC that 
was used to purify fraction 3 and the chromatogram showed the peak detection of 
skimmianine at a retention time of 17.596 minutes.  
3.2.3 Nuclear magnetic resonance (NMR) and Mass spectrometry  
The use of NMR spectroscopy has been reported to be significant in elucidation of 
compound structure by providing structural information about components in a 
molecule. Studies have shown that proton NMR (1H-NMR) detects the number of 
hydrogen present in a compound and describes how they are connected to each 
other while carbon NMR (13C NMR) provides information about the number of 
carbons in a compound. Hence, the use of 1H -NMR and 13C NMR are both 
important in structure elucidation of unknown compounds, especially isolated 
compounds from medicinal plants. The structure of skimmianine was determined 
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using spectroscopic analyses which includes proton (1H) and carbon (13C) NMR 
while 2D NMR experiments are1H-1H COSY (Correlation Spectroscopy), HMBC (1H-
13C Heteronuclear Multiple Bond Correlation Spectroscopy) and HSQC (1H-13C 
Heteronuclear Single Quantum correlation). Experiments were performed on either a 
Bruker AMX 600 or a Bruker AMX 300 instrument (Bruker, Germany). Chemical 
shifts (δ) are given in part by millions (ppm) and the coupling constants J in Hertz 
(Hz). Mass spectrometry (MS) is a technique that provides information about the 
molecular weight and fragmentation pattern of a compound (De Hoffmann & 
Edmond, 2000). MS was used in confirming and to provide more information from 
result obtained in NMR spectroscopy. High resolution mass spectra (HR-MS) were 
recorded at the National Mass Spectrometry Facility, Swansea, UK on a LTQ 
Orbitrap XL1 spectrometer. The analytes were prepared in methanol and the mass 


















Figure 3-1: Isolation of bioactive compound (skimmianine) from fraction 3 of Z. 
zanthoxyloides extract 
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Previous Investigations on Z. zanthoxyloides extract in this current study showed an 
inhibitory activity of this extract on neuroinflammation. This further led to interest of 
isolating and identifying compounds in this extract that has inhibitory effect on 
neuroinflammation in BV2 microglia cells. In order to isolate and identify compounds 
from this extract that has anti-neuroinflammatory activity, bioassay guided 
fractionation was required to achieve this aim. Figure 3-1: summarises the process 
adopted in bioassay guided fractionation to isolate and identify bioactive compounds 
from Z. zanthoxyloides extract. Firstly, solid phase extraction (SPE) technique was 
used to separate this extract into four fractions (F1, F2, F3 and F4). Afterwards, an 
ELISA technique was used in investigating the inhibitory activity of F1, F2, F3 and F4 
on the level of TNFα production in LPS-stimulated BV2 microglia cells. The outcome 
of this investigation showed fraction 3 as the most active by significantly reducing the 
elevated level of TNFα in LPS- activated BV2 microglia cells. Subsequently, 
purification of fraction 3 was done using HPLC and a major pure compound was 
detected as peak in fraction 3 which was significant from the chromatogram. 
Thereafter, structure elucidation of this compound was determined by nuclear 
magnetic resonance (NMR) and its molecular weight were obtained by mass 
spectrophotometer. Observation from this bioassay guided fractionation showed 
skimmianine as the main compound isolated in fraction 3 of Z. zanthoxyloides extract. 
Skimmianine is the most abundant furoquinoline alkaloid that is isolated from 
Zanthoxylum genus (Phuyal, Jha, Raturi, & Rajbhandary, 2019; Queiroz et al., 2006b). 
Furoquinoline alkaloids are true alkaloids as they are organic nitrogen-containing 
compounds that serve as an important pool for discovery of drugs (Adamska-
Szewczyk, Aldona, Glowniak, & Baj, 2016). Skimmianine (also known as beta-fagarine 
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or chloroxylonine) has an IUPAC name called 4, 7, 8-Trimethoxyfuro [2, 3-b] quinoline. 
The chemical structure of skimmianine is shown below with a molecular formula of 
C14H13NO4 and molecular weight of 259.261 g/mol.  
 
Figure 3-2: Chemical structure of skimmianine 
Reports have shown previous isolation of skimmianine from stem bark of Melicope 
madagascariensis (Rasamison et al., 2016), leaves of Oricia renieri and Oricia 
suaveolens (Nouga et al., 2016), Zanthoxylum buesgenii (Sandjo, Kuete, Tchangna, 
Efferth, & Ngadjui, 2014)  and leaves of Evodia lepta (Sichaem et al., 2014). Examples 
of furoquinoline alkaloids that are isolated from Zanthoxylum are kokusaginine, 
dictamnine and skimmianine (Aniszewski, 2015; Patiño et al., 2012).  
 
3.2.4.1 Pharmacological activities of skimmianine 
Previous studies have demonstrated that skimmianine isolated from stems of 
Esenbeckia leioncarpa showed an anti-acetylcholinesterase activity (Cardoso-Lopes 
et al., 2010). Similarly, isolated skimmianine from Zanthoxylum nitidum was 
demonstrated to have anti-cholinesterase activity by increasing the level of 
acetylcholine (Yang, Zhang, Ren, & Yang, 2012). Furthermore, a study by Ratheesh 
et al (2013) reported an anti-inflammatory activity of isolated skimmianine from Ruta 
graveolens by significantly reducing the levels of pro-inflammatory cytokines (IL-6 and 
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TNFα), nitrite, prostaglandin E2 and COX-2 expression in carrageenan induced rat 
(Ratheesh, Sindhu, & Helen, 2013). Furthermore, isolated skimmianine from root 
barks of Dictamnus dasycarpus has been reported to attenuate the increased level of 
nitric oxide produced in LPS-stimulated BV2 cells (Yoon et al., 2012) .However, this 
study did not further investigate the effect of isolated skimmianine on expression of 
iNOS enzyme, which is an important mediator for secretion of NO in LPS stimulated 
BV2 cells. Moreover, investigations of skimmianine isolated from Zanthoxylum 
avicennae and tetradium ruticarpum showed an inhibitory activity on elevated level of 
secreted superoxide anion in human neutrophils (Cho et al., 2012; T. Y. Wang et al., 
2010). This study indicates the anti-inflammatory effect of skimmianine by reducing 
one of the reactive oxygen metabolites (superoxide anion) produced in inflammatory 
cells. However, studies to show the effect of skimmianine on important inflammatory 
mediators such as COX-2 and pro-inflammatory cytokines including IL-6 and TNFα in 
LPS-activated BV2 microglia cells are yet to be determined. In addition, investigations 
to elucidate the effect of skimmianine on NF-B activation is unknown. Hence, effect 




3.3 Investigations on the effect of Fractions 1, 2, 3 and 4 of Z. 
zanthoxyloides extract and skimmianine on neuroinflammation 
induced by LPS in BV2 microglia cells 
3.3.1 Drug preparation and treatment 
Fractions 1, 2, 3 and 4 of Z. zanthoxyloides extract were prepared in DMSO (Sigma, 
UK). A stock concentration of 2, 3 and 6 mg/ml of these fractions were prepared 
separately to working concentrations of 4, 6 and 8 µg/ml prior to experiments. 
Skimmianine was dissolved in DMSO to a stock concentration of 0.1M. BV2 microglia 
cells were treated with skimmianine (10, 20 and 30 µM) for 30 minutes and stimulated 
with LPS at 100 ng/ml. Subsequently, further quantities of skimmianine (PhytoLab, 
Germany) were purchased for further investigations on effect of skimmianine on 
neuroinflammation. NMR spectroscopy was used to authenticate this compound 
before experiments. Lipopolysaccharide (LPS) at 1 mg/ml, derived from Salmonella 
enterica serotype typhimurium (Sigma, UK) was used in preparing a working 
concentration of 100 µg/ml and kept in 4°C.  
3.3.2 Cell culture  
3.3.2.1 BV2 Cells  
BV2 microglia cell line ICLCATL03001 (Banca Biologica e Cell Factory, Italy) were 
cultured in RPMI 1640 medium (Life Technologies, UK) supplemented with 10% fetal 
bovine serum (Sigma), 1mM sodium pyruvate (Sigma), 100U/ml Penicillin and 
100mg/ml Streptomycin (Sigma). Prior to experiments, the cells were sub-cultured, 
maintained in the incubator and seeded out in plates as described in 2.2.3.1.  
3.3.2.2 HEK293 Cells  
HEK293 cells were cultured in Minimum Essential Media (MEM) (ThermoFisher 
Scientific, UK) and generally maintained as shown in text 2.2.3.2. HEK293 cells 
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seeded out in plates once they became confluent for the purpose of transfection 
experiments. In this study, the effect of skimmianine on NF-ĸB mediated gene 
expression were investigated in TNFα-stimulated HEK293 cells.  
3.3.2.3 HT22 neuronal cell culture 
HT22 cells are immortalised cell line from culture of primary mouse hippocampal 
neuron and was derived from HT4 cells (Davis & Maher, 1994). HT22 neuronal cell 
line were kindly provided by Dr Jeff Davis (University of Swansea, UK). HT22 cells 
were maintained and cultured in a cell culture flask (T75 cm2) that contains DMEM 
(Life Technologies, UK), with addition of 1mM sodium pyruvate, 2mM L-glutamine, 
10% FBS (heat inactivated), 100 μg/ml of streptomycin and 100 U/mL of penicillin as 
supplements. T75 flask containing HT22 cells were kept in a 5% CO2 incubator at a 
temperature of 37o C. Cultured cells were sub-cultured at 70 - 75% confluence. PBS 
(5 mls) was added to wash the cells in the flask and aspirated. There was addition of 
2 mL of 0.25% trypsin-EDTA solution to dissociate HT22 cells in flask. Trypsinization 
of cells were terminated by adding 8 mL of DMEM complete medium to the flask. 
Afterwards, the dissociated cells were collected in a tube and centrifuged at 1200 rpm 
for 5 minutes. The supernatant was aspirated, followed by re-suspension of cell pellets 
in 10 mL of new complete DMEM. HT22 cells were counted with haemocytometer and 
subsequently seeded out in cell culture plates at a concentration of 2×105 cells/ml in 
preparation for experiments.  
3.3.3 MTT assay for cell viability  
MTT assay (as previously described in 2.2.16) was performed to assess the viability 
of cells after pre-treatment with skimmianine (10, 20 and 30 µM) and stimulated with 
LPS (100 ng/ml).  
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3.3.4 Measurement of Nitrite (Griess assay) 
Cultured BV2 cells were pre-treated with skimmianine (10, 20 and 30 µM) for 30 
minutes and then stimulated with LPS (100 ng/ml) for 24 hours. After incubation, cell 
culture supernatants were collected and centrifuged at 1500 rpm for 5 minutes. Nitrite 
concentration in the cell culture supernatant was measured using the Griess assay 
(earlier described in section 2.2.5). 
3.3.5 Determination of TNFα, IL-6, IL-1β, IL-10 and Pro-IL-1β by Enzyme 
linked immunosorbent assay (ELISA 
Skimmianine (10, 20 and 30 µM) was incubated with cultured BV2 cells and then, 
stimulated with LPS (100 ng/ml) for 24 hours. Afterwards, cytokine levels of TNFα, IL-
1β, IL-6 and IL-10 were analysed in the cell culture supernatants using ELISA 
technique (as previously demonstrated in section 2.2.6). 
3.3.6 Prostaglandin E2 measurement using enzyme immunoassay (EIA) 
Cultured microglia BV2 cells were treated with skimmianine (10, 20 and 30 µM) for 30 
minutes and subsequently activated with LPS (100 ng/ml) for 24 hours. At the end of 
incubation, Prostaglandin E2 level in the cell culture supernatants was measured (as 
initially described in section 2.2.8). 
3.3.7 Extraction of cytoplasmic cell lysates from cultured BV2 cells 
BV2 cells were treated with skimmianine (10, 20 and 30 µM) for 30 minutes and further 
activating with LPS (100 ng/ml) for the time required for each experiment, cytoplasmic 
cell lysates were extracted as explained in section 2.2.9. 
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3.3.8 Extraction of nuclear cell lysates from cultured BV2 cells 
Cultured microglia BV2 cells were treated with skimmianine (10, 20 and 30 µM) for 30 
minutes and subsequently activated with LPS (100 ng/ml) for duration required for 
each investigation. Nuclear cell lysates were extracted as described in section 2.2.10. 
3.3.9 Measurement of protein concentration  
After cytoplasmic and nuclear extraction, concentrations of proteins were determined 
(as shown in text 2.2.11) by Pierce Coomassie (Bradford) protein assay kit (Thermo 
Scientific, UK) before western blot experiments 
3.3.10 Western blotting  
Western blotting (as described in 2.2.12) is a technique that is useful in detection 
of target protein according to their molecular weights. This technique mainly 
involves separation of proteins in lysates by gel electrophoresis, transfer of 
proteins from gel onto membrane blot and detection of target proteins based on 
their molecular weights. Following the determination of protein concentration in 
cell lysates, western blotting technique were used to investigate the effect of 
skimmianine on expression of iNOS, COX-2, NF-B p65, phospho-IB-α, IB-α. 
 
3.3.11 NF-κB p65 transciption factor assay  
NF-B transcription factor assay (as described in 2.2.13) is an assay that investigates 
the binding of NF-B to the consensus binding site on the DNA. In this study, the effect 
of skimmianine (10, 20 and 30 µM) on binding of NFB-DNA binding in LPS-stimulated 
BV2 microglia cells were determined. 
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3.3.12 Immunofluorescence technique 
Immunofluorescence is an imaging technique (described in 2.2.14) that is important 
in detection of antigen by a specific antibody and this reaction is observed under 
fluorescence microscope. In this study, the effect of skimmianine (10, 20 and 30 µM) 
on expression of NF-B p65 were investigated in LPS-activated BV2 microglia cells 
3.3.13 Reporter gene assay  
As described in 2.2.15, HEK293 cells were transfected with Cignal NF-κB (LUC) 
(CCS-013L) vector to investigate the effect skimmianine on luciferase activity of NF-
КB in the nucleus. 
3.3.14 BV2 microglia conditioned medium) 
Studies have shown that increased levels of inflammatory stimuli including TNFα and 
IL-6 from activated microglia cells cause neurotoxicity to surrounding neurons in CNS, 
which could increase the progression of neurodegenerative diseases(Kraft, Harry, & 
health, 2011). Cultured BV2 cells were seeded in a 6-well plate at a concentration of 
2×105 cells/ml and put in the incubator at 37o C. After the cells had reached confluence, 
they were treated with skimmianine at 10, 20 and 30 μM for 30 minutes and then 
stimulated with LPS (1μg/ml) for 24 hours. At the end of the incubation, supernatants 
were collected from the cells in plate, transferred to an eppendorf tube and centrifuged 
for 5 minutes at 1200 rpm in order to remove cell debris from the conditioned medium. 
Following centrifugation, the conditioned medium was made into aliquot in eppendorf 
tube and then stored in -80o C freezer. Afterwards, levels of NO and TNFα were 
analysed in the conditioned medium to verify if these inflammatory mediators had been 
secreted from LPS induced BV2 cells.  
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3.3.15  Viability studies on HT22 hippocampal cells in conditioned medium 
from LPS-activated BV2 cells 
MTT assay was used in assessing the viability of HT22 cells on exposure to 
conditioned medium from LPS activated microglia cells. Firstly, HT22 cells were 
seeded out in a 96 well plate at a concentration of 2×105 cells/ml (200 µl/ in each well) 
and incubated until the cells reached confluence. At the end of the incubation, cultured 
medium was aspirated carefully from each well and replaced with 200 µl of conditioned 
medium (from activated BV2 cells) and then incubated for 24 hours. Thereafter, MTT 
assay was used in determining the viability of HT22 neuronal cells. 
3.3.16 Detection of MAP2 protein in conditioned medium–treated HT22 cells 
by immunofluorescence  
Investigations have associated a reduced expression levels of microtubule-associated 
protein 2 (MAP2) with activated microglia cells to cause neuronal toxicity (Froger et 
al., 2010). MAP2 protein plays an important role in neuronal growth and stability and 
reduced expression of MAP2 have been shown to contribute to the progression of 
neurodegenerative diseases (Avila, Pallas, Bolós, Sayas, & Hernandez, 2016). The 
effect of skimmianine on expression of MAP2 protein in conditioned medium –




3.4.1 Effect of fractions 1, 2, 3 and 4 on TNFα production in LPS-activated 
BV2 microglia 
The role of excessive secretion of TNFα from activated microglia cells has been shown 
to be involved in neuroinflammation, a contributing factor to the progression of 
neurodegenerative diseases (Probert, 2015; Sedger & McDermott, 2014). Hence, 
inhibiting overproduction of TNFα from stimulated microglia cells is important in 
reducing the level of TNFα in neuroinflammation. Inhibitory effect of Z. zanthoxyloides 
extract on pro-inflammatory cytokines (TNFα, IL-1β and IL-6) and inflammatory 
mediators (COX-2, iNOS) and NF-κB proteins led to further studies in isolating 
compounds present in this extract. Subsequently, Z. zanthoxyloides extract was 
subjected to solid phase extraction (SPE) to obtain four fractions: FR1, FR2, FR3 and 
FR4. Subsequently, effects of FR1, FR2, FR3 and FR4 on elevated levels of TNFα in 
LPS activated BV2 cells were investigated to guide the isolation of compounds from 
the bioactive fraction(s). Result in Figure 3-3 shows a significant reduction (p<0.001) 
in the levels of TNFα secreted when pre-treated with 4 μg/ml of FR3 ( ~1.2-fold 
reduction), 6 μg/ml of FR3 ( ~1.4-fold ) and 8 μg/ml of FR3 ( ~1.6-fold) when compared 
to LPS stimulated cells Moreover, there was no significant reduction in the elevated 
levels of TNFα produced on treatment of LPS-stimulated cells with FR1, FR2 and FR4 





Figure 3-3: Effect of fraction 1, 2, 3 and 4 on TNFα in LPS activated BV2 microglia 
ELISA (TNFα) experiment was done on all the fractions. The result showed that fraction 3 significantly 
reduced TNFα cytokine level. This was done to guide and determine the fraction with biological that 
activity before further purification. Cells were treated with or without fraction 1, 2, 3, 4 and stimulated 
with LPS (100 ng/ml) for 24 hours. At the end of the incubation period, supernatants were collected for 
ELISA measurements. Data are expressed as mean ±SEM for 3 passages. Analysis was done using 

































3.4.2 Fractions (1, 2, 3 and 4) from Z. zanthoxyloides extract did not affect 
viability of BV2 cells 
The viability of BV2 cells pre-treated with the fractions (FR 1, FR 2, FR 3 and FR 4) 
isolated from Z. zanthoxyloides extract were investigated. Results showed that there 
was no significant difference in viability of cells treated with FR 1, FR 2, FR 3 and FR 
4 in LPS-stimulated cells when compared with untreated cells. 
 
Figure 3-4: Effect of fraction 1, 2, 3 and 4 on BV2 cell viability 
Pre-treatment with fraction 1, 2, 3 and 4 did not affect the viability of BV2 microglia stimulated with LPS. 
Cells were stimulated LPS (100 ng/ml) in the presence or absence of all the fractions for 24 h. At the 
end of the incubation period, MTT assay was carried out on cells. All values are expressed as mean ± 
SEM for 3 independent experiments. Statistical analysis was performed using one-way ANOVA with 














































3.4.3 Structure elucidation of compound isolated from Z. zanthoxyloides 
extract  
Investigations on effect of fraction 1, 2, 3 and 4 (isolated from Z. zanthoxyloides 
extract) on elevated TNFα level in stimulated microglia cells showed that fraction 3 
significantly inhibited TNFα produced from activated microglia cells (as shown in 
Figure 3-3). Consequently, fraction 3 was further separated and purified by HPLC 
technique leading to isolation of a main compound from fraction 3. NMR 
spectroscopy have been used in previous studies for structural elucidation of 
unknown compounds from plants extracts and their isolates (Akitt & Mann, 2017) . 
Structure of isolated compound from fraction 3 was elucidated by NMR 
spectroscopy. In Figure 3-5, proton (1H) NMR spectrum of isolated compound shows 
a pair of doublets at δ 7.28 and δ 7.75 (each 1H, J = 2.6 Hz), characteristic of the H-
1’ and H-2’ furan ring protons, and a downfield 3H singlet at δ 4.39, characteristic of 
the methoxy group at C-4 in the structure of isolated compound. Another pair of 
doublets at δ 8.05 and δ 7.36 (each 1H, J = 9.4 Hz), characteristic of H-5 and H-6 of 
the quinolone ring respectively. The signals of two other methoxy group at δ 3.92 
and δ 3.87 corresponding to 7-OCH3- and 8-OCH3. The carbon (13C) NMR spectrum 
of isolated compound in Figure 3-614 shows signals corresponding to three methoxyl 
groups at δ 58.4 (4-OCH3), 55.8 (7-OCH3 and 60.3 (8-OCH3); four methines and 
seven quaternary carbons. The NMR results showed that the structure of isolated 
compound from fraction 3 is skimmianine with a molecular formula, C14H13NO4. 
Furthermore, HR-MS mass spectrum was used to confirm and determine the 
molecular weight of skimmianine. Result in  
Figure 3-7 shows the pseudomolecular ion peak at m/z 260 [M+H+] - corresponding to 






























3.4.3.1 Skimmianine reduced TNFα, IL-1β and IL-6 production and increased 
IL-10 secretion in LPS activated BV2 microglia 
Excessive secretion of pro-inflammatory cytokines (TNFα, IL-1β and IL-6) have been 
reported to contribute to neuroinflammation in macrophage cells stimulated with stimuli 
such as LPS (Turner, Nedjai, Hurst, & Pennington, 2014). Therefore, inhibition of pro-
inflammatory cytokines is important and may result in reducing neuroinflammation. 
Effect of skimmianine on production of TNFα, IL-1β, IL-6 and IL-10 in LPS-induced 
BV2 microglia cells were investigated. Result showed that LPS-induced a significant 
increase (p<0.001) in the production of TNFα (~14.8-fold) when compared to 
untreated cells. However, pre-treatment with skimmianine at 10 µM (~1.2-fold) 
reduced TNFα production significantly (p<0.01) in comparison with LPS control. In 
addition, there was a further significant reduction (p<0.001) in the level of TNFα 
released at 20 µM, (~1.5-fold reduction) and 30 µM (~2-fold decrease). Furthermore, 
there was a significant elevation in degree production of IL-6 (~11.2-fold increase) in 
LPS-stimulated BV2 cells with in comparison to untreated cells. In contrast, pre-
treatment with skimmianine at 20 µM showed a significant decrease (p<0.05) in the 
release of IL-6 (66.6% reduction) while at 30 µM (44.6% decrease) of this compound, 
there was a further decrease (p<0.001) in comparison to LPS treated cells. Effect of 
skimmianine at 10 µM was insignificant on production of IL-6 secreted in LPS-
stimulated BV2 cells. Moreover, there was a significant increase (p<0.001) in the 
secretion of level of IL-1β (~1.6-fold increase) in LPS-stimulated BV2 cells. On the 
other hand, skimmianine (10 µM) significantly inhibited (p<0.01) the level of production 
of IL-1β (~ 1.2-fold) in LPS-stimulated BV2 cells in relation to LPS stimulated cells 
alone. A further significant inhibition (p<0.001) was observed at 20 µM (~1.4-fold) and 
30 µM (~1.5-fold) of skimmianine.  
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The effect of skimmianine on the level of IL-10 secreted in LPS induced 
neuroinflammation were investigated. Result showed a significant decrease (p<0.001) 
in the production of IL-10 (~0.6-fold decrease) in LPS-stimulated BV2 cells when 
compared to unstimulated cells. However, skimmianine at 10 µM significantly 
increased (p<0.01) the secretion of IL-10 (~0.8-fold decrease) in LPS-induced BV2 
cells in comparison to LPS control. Moreover, skimmianine exerted a further increase 
(p<0.001) in the level of IL-10 produced at 20 µM and 30 µM. Collectively, these results 
show that skimmianine at 10, 20 and 30 µM reduced neuroinflammation by inhibiting 
the levels of pro-inflammatory cytokines (TNFα, IL-1β and IL-6) secretion and 






Figure 3.3-9: Skimmianine decreased TNFα, IL-1β and IL-6 production and increased 
IL-10 secretion in BV2 microglia cells stimulated with LPS 
BV2 cells were treated with or without skimmianine (10, 20 and 30 µM) and then, stimulated with LPS 
(100 ng/ml) for 24 hours. Afterwards, cytokine levels of (a) TNFα, (b) IL-1β, (c) IL-6 and (d) IL-10 were 
analysed in the cell culture supernatants using ELISA technique. Three independents experiments were 
done and values obtained were calculated as mean ± SEM. Statistical analysis was done by post-hoc 
Student Newman-Keuls test with one-way ANOVA (multiple comparisons ααα p<0.001 in comparison 
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3.4.3.2 Skimmianine reduced nitrite production and iNOS protein levels in 
LPS-activated BV2 microglia 
Studies have shown an increased production of NO through iNOS from activated 
microglia cells in neuroinflammation (Asiimwe et al., 2016). In addition, excessive 
generation of NO and iNOS in activated cells have been shown to cause neurotoxicity 
and neuroinflammation (Yuste et al., 2015). Hence, inhibition of secreted NO and 
iNOS from activated microglia cells reduces their excessive production level in 
neuroinflammation. Effect of skimmianine on the levels of nitric oxide (NO) production 
in LPS activated BV2 cells were determined. The outcome of this study showed a 
significant increase (p<0.001) in the levels of NO (~16.3-fold increase) released from 
BV2 cells stimulated with LPS in comparison to untreated BV2 cells. Pre-treatment 
with skimmianine significantly reduced (p<0.001) the level of NO produced at a 
concentration of 10 µM (~1.4-fold decrease) in LPS activated BV2 cells when 
compared to LPS stimulated cells alone. A further significant reduction (p<0.001) was 
detected on treatment of LPS stimulated BV2 cells with skimmianine at 20 µM (~1.4-
fold) and 30 µM (~1.8-fold). Following the inhibitory effect of skimmianine on NO, there 
was a further investigation on the effect of skimmianine on expression of iNOS protein 
using immunoblotting method. A marked increased (p<0.001) level of iNOS 
expression (~3.2-fold increase) was observed on treatment with LPS when compared 
to untreated cells. However, pre-treatment with skimmianine significantly inhibited 
(p<0.01) expression of iNOS at 10 µM (16% reduction) in LPS activated BV2 cells in 
relation to LPS induced cells alone. In addition, further significant inhibition (p<0.001) 
were observed at 20 and 30 µM of skimmianine (40.7% and 62.4% decrease 
respectively) when compared to BV2 cells treated with LPS only. These results 
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suggest the inhibitory role of skimmianine on increased level of NO and iNOS protein 






Figure 3.3-10: Skimmianine suppressed nitric oxide (NO) release (a) and inducible 
nitric oxide (iNOS) protein expression (b) in cultured BV2 cells activated with LPS 
Skimmianine (10, 20 and 30 µM) was used to pre-treat BV2 cells for 30 minutes and then stimulated 
with LPS (100 ng/ml) for 24 hours. Subsequently, cell culture supernatants and cytoplasmic extract 
were collected and analysed for production of NO and protein expression of iNOS. Skimmianine 
inhibited nitric oxide (NO) production (a) through inhibiting inducible nitric oxide (iNOS) protein 
expression (b) in BV2 cells stimulated with LPS. Values are expressed as mean ±SEM for 3 separate 
experiments. Analysis was done using one-way ANOVA with post-hoc Student Newman-Keuls test ( ααα 
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3.4.3.3 Skimmianine reduced PGE2 production and inhibited COX-2 protein 
expression in LPS activated BV2 microglia 
Reports have shown the involvement of PGE2/ COX-2 pathway in activated microglia 
cells to induce neuroinflammation in neurodegenerative diseases (Sil & Ghosh, 2016; 
Weiwer, 2018). As a result, inhibition of secreted PGE2 level through reducing 
expression of COX-2 protein in activated microglia cells is crucial in regulating 
neuroinflammatory responses. Effect of skimmianine on production of PGE2 and COX-
2 expression in LPS stimulated BV2 cells were investigated in this study. 
Result shows that in BV2 cells, LPS induced a significant increase (p<0.001) in the 
level of PGE2 produced (~5.2-fold increase) relative to untreated cells. However, there 
was a marked reduction (p<0.01) on treatment of LPS stimulated BV2 cells with 
skimmianine at 10 µM (~ 1.2-fold decrease) in comparison to LPS stimulated cells 
alone. A further significant decrease (p<0.001) was observed at 20 (~1.5-fold) and 30 
µM (~2-fold reduction) of this compound. Afterwards, immunoblotting experiments 
were done on COX-2 protein in explaining the mechanism by which PGE2 were 
secreted. Observation from this result revealed a significant increase (p<0.001) in 
expression of COX-2(~3.8-fold). On the other hand, skimmianine at 10 µM inhibited 
COX-2 significantly (p<0.01) (16% reduction), while 20 and 30 µM of skimmianine 
showed a further significant inhibition (p<0.001) of COX-2 expression (38% and 62% 
decrease respectively), in relation to LPS control. Observed results indicates that 
skimmianine decreased of PGE2 production by suppressing the expression of COX-2 







Figure 3.3-11: Skimmianine attenuated PGE2 production and COX-2 protein 
expression in LPS activated BV2 microglia 
Cultured microglia BV2 cells were incubated with or without skimmianine (10, 20 and 30 µM) for 30 
minutes and subsequently stimulated with LPS (100 ng/ml) for 24 hours. Skimmianine attenuated PGE2 
production (a) and COX-2 protein expression (b) in BV2 microglia. Values are calculated as mean ±SEM 
for 3 separate experiments Statistical analysis was done using one-way ANOVA with post-hoc Student 
Newman-Keuls test (multiple comparisons ααα p<0.001 in comparison with the untreated cells and 
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3.4.3.4 Skimmianine inhibited activated NF-КB signaling pathway 
NF-ΚB has been described to play an important role to control the expression of pro-
inflammatory cytokines and enzymes such as iNOS, COX-2, TNFα and IL-6 (Biswas 
& Bagchi, 2016). Following the inhibitory effect of skimmianine on the increased level 
of COX-2, iNOS, and pro-inflammatory cytokines (TNFα, IL-1β and IL-6), a luciferase 
reporter gene assay was used to elucidate the effect of skimmianine on NF-ΚB-
dependent gene transcription. Result in Figure 3.3-12a shows a significant activation 
(p<0.001) of NF-ΚB-driven gene transcription (~5.5-fold increase) in transfected 
HEK293 cells stimulated with TNFα in comparison to untreated cells. However, there 
was a marked reduction (p<0.01) of NF-ΚB mediated luciferase reporter gene by 
skimmianine at 10 µM (~1.2-fold reduction) and a further significant inhibition 
(p<0.001) at 20 µM (~1.4-fold decrease) and 30 µM (~2.1-fold decrease) of this 
compound when compared to HEK293 cells treated with TNFα. Moreover, 
translocation of NF-ΚB into the nucleus after degradation of IΚB causes activation of 
genes with DNA binding sites for NF-ΚB including, genes that encodes for pro-
inflammatory cytokines, iNOS and COX-2 to regulate their production(Biswas & 
Bagchi, 2016; Feng et al., 2017). Hence, inhibiting the binding of NF-ΚB to DNA is 
important in reducing transactivation of NF-ΚB. The effect of skimmianine on the DNA-
binding activity of NF-ΚB was further elucidated in BV2 microglia stimulated by LPS. 
Investigation in Figure 3.3-12b indicates an increase in the DNA binding of NF-ΚB 
(~2.2-fold increase) significantly (p<0.001) in comparison to unstimulated BV2 cells. 
Conversely, skimmianine at 20 µM significantly decreased (p<0.01) the DNA binding 
of NF-ΚB (21% decrease) while there was a further marked reduction (p<0.001) at 30 






Figure 3.3-12: Skimmianine inhibited neuroinflammation through NF-κB signaling 
pathway  
(A) Skimmianine significantly inhibited activity of NF-κB in transfected HEK293 cells induced by TNFα. 
Transfected HEK293 cells were stimulated with TNFα (1ng/ml) in presence or absence of skimmianine 
(10, 20 and 30 µM) for 6 hours. (B) Skimmianine at 20 and 30 µM decreased DNA binding activity of 
NFκB in LPS stimulated BV2 microglia cells. Subsequently, luminescence was measured. Nuclear cell 
lysates were added to wells pre-coated with NFκB oligonucleotide, followed by addition of NFκB p65 
antibody and secondary antibody. Thereafter, absorbance was measured on a microplate reader. 
Analysis of data was done on 3 independent experiments using one-way ANOVA with post-hoc Student 
Newman-Keuls test (multiple comparisons ααα p<0.001 in relation to untreated cells and **p<0.01, 
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3.4.3.5 Skimmianine inhibits nuclear translocation of NF-κB p65, 
phosphorylation and degradation of IκB in LPS-activated BV2 cells 
Based on the inhibitory effect of skimmianine on transcriptional activity of NF-κB, 
investigation was further done to elucidate whether anti-neuroinflammatory effect of 
skimmianine was mediated by interfering with the NF-κB signalling pathway. In the 
cytoplasm, inactive NF-κB remains bound to the inhibitor of κB (IκB) until an 
inflammatory stimulus such as LPS causes an activation to phosphorylate IκB kinase 
(IKK). Subsequently, IKK phosphorylates IκB leading to dissociation and translocation 
of active NF-ΚB-p65 subunit into the nucleus to initiate the transcription of inflammatory 
genes including iNOS and COX-2. Also, proteasomal degradation of IκBα occurred in 
the cytoplasm.  
Firstly, western blot experiments were done to elucidate the effect of skimmianine on 
IKK and IκB phosphorylation in LPS-activated microglia cells. On stimulation of BV2 
cells with LPS, result in Figure 3.3-13a reveal a significant (p<0.001) increase in the 
level of IKK phosphorylation (~5-fold increase) in comparison to unstimulated cells. 
However, pre-treatment with skimmianine at 10, 20 and 30 µM did not significantly 
reduce the increased level of IKK phosphorylation when compared to LPS control. 
Furthermore, results inFigure 3.3-13b shows a significant increase (p<0.001) in the 
level of IκBα phosphorylation (~2.8-fold increase) was observed on stimulation of BV2 
cells with LPS in relation to untreated cells. In addition, there was a marked level 
(p<0.001) of total IκB degradation (~1.8-fold decrease) in BV2 cells induced by LPS 
when compared to unstimulated cells. On the other hand, there was a marked 
reduction (p<0.05) in the phosphorylation of IκBα (1.1-fold decrease) on treatment of 
BV2 cells with 10 µM of skimmianine. In addition, skimmianine at 20 µM (~1.3-fold) 
and 30 µM (~1.8-fold) inhibited phosphorylation of IκB significantly (p<0.001) in 
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comparison to LPS stimulated cells. Moreover, Figure 3.3-13c shows that skimmianine 
at 10, 20 and 30 µM increased the level of total IκB (88%, 91% and 94% respectively) 
in LPS-stimulated BV2 cells when compared to untreated cells. Observations from the 
inhibitory activity of skimmianine on phosphorylation and degradation of IκBα led to 
further studies in determining the effect of skimmianine on translocation of NF-ΚB-p65 
subunit into the nucleus. Cultured BV2 cells were treated with skimmianine for 30 
minutes and followed by stimulation with LPS (100 ng/ml) for 1 hour. Figure 3.3-13d 
shows results from immunoblotting experiments and revealed a significant increase in 
the level (p<0.001) of NF-ΚB p65 phosphorylation (~4-fold increase) in LPS stimulated 
BV2 cells when compared to unstimulated cells. However, the levels of 
phosphorylated p65 were markedly inhibited (p<0.01) on pre-treatment with 
skimmianine 10 µM (15.9% reduction) in relation to LPS treated cells. Additionally, 
skimmianine showed a marked inhibition of phosphorylated p65 (p<0.001) at 20 and 
30 µM (37% and 60.1% decrease respectively) when compared to untreated cells. 
Afterwards, immunofluorescence analysis was performed to further investigate the 
effect of skimmianine on levels of phosphorylated p65 in BV2 cells. Results showed 
an increase in the expression of NF-ΚB p65 in LPS induced BV2 cells when compared 
to untreated cells. In contrast, skimmianine (10, 20 and 30 µM) reduced the expression 




    
 
   
 
Figure 3.3-13: Skimmianine inhibits IкB phosphorylation, degradation and nuclear 
translocation of NF-КB p65 in BV2 cells activated with LPS 
(a) Skimmianine did not significantly reduce phosphorylation of IKK. In contrast, skimmianine 
significantly inhibited (b) phosphorylation of IкB, (c) degradation of IKB and (d) translocation of NF-КB 
p65 subunit in LPS activated BV2 cells. Cultured BV2 cells were stimulated with LPS (100 ng/ml) in 
the presence or absence of skimmianine (10, 20 and 30 µM)) for 1 hour. At the end of the incubation, 
cytoplasmic or nuclear extract was collected and western blot was performed to analyse p65 subunit 
and IҡB protein expression. Analysis was done using one-way ANOVA with post hoc Student 
Newman–Keuls test (multiple comparisons, ααα p<0.001 in comparison with the untreated cells and 
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Figure 3-3-14: Effect of skimmianine on p65 NF-кB protein expression in LPS 
activated microglia 
Immunofluorescence experiments was done to evaluate the effects of skimmianine (10, 20 and 30 
µM) on p-p65 NF-кB protein expression in LPS activated microglia at 1 hour. Activated microglia cells 
were labelled with p-p65 antibody and counterstained with DAPI. Images were acquired using EVOS® 
Floid ® cell imaging and analysed using image J   
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3.4.3.6 Skimmianine reduced neuroinflammation-mediated neurotoxicity in 
HT22 hippocampal neuronal cells  
Numerous studies have associated neuroinflammation as a result of activated 
microglia cells activation with the pathogenesis of neurodegenerative diseases 
(Bronzuoli, Rosanna, Iacomino, Steardo, & Scuderi, 2016). In addition, excessive 
production of pro-inflammatory cytokines from activated microglia cells have been 
reported to cause neurotoxicity and neuronal death (Schain et al., 2017). Considering 
the inhibitory effect of skimmianine on LPS-activated neuroinflammation, further study 
was done to investigate the neuroprotective effect of skimmianine on HT22 cells 
induced by conditioned medium from LPS-induced BV2 microglia cells. BV2 cells were 
treated with skimmianine (10, 20 and 30 μM) for 30 minutes and subsequently 
stimulated with LPS (1μg/ml) for 24 hours. Afterwards, the levels of NO and TNFα 
were analysed in conditioned medium from LPS-stimulated BV2 microglia cells prior 
to experiments on the neuroprotective effect of skimmianine. This was done to confirm 
LPS stimulation resulted in neuroinflammation and also to show the inhibitory effect of 
skimmianine on neuroinflammation before HT22 cells were exposed to the conditioned 
medium. Results showed a significant (p<0.001) elevation in levels of NO (~4.5-fold 
increase) and TNFα (~4.6-fold increase) in LPS induced BV2 microglia cells in 
comparison to untreated cells. However, pre-treatment with skimmianine at 10, 20 and 
30 µM showed a significant reduction (p<0.001) in the levels of NO (20.4%, 42.1% 
and 62% inhibition, respectively) in comparison to LPS stimulated cells. In addition, 
the elevated levels of TNFα was significantly (p<0.01) inhibited by skimmianine at 10 
µM (~1.2-fold decrease) and a further marked reduction (p<0.001) was observed at 
20 (~1.5-fold) and 30 µM (~2.3-fold) of this compound when compared to LPS-
activated BV2 cells.  
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Subsequently, investigations to assess the viability of HT22 cells (as an indication for 
neurotoxicity) induced by conditioned medium were determined by MTT assay. 
Results showed a significant (p<0.001) 45.4% decrease in viability of HT22 cells 
induced by conditioned medium from LPS stimulated BV2 cells. In contrast to this, pre-
treatment with skimmianine at 10 µM in conditioned medium from BV2 significantly 
increased (p<0.01) HT22 cell viability (68.6%. increase) In addition, concentrations of 
skimmianine at 20 and 30 µM elevated (p<0.001) the viability of HT22 cells (77.5% 
and 85.3% increase respectively) when compared to LPS treated cells in conditioned 
medium. In neuroinflammation, reduced level of microtubule associated protein 2 
(MAP2) have been associated with neurotoxicity (Karalija, Kelk, Wiberg, & Kingham, 
2016; Kaushal, Kumar, Mehra, & Dhar, 2018).  Investigation was done to show the 
expression of MAP2 in HT22 cells after treatment with conditioned medium from LPS-
activated BV2 cells. Results from immunofluorescence assay reveals a decrease in 
the expression of MAP2 protein in HT22 cells treated with conditioned medium from 
LPS activated BV2 cells. On the other hand, skimmianine (10, 20 and 30 µM) treated 
BV2 cells in the conditioned medium was observed to increase the expression of 






Figure 3.3-15: Skimmianine reduced neuroinflammation-mediated neurotoxicity in 
HT22 hippocampal neuronal cells  
Cultured BV2 cells were pre-incubated with skimmianine for 30 minutes and activated with LPS (1μg/ml) 
for 24 hours. Subsequently, determination of the levels of (a) NO by Griess assay and (b) TNFα by 
ELISA technique were analysed in the conditioned medium in LPS stimulated BV2 cells. Furthermore 
(c) MTT assay was used to assess the viability of HT22 cells stimulated by conditioned medium from 
LPS activated BV2 cells. Analysis was done using one-way ANOVA with post hoc Student Newman–
Keuls test (multiple comparisons, ααα p<0.001 in comparison with the untreated cells and **p<0.01 
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Figure 3-16: Effect of skimmianine on p65 NF-кB protein expression in LPS induced 
BV2 microglia 
Immunofluorescence assay were performed to elucidate the effect of conditioned medium from LPS 
activated microglia cells on MAP2 protein in HT22 cells. Skimmianine (10, 20 and 30 µM) on p-p65 NF-
кB protein expression in LPS (1 µg/ml) activated microglia at 1 hour. Activated microglia cells were 
labelled with p-p65 antibody and counterstained with DAPI. Images were acquired using EVOS® Floid 
® cell imaging and analysed using image J   
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3.4.3.7 Skimmianine did not affect the viability of BV2 cells  
MTT assay was used to elucidate the viability of BV2 microglia cells on pre-treatment 
with skimmianine (10, 20 and 30 µM) for 30 minutes and then, stimulation with LPS 
(100 ng/ml) for 24 hours. Observation from the result shows that skimmianine did not 
affect the viability of BV2 cells at the concentrations used in this experiment. 
 
Figure 3-17: Skimmianine did not decrease the viability of BV2 microglia cells 
Pre-treatment with skimmianine at concentration of 10, 20 and 30 µM did not decrease the viability of 
BV2 cells when stimulated with LPS (100 ng/ml) for 24 hours. MTT assay was used to determine the 
viability of BV2 cells after treatment. All values are expressed as mean ± SEM for 3 independent 
experiments. Statistical analysis was performed using one-way ANOVA with post-hoc Student 
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Research in the past have identified the involvement of activated microglia cells in 
neuroinflammation (Kempuraj et al., 2016). The role of neuroinflammation has been 
described to be a contributing factor to the progression of neurodegenerative diseases 
such as Parkinson’s disease, Multiple sclerosis and Alzheimer’s diseases (Chen et al., 
2016; Schain et al., 2017).In neuroinflammation, studies have shown activated 
microglia cells to cause excessive production of pro-inflammatory cytokines, which 
results in neurotoxicity (Schain et al., 2017). Therefore, reducing the elevated level of 
pro-inflammatory cytokines in neuroinflammation is crucial in treating neuro-
inflammatory related disorders. It is well-established that isolated compounds from 
medicinal plants are important in drug discovery and are beneficial in reducing 
inflammation in the CNS (Subedi, Gaire, Do, Lee, & Kim, 2016; Tomlinson & Akerele, 
2015).  
Results from bioassay guided fractionation of Z. zanthoxyloides extract showed the 
isolation of skimmianine from fraction 3 of Z. zanthoxyloides extract. Previous studies 
on Z. zanthoxyloides extract have reported the isolation of skimmianine and the proton 
and carbon NMR were similar to the results obtained in this current study (Adamska-
Szewczyk et al., 2016; Guetchueng et al., 2018). Skimmianine is a member of 
furoquinoline alkaloids isolated from Z. zanthoxyloides extract and its isolation is 
important in the development of drugs for therapeutic purpose.  
Investigations to determine the anti-neuroinflammatory activity of skimmianine are still 
unknown. In this current research, inhibitory effect of isolated skimmianine from Z. 
zanthoxyloides on neuroinflammation was elucidated in BV2 cells stimulated with LPS. 
Results in this study revealed that skimmianine reduced the level of significant pro-
inflammatory cytokines which includes IL-6, TNFα and IL-1β secreted from LPS-
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stimulated BV2 cells. In addition, a reduced level of IL-10, an anti-inflammatory 
cytokine was observed in BV2 cells activated with LPS. However, skimmianine 
elevated the level of IL-10 produced in LPS-activated microglia cells Observations 
from this results suggest that skimmianine inhibited neuroinflammation through 
reducing the secreted level of pro-inflammatory cytokines and increasing the degree 
of anti-inflammatory cytokine in LPS stimulated BV2 microglia cells. A previous in vivo 
study by Ratheesh et al; 2013 reported that isolated skimmianine from Ruta 
graveolens reduced the mRNA levels of IL-6 and TNFα in carrageenan induced rats 
(Ratheesh et al., 2013), hence supporting the outcome of this current study. The 
results in this study provides new evidence on the inhibitory effect of skimmianine on 
important pro-inflammatory cytokines (IL-6, TNFα and IL-1β) and anti-inflammatory 
cytokine (IL-10) using an in vitro model in BV2 microglia cells (brain resident 
macrophage cells).  
The role of excessive production of NO and increased expression of iNOS in 
neuroinflammation have been reported to cause neurotoxicity and play a major role in 
the pathology of neurodegenerative diseases (Yuste et al., 2015). Furthermore, 
elevated levels of nitric oxide (NO) and inducible nitric oxide synthase (iNOS) were 
observed on stimulation of BV2 cells with LPS in this study. Skimmianine significantly 
reduced the production of NO by inhibiting the expression of iNOS enzyme in LPS-
activated BV2 cells. These results indicate inhibitory effect of skimmianine on 
neuroinflammation by reducing the level of released NO and expressed iNOS enzyme 
in LPS-stimulated microglia cells. In other studies, skimmianine has been reported to 
inhibit the increased level of nitric oxide released in LPS-stimulated BV2 cells (Yoon 
et al., 2012). In addition, elevated level of NO in carrageenan induced rats was 
significantly inhibited by skimmianine (Ratheesh et al., 2013). Collectively, these 
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results suggest the inhibitory effect of skimmianine on NO production in 
neuroinflammation. 
Moreover, skimmianine suppressed the production of PGE2 by reducing the 
expression of COX-2 in BV2 cells stimulated with LPS. These results suggest 
skimmianine could suppress neuroinflammation in activated microglia cells by 
inhibiting COX-2 enzyme and its released PGE2 mediator. Observations from these 
results were also reported in a study by Ratheesh et al; 2013, that skimmianine caused 
a significant reduction in the concentration of PGE2 and activity of COX-2 in 
carrageenan induced rats. Hence, these studies suggest the inhibitory activity of 
skimmianine on neuroinflammation by reducing the level PGE2 and COX-2 enzyme. 
NF-κB, an essential transcription factor in neuroinflammation, has been well known to 
regulate the gene expression of COX-2, iNOS and genes that encodes pro-
inflammatory cytokines which includes IL-6 and TNFα (Serasanambati & Chilakapati, 
2016; Q. Zhang, Lenardo, & Baltimore, 2017). Investigations on the important role of 
NF-κB signalling pathway in neuroinflammation has made its inhibition a promising 
target, especially in treatment of neurodegenerative diseases. Following the result 
showing the inhibitory effect of skimmianine on produced pro-inflammatory cytokines, 
NO/iNOS and PGE2/COX-2 released from activated microglia cells, a further study 
showing the effect of skimmianine on translocation of NF-κB p65 and DNA binding 
were investigated. In neuroinflammation, there is translocation of activated NF-κB into 
the nucleus and binding of NF-κB to the DNA of inflammatory genes to mediate the 
transcription of inflammatory cytokines and mediators (Biswas & Bagchi, 2016). 
Outcome of this study showed that skimmianine inhibited NF-κB mediated luciferase 
transcription in HEK293 cells stimulated with TNFα. Furthermore, skimmianine 
reduced the binding of NF-κB to DNA in the nucleus. These results suggest that 
154 
 
skimmianine inhibited neuroinflammation by reducing NF-κB-DNA binding activity and 
transcription of activated NF-κB in the nucleus.  
As a result of the inhibitory role of skimmianine on activated NF-κB in BV2 cells, effect 
of skimmianine on upstream kinases of NF-κB signalling pathway were subsequently 
targeted. Result showed that skimmianine did not inhibit the phosphorylation of IKK. 
Reports have demonstrated one of the ways through which IKK inhibitors exerts its 
effect is by acting on adenosine triphosphate (ATP) binding site found on IKK molecule 
(Herrington et al., 2016). However, some IKK inhibitors have been reported not to be 
effective because other kinases cross react and compete with the binding site on IKK 
molecule (Prescott & Cook, 2018). Consequently, these reasons may explain why 
skimmianine could not inhibit IKK phosphorylation. Further investigation on the direct 
effect of skimmianine on IKK using kinase enzyme assays was not done in this study.  
Afterwards, the effect of skimmianine on IκB-α and NF-κB p65 subunit was 
determined. Result showed that skimmianine significantly blocked p-IκB-α and NF-κB 
p65 subunit phosphorylation. In addition, skimmianine restored the degradation of IκB-
α in LPS activated microglia cells. Taken together, these results showed that 
skimmianine did not exert its inhibitory effect on upstream of IκB-α but it attenuates 
neuroinflammation by targeting IκB-α/ NF-κB pathway in BV2 cells stimulated with 
LPS. These results are presented for the first time indicating the inhibitory activity of 
skimmianine on activated NF-κB signalling pathway in LPS-induced 
neuroinflammation in BV2 cells. Results from this study presents the first evidence in 
LPS-stimulated BV2 microglia cells suggesting that skimmianine reduces 
neuroinflammation by targeting IκB/ NF-κB signalling pathway but skimmianine was 
not effective on the upstream of IκB-α at the concentrations used in this study. 
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Furthermore, the neuroprotective effect of skimmianine on HT22 hippocampal 
neuronal cells were investigated. In neuroinflammation, the role of pro-inflammatory 
cytokines and mediators including NO, TNFα and reactive oxygen species (ROS) have 
been demonstrated to be neurotoxic. Results in this study revealed that skimmianine 
increased the viability of HT22 cells and also elevated the expression of MAP2 by 
reducing the increased levels of NO and TNFα in conditioned medium from LPS 
activated BV2 cells. The outcome of this study is presented for the first time suggesting 
the neuroprotective effect of skimmianine on HT22 cells. 
In summary, results from this study showed the isolation of skimmianine from Z. 
zanthoxyloides extract and previous studies have confirmed the isolation of this 
compound in same extract. Moreover, anti-neuroinflammatory activity of skimmianine 
on pro-inflammatory cytokines and inflammatory mediators in BV2 microglia cells were 
investigated. Also, neuroprotective effects of skimmianine on HT22 cells were 
determined. Previous studies on anti-inflammatory activity of skimmianine were done 
using in vivo model. This current study was done in BV2 microglia cell line and further 
investigations were done on the mechanisms involving the anti-neuroinflammatory 




4 Investigations on the effect of skimmianine on 
neuroinflammation induced by hemozoin in BV2 
microglia cells 
4.1 Background of this study 
Previous studies have shown an increased level of pro-inflammatory cytokines (IL-1β, 
IL-6 and TNFα) production on incubation of monocytes and macrophages with 
hemozoin (Dunst et al., 2017; Olivier et al., 2015; Perkins et al., 2011). Hemozoin is a 
malaria pigment derived from Plasmodium falciparum, a parasite that initiates the 
development of malaria in human through the bite of Anopheles mosquitoes 
(Ghazanfari et al., 2018; Hora et al., 2016). In addition, macrophages have been 
described to be the main site of cytokine secretion leading to increase in 
neuroinflammation observed in cerebral malaria (CM), a neurological complication of 
severe Plasmodium falciparum infections (Schofield & Grau, 2005; Urquhart, 1994). 
These reports suggest a role for neuroinflammation as one of the factors involved in 
the pathology of cerebral malaria. Studies conducted in vitro have also demonstrated 
a significant increase in production of nitric oxide (NO) in macrophage cells stimulated 
with hemozoin (Maritza Jaramillo, Gowda, Radzioch, & Olivier, 2003; Maneerat et al., 
2000). This suggests that hemozoin contributes to the progression of inflammation by 
increasing the level of NO production. Research in the past have also reported that 
hemozoin stimulates macrophages to increase the release of IL-1β cytokine and pro- 
IL-1β production by activating NLRP3 and caspase-1 enzyme (Shao et al., 2018). This 
implies that hemozoin elevated the level of IL-1β production in inflammation through 
activation of NLRP3 pathway. 
The role of hemozoin on brain macrophage cells has also been reported to cause an 
increase in pro-inflammatory factors, suggesting the effect of hemozoin in increasing 
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neuroinflammation in cells. A marked increase in the level of NO and pro-inflammatory 
cytokines (IL-1β, IL-6 and TNFα) was reported to be released by BV2 microglia cells 
stimulated with synthetic hemozoin (Velagapudi et al., 2019). Furthermore, previous 
studies have shown that hemozoin causes inflammation by stimulating TLR 2 and TLR 
9 which in turn activates NF-κB signalling pathway (Bafica et al., 2006; Coban et al., 
2005). This suggests the involvement of hemozoin in inflammation through activation 
of TLR/NF-κB signalling pathway. Moreover, an increase in phosphorylation of IκBα 
and p65 subunit of NF-κB was observed in human monocytes stimulated with 
hemozoin (M. Jaramillo et al., 2009; Olivier et al., 2015). Similarly, in hemozoin-
activated BV2 cells, an elevation in the phosphorylation of NF-κB p65 subunit and 
DNA binding activity of NF-κB were detected (Velagapudi et al., 2019). Observation 
from these studies indicate that hemozoin could increase the production of 
inflammatory cytokines and mediators in neuroinflammation through activation of NF-
κB signalling pathway in peripheral and brain macrophage cells. Therefore, inhibition 
of NF-κB and NLRP3 pathway in hemozoin activated microglia cells may reduce the 
level of inflammatory cytokines and mediators produced in neuroinflammation, an 
important factor involved in the pathogenesis of cerebral malaria.  
So far, investigation to determine the effect of skimmianine on hemozoin-induced 
neuroinflammation in BV2 microglia cells is unknown. This study therefore aims to 
investigate the effect of skimmianine on neuroinflammation induced by hemozoin in 
BV2 microglia cells with these specific objectives: 
1. To determine the effect of skimmianine on pro-inflammatory cytokines, NO and 
PGE2, iNOS and COX-2 in hemozoin-stimulated BV2 microglia cells 
2. To determine effects of skimmianine on NF-κB activity in BV2 microglia cells 
stimulated with hemozoin 
158 
 
3. To examine the role of skimmianine on NLRP3 inflammasome activation in 






4.2.1 Drug preparation and treatment 
Skimmianine was purchased from PhytoLab GmbH & Co.KG, Germany and dissolved 
in DMSO to a stock concentration of 0.1M. BV2 microglia cells were treated with 
skimmianine (10, 20 and 30 µM) for 30 minutes and then stimulated with hemozoin 
(400 µg/ml) for 24 hours or 1 hour, depending on each experiment. 
4.2.2 Cell culture 
4.2.2.1 Culture of BV2 cells 
BV2 microglia cell line ICLCATL03001 (Banca Biologica e Cell Factory, Italy) were 
cultured in RPMI 1640 medium (Life Technologies, UK) supplemented with 10% fetal 
bovine serum (Sigma), 1mM sodium pyruvate (Sigma), 100U/ml Penicillin and 
100mg/ml Streptomycin (Sigma). For the purpose of experiments, the cells were sub-
cultured, maintained in the incubator and seeded out in plates as described in 2.2.3.1.  
4.2.2.2 MTT assay for cell viability  
The viability of BV2 microglia cells pre-treated with skimmianine (10, 20 and 30 µM) 
and stimulated with hemozoin (400 µg/ml) were analysed by MTT assay (described in 
2.2.16) 
4.2.3 Measurement of Nitrite (Griess assay) 
Once cultured BV2 microglia cells reached confluence, the cells were pre-treated with 
skimmianine (10, 20 and 30 µM) for 30 minutes and then stimulated with hemozoin 
(400 µg/ml) for 24 hours. After incubation, cell culture supernatants were collected in 
epperndorf tubes and centrifuged at 1500 rpm for 5 minutes. Griess assay as 




4.2.4 ELISA assay 
In order to measure the levels of pro- and anti-inflammatory cytokine production in cell 
culture supernatants, BV2 cells were treated with skimmianine (10, 20 and 30 µM) and 
then, stimulated with hemozoin (400 µg/ml) for 24 hours. After incubation, levels of 
TNFα, IL-1β, IL-6 and IL-10 were measured in cell culture supernatants using ELISA 
technique as described in 2.2.6. 
4.2.5 Prostaglandin E2 measurement using enzyme immunoassay (EIA)  
Prostaglandin E2 levels in BV2 cell culture supernatants were measured (as described 
in 2.2.8) after treatment of BV2 microglia cells with skimmianine (10, 20 and 30 µM) 
for 30 minutes and activation with hemozoin (400 µg/ml) for 24 hours. 
4.2.6 Extraction of cytoplasmic cell lysates 
Prior to western blot experiments, extraction of cytoplasmic lysates (described in 2.2.9) 
was a step required to isolate lysates in the cytoplasm at the end of incubation of 
hemozoin-stimulated BV2 cells treated with skimmianine (10, 20 and 30 µM). 
4.2.7 Extraction of nuclear cell lysates 
Following incubation of hemozoin-stimulated BV2 cells treated with skimmianine (10, 
20 and 30 µM), nuclear extraction was performed as described in 2.2.10. 
4.2.8 Measurement of protein concentration  
After cytoplasmic and nuclear extraction, concentrations of proteins were determined 
(as shown in text 2.2.11) by Pierce Coomassie (Bradford) protein assay kit (Thermo 
Scientific, UK) before western blot experiments. 
4.2.9 Western blotting  
Western blotting (as described in 2.2.12) is a technique that is useful in detection 
of target protein according to their molecular weights. This technique mainly 
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involves separation of proteins in lysates by gel electrophoresis, transfer of 
proteins from gel onto membrane blot and detection of target proteins based on 
their molecular weights. Following the determination of protein concentration in 
cell lysates, western blotting technique were used to investigate the effect of 
skimmianine on expression of iNOS, COX-2, NF-B p65, phospho-IB-α, IB-α, 
NLRP3 and caspase-1 protein. 
4.2.10 NF-κB p65 transcription factor assay 
NF-B transcription factor assay (as described in 2.2.13) is an assay that investigates 
the binding of NF-B to the consensus binding site on the DNA. In this study, the effect 
of skimmianine (10, 20 and 30 µM) on binding of NFB-DNA binding in hemozoin-
stimulated BV2 microglia cells were determined. 
4.2.11  Immunofluorescence technique 
Immunofluorescence is an imaging technique (described in 2.2.14) that is important in 
detection of antigen by a specific antibody and this reaction is observed under 
fluorescence microscope. In this study, the effect of skimmianine (10, 20 and 30 µM) 





4.3.1 Skimmianine inhibited IL-6 and TNFα production and increased IL-10 
secretion in hemozoin-stimulated BV2 cells 
An increase in the production of pro-inflammatory cytokines (TNFα and IL-6) has been 
associated with neuroinflammation causing reduced neurocognitive function in 
cerebral malaria. Hence, reducing the levels of pro-inflammatory cytokines is crucial 
in targeting hemozoin-induced neuroinflammation. In this investigation, effect of 
skimmianine on level of TNFα in hemozoin-stimulated BV2 microglia cells were 
determined. Results in Error! Reference source not found. shows a significant 
elevation (p<0.001) in production of TNFα (~4.4-fold-increase) in hemozoin-stimulated 
BV2 microglia cells when compared to untreated cells. However, skimmianine at 10 
µM significantly reduced (p<0.01) the secretion of TNFα (74.3% decrease) in 
hemozoin-stimulated BV2 microglia cells when compared to hemozoin-stimulated BV2 
cells. A further significant inhibition (p<0.001) was observed in the level of TNFα in 
hemozoin-activated cells treated with 20 and 30 µM of skimmianine (56.7% and 49.3% 
inhibition respectively), in comparison to hemozoin stimulated BV2 cells. Furthermore, 
hemozoin (400 µg/ml) produced a marked elevation in the level of IL-6 (~5-fold 
increase) in BV2 microglia cells. However, results show that skimmianine (10 µM) 
produced a decrease in IL-6 production (~1.2-fold reduction) in hemozoin-stimulated 
BV2 microglia cells when compared to hemozoin activated cells alone. Further 
significant reduction (p<0.001) was detected in hemozoin-stimulated BV2 microglia 
cells when treated with 20 µM and 30 µM of skimmianine (~1.4-fold and ~1.9-fold 
decrease respectively), in comparison with BV2 cells stimulated with hemozoin only. 
Moreover, the effect of skimmianine on secretion of IL-10 was investigated in 
hemozoin-induced BV2 cells. The outcome of the investigation shows a ~0.54-fold 
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reduction in IL-10 production from hemozoin stimulated BV2 cells when compared to 
unstimulated cells. However, skimmianine at 10 µM significantly raised (p<0.01) the 
level of IL-10 (~1.3-fold increase) when compared with hemozoin stimulated cells. 
Further significant upregulation (p<0.001) of IL-10 production were detected in 
hemozoin stimulated cells when treated with skimmianine at 20 and 30 µM (~1.6-fold 






Figure 4-1: Skimmianine inhibited IL-6 and TNFα secretion and increased IL-10 
production in BV2 microglia cells induced by synthetic hemozoin 
Cultured BV2 cells were treated with skimmianine (10, 20 and 30 µM) for 30 minutes and then, induced 
by hemozoin (400 µg/ml) for 24 hours. Thereafter, cytokine levels of (a) TNFα, (b) IL-6 and (c) IL-10 
were measured in the cell culture supernatants by ELISA technique. Data were plotted as mean ± SEM 
for three separate experiments. Student Newman-Keuls test followed by one-way ANOVA were used 
for statistical analysis (multiple comparisons, ααα p<0.001 in comparison with the unstimulated cells 
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4.3.2 Skimmianine inhibited nitrite production by reducing the expression 
of iNOS protein in hemozoin-stimulated BV2 microglia cells 
Reports have shown that increased secretion of nitric oxide (NO) caused by hemozoin 
leads to neurotoxicity which has been associated with cognitive dysfunction observed 
in cerebral malaria patients. (Sahu et al., 2015). This suggests a role for nitric oxide in 
neuroinflammation detected in pathogenesis of cerebral malaria. Therefore, inhibition 
of NO is important in reducing neuroinflammation, especially in neurological sequelae 
of malaria infection. Results of this study revealed that incubation of hemozoin with 
BV2 microglia cells resulted in a significant increase (p<0.001) in NO production. 
However, secretion of NO was reduced at 10 µM of skimmianine (~1.2-fold decrease) 
in hemozoin-stimulated BV2 cells in comparison to hemozoin stimulated cells only. In 
addition, there was a further significant decrease in the levels of NO by skimmianine 
at 20 µM (~1.7-fold decrease) and 30 µM (~2.1-fold decrease). Thereafter, studies 
were carried out to investigate the effect of skimmianine on expression of iNOS protein 
by western blot experiment. Results show a significant increase (p<0.001) in the level 
of iNOS protein in BV2 cells stimulated with hemozoin when compared to untreated 
cells. In contrast, a significant reduction (p<0.05) in the level of iNOS protein was 
observed at 10 µM of skimmianine in hemozoin induced BV2 cells when compared to 
hemozoin treated cells. Further significant inhibition of iNOS protein expression was 
detected in hemozoin stimulated BV2 cells treated with 20 µM and 30 µM of 







Figure 4-2: Skimmianine decreased nitric oxide (NO) release (a) and inducible nitric 
oxide (iNOS) protein expression (b) in hemozoin-induced BV2 cells 
Cultured BV2 cells were pre-treated with skimmianine (10, 20 and 30 µM) for 30 minutes and 
subsequently stimulated with hemozoin (400 µg/ml) for 24 hours. Then, cell culture supernatants and 
cytoplasmic extract were collected and analysed for secretion of NO and protein expression of iNOS. 
Skimmianine inhibited (a) nitric oxide (NO) production through inhibiting (b) inducible nitric oxide (iNOS) 
protein expression in BV2 cells stimulated with hemozoin. Values are represented as mean ±SEM for 
3 separate experiments. Analysis was done using one-way ANOVA with post-hoc Student Newman-
Keuls test ( ααα p<0.001 in comparison with the untreated cells and (*p<0.05, **p<0.01,***p<0.001) shows 
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4.3.3 Skimmianine inhibited PGE2 production by reducing COX-2 protein 
expression in hemozoin-stimulated BV2 microglia cells 
The role of COX-2 protein expression in the brain have been reported to play an 
important role in murine model of CM infected with plasmodium berghei ANKA to 
increase the level of PGE2 in neuroinflammation (Ball, MacDougall, McGregor, & Hunt, 
2004; Dunst et al., 2017) . This suggests the involvement of neuroinflammation in the 
pathogenesis of cerebral malaria. Therefore, inhibition of PGE2 secretion and COX-2 
protein expression may be beneficial in reducing neuroinflammation observed in CM. 
This study investigates the effect of skimmianine on level of PGE2 and COX-2 protein 
in hemozoin-activated BV2 cells. Stimulation of BV2 cells with hemozoin resulted in a 
marked increase (p<0.001) of PGE2 production (~7-fold increase) in comparison to 
unstimulated BV2 cells. However, pre-treatment with skimmianine at 10 µM 
significantly decreased (p<0.01) the level of PGE2 (74.4% decrease) in hemozoin-
stimulated cells in comparison to hemozoin-activated cells. A further significant 
reduction in PGE2 secretion was detected at 20 and 30 µM of skimmianine (53.3% and 
57.2% reduction respectively) in hemozoin-stimulated cells in relation to hemozoin-
activated cells only. Thereafter, effect of skimmianine on level of COX-2 protein were 
determined with western blots experiments. Result showed an elevated level 
(p<0.001) of COX-2 protein (~3.2-fold increase~) in hemozoin treated cells in relation 
to untreated cells. In contrast, 10 µM of skimmianine significantly (p<0.05) reduced the 
expression of COX-2 protein (1.1-fold decrease) in hemozoin-induced BV2 cells when 
compared to BV2 cells stimulated with hemozoin alone. Moreover, in hemozoin 
stimulated cells, there was a further inhibition of expression of COX-2 protein at 20 
and 30 µM of skimmianine (1.4-fold and ~2.1-fold decrease, respectively), in relation 
to hemozoin activated cells. These results suggest that skimmianine inhibited PGE2 
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Figure 4-3: Skimmianine reduces PGE2 production and COX-2 protein expression in 
hemozoin induced BV2 cells 
BV2 cells were treated with or without skimmianine (10, 20 and 30 µM) for 30 minutes and activated 
with hemozoin (400 µg/ml) for 24 hours. Skimmianine inhibited PGE2 production (a) and COX-2 protein 
expression (b) in BV2 microglia. Values are presented as mean ±SEM for 3 separate experiments 
Statistical analysis was done using one-way ANOVA with post-hoc Student Newman-Keuls test 
(multiple comparisons ααα p<0.001 in comparison with the untreated cells and (*p<0.05, **p<0.01, 
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4.3.4 Skimmianine suppressed pro-IL-1β and IL-1β secretion through 
inhibition of NLRP3 protein and caspase-1 activity in hemozoin 
activated BV2 microglia 
In the CNS, NLRP3 inflammasome has been demonstrated to be involved in 
progression of neuroinflammation by causing regulating the secretion of cytokines 
including IL-1β (Shao et al., 2018). Activation of NLRP3 inflammasome by stimuli such 
as hemozoin causes activation of pro-caspase -1 to caspase-1 and this further leads 
to conversion of pro-IL-1β to IL-1β (Mendiola & Cardona, 2017). This study determines 
the effect of skimmianine on pro-IL-1β and IL-1β in hemozoin activated BV2 microglia 
cells. The outcome of this study shows in Figure 4-4: Skimmianine suppressed the 
levels of IL-1β and pro-IL-1β secretion by inhibiting NLRP3 protein and caspase-1 
activity in hemozoin activated BV2 microglia 
 a significant increase (p<0.001) in the secretion of pro-IL-1β and IL-1β (~2.7-fold and 
~4.2-fold increase, respectively) in BV2 cells stimulated with hemozoin when 
compared to unstimulated cells. However, there was a marked decrease (p<0.01) in 
the degree of pro-IL-1β when treated with 10 and 20 µM of skimmianine (~1.1-fold and 
~1.4-fold reduction respectively) in hemozoin activated BV2 microglia cells when 
compared to hemozoin stimulated cells. Further significant reduction (p<0.001) of pro-
IL-1β secretion was detected at 30 µM of skimmianine (~1.8-fold decrease). 
Furthermore, in hemozoin activated BV2 microglia cells, the level of IL-1β reduced 
significantly (p<0.01) on pre-treatment with 10 and 20 µM of skimmianine (87.2%.and 
82.9% respectively) in relation to hemozoin stimulated cells. Moreover, 30 µM of 
skimmianine produced a more significant inhibition (p<0.001) of secretion of IL-1β 
(72.4% decrease) in hemozoin stimulated BV2 microglia cells when compared to 
hemozoin activated cells.  
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Moreover, the effect of skimmianine on caspase-1 and NLRP3 protein in hemozoin 
activated BV2 microglia cells were also determined. Caspase-1 activity was measured 
by caspase-1 inflammasome assay and immunoblotting technique. Stimulation of BV2 
cells with hemozoin resulted in a significant elevation (p<0.001) in caspase-1 activity 
(~7.6-fold increase) in comparison to unstimulated BV2 cells. However, skimmianine 
at 10, 20 and 30 µM significantly (p<0.001) reduced caspase-1 activity (~1.3-fold, 
~1.9-fold and ~2.9-fold decrease respectively) in hemozoin stimulated cells in relation 
to hemozoin-activated cells. Afterwards, skimmianine (10, 20 and 30 µM) significantly 
reduced the expression of caspase-1 protein.by western blotting technique in 
hemozoin stimulated cells when compared to hemozoin stimulated cells. Moreover, in 
hemozoin-stimulated BV2 cells, an elevated (p<0.001) level of NLRP3 protein (~2.5-
fold increase) was observed when compared to unstimulated BV2 cells. However, a 
decrease in the level of NLRP3 protein was detected in hemozoin –stimulated BV2 
cells treated with 10 µM of skimmianine (~1.2-fold reduction) in comparison to 
hemozoin-stimulated BV2 cells. Additionally, in hemozoin –stimulated BV2 cells, 
further inhibition of NLRP3 protein expression was observed in BV2 microglia cells 
when treated with 20 and 30 µM of skimmianine (1.3-fold and ~1.8-fold reduction, 
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Figure 4-4: Skimmianine suppressed the levels of IL-1β and pro-IL-1β secretion by 
inhibiting NLRP3 protein and caspase-1 activity in hemozoin activated BV2 microglia 
Skimmianine (10, 20 and 30 µM) significantly inhibited (a) pro-IL-1β and (b) IL-1 β production (c) 
caspase-1 activation measured by caspase-1 Glo inflammasome assay in hemozoin induced BV2 
microglia (d) expression of caspase-1 by immunoblotting experiment and (e) expression of NLRP3 
protein. BV2 cells were stimulated with hemozoin (400 μg/ml) in the presence or absence of 
Skimmianine (10, 20 and 30 µM) for 24 hours. At the end of the incubation period, supernatants were 
collected for ELISA measurements. For western blot experiment, cytoplasmic extract was collected at 
the end of 24 hours’ incubation and western blot was performed to measure protein expression of 
caspase-1 and NLRP3 protein. Data were expressed as mean ±SEM for 3 separate experiments. 
Analysis was done using one-way ANOVA with post-hoc Student Newman-Keuls test (multiple 
comparisons. ααα p<0.001 in comparison with the untreated cells and * p<0.05, **p<0.01, ***p<0.001) in 
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4.3.5 Skimmianine reduces neuroinflammation through NF-κB signaling 
pathway in hemozoin-stimulated BV2 microglia cells 
Previous studies have shown the role of hemozoin on activation of NF-ΚB signalling 
pathway by toll-like receptor 2 (TLR-2) and toll like receptor-9 (TLR9) (Bafica et al., 
2006; Wagner, 2010). This suggests that there is an involvement of hemozoin in 
neuroinflammation through NF-ΚB signalling pathway. Reports have further 
demonstrated that activation of NF-ΚB leads to the translocation of NF-ΚB p65 into the 
nucleus and subsequently binds to the DNA for transcription of genes including iNOS. 
The production of NO, IL-6 and TNFα as a result of activated NF-ΚB have been 
reported to increase neuroinflammation, which is involved in cognitive dysfunction 
observed in CM patients. Hence, inhibition of activated NF-κB pathway is important 
and may be a potential target in reducing neuroinflammation in cerebral malaria. Effect 
of skimmianine on DNA binding activity of NF-κB in hemozoin stimulated BV2 cells 
were determined in this study 
Result in Figure 4-5 shows a significant increase (p<0.001) in the DNA binding of NF-
ΚB (~ 1.9-fold) in BV2 microglia cells stimulated with hemozoin when compared to 
unstimulated BV2 cells. In contrast, skimmianine at 10 μM significantly reduced 
(p<0.05) the DNA binding activity to NF-ΚB (~ 1.1-fold decrease) in hemozoin 
stimulated BV2 cells when compared to hemozoin stimulated cells. Moreover, in 
hemozoin stimulated cells, skimmianine at 20 and 30 µM resulted in a further inhibition 
(p<0.001) of DNA binding activity to NF-ΚB (~ 1.2-fold and ~ 1.4-fold respectively) 
when compared to hemozoin stimulated cells. Furthermore, the effect of skimmianine 
on expression of IκB and NF-κB -p65 subunit in BV2 cells stimulated with hemozoin 
were investigated. Result showed a significant increase (p<0.001) in the 
phosphorylation of NF-ΚB p65 subunit (~3.4-fold increase) in hemozoin stimulated BV2 
174 
 
cells when compared to unstimulated cells. However, skimmianine at 10 µM 
significantly (p<0.05) inhibited phosphorylation of NF-ΚB p65 (~1.1-fold decrease) in 
hemozoin-stimulated BV2 cells in comparison to hemozoin-activated cells. Moreover, 
in hemozoin-stimulated cells, skimmianine.at 20 and 30 µM significantly reduced 
(p<0.001) the phosphorylation of NF-ΚB p65 subunit (~1.3-fold and ~2.1-fold decrease 
respectively) in comparison to hemozoin-stimulated cells. 
Thereafter, immunoblotting experiments were done to investigate the effect of 
skimmianine on p-IκBα phosphorylation and IκBα degradation in BV2 cells stimulated 
by hemozoin. The outcome of this experiment shows a significant increase (p<0.001) 
in the level of p-IκBα phosphorylation (~2.3-fold increase) in hemozoin-induced BV2 
cells when compared to unstimulated BV2 cells. However, pre-treatment with 
skimmianine at 10 µM resulted in a marked reduction (p<0.01) of p-IκBα 
phosphorylation (~1.1-fold decrease) in hemozoin-stimulated BV2 cells in comparison 
to hemozoin-stimulated cells. Furthermore, 20 and 30 µM of skimmianine caused a 
significant inhibition (p<0.001) of IκBα phosphorylation (~1.2-fold and ~2-fold 
reduction respectively) in relation to BV2 cells treated with hemozoin alone. Moreover, 
in hemozoin-stimulated BV2 cells, there was a marked degradation (p<0.001) of total 
IκB (44.6% decrease) in comparison to unstimulated cells. In contrast to this, Error! 
Reference source not found.d present that skimmianine (10, 20 and 30 µM) 
significantly increased (p<0.001) total IκB ( 68%, 85% and 93% respectively) in 








Figure 4-5: Skimmianine inhibited neuroinflammation through NF-κB signaling 
pathway in hemozoin activated BV2 microglia cells 
Skimmianine (10, 20 and 30 µM) (a) decreased DNA binding activity of NFκB in hemozoin stimulated 
BV2 microglia cells. (b) translocation of NF-КB p65 subunit (c) phosphorylation of IкB, (d) degradation 
of IKB and in hemozoin stimulated BV2 cells. Cultured BV2 cells were stimulated with hemozoin (400 
μg/ml) in the presence or absence of skimmianine (10, 20 and 30 µM)) for 1 hour. At the end of the 
incubation, cytoplasmic or nuclear extract was collected and western blot was performed to analyse 
p65 subunit and IҡB protein expression. Analysis of data was done on 3 independent experiments using 
one-way ANOVA with post-hoc Student Newman-Keuls test (multiple comparisons ααα p<0.001 in 
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4.3.6  Pre-treatment with skimmianine did not affect the viability of BV2 
cells in hemozoin-stimulated BV2 cells 
The viability of BV2 microglia cells were assessed when pre-treated with skimmianine 
(10, 20 and 30 µM) for 30 minutes and then stimulated with hemozoin (400 µg/ml) for 
24 hours. Results in Figure 4-6: Skimmianine did not suppress the viability of BV2 
microglia cells in hemozoin-activated BV2 microglia cells 
 shows that skimmianine did not affect the viability of BV2 cells at the concentrations 
used in this experiment.  
 
Figure 4-6: Skimmianine did not suppress the viability of BV2 microglia cells in 
hemozoin-activated BV2 microglia cells 
Skimmianine (10, 20 and 30 µM) did not reduce the viability of BV2 cells when stimulated with hemozoin 
(400 μg/ml) for 24 hours. MTT assay was used to determine the viability of BV2 cells after treatment. 
All values are expressed as mean ± SEM for 3 separate experiments. Statistical analysis was performed 
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Investigations on the role of neuroinflammation in cerebral malaria have demonstrated 
a decline in neurocognitive function of CNS (Song, Pei, Yao, Wu, & Shang, 2017). 
Studies have further reported an association between hemozoin and secretion of pro-
inflammatory cytokines in post-mortem analysis done on brain tissue of CM patients 
(Dunst et al., 2017). In BV2 microglia cells, effect of skimmianine on hemozoin induced 
neuroinflammation were investigated in this study.  
Skimmianine significantly reduced the level of TNFα and IL-6 in hemozoin-stimulated 
BV2 microglia cells. In addition, skimmianine evidently increased the secretion of IL-
10 in hemozoin-induced BV2 microglia cells. The outcome of this finding is reported 
for the first time in this study. Other studies have identified the potential role of a related 
quinolone alkaloid, berberine in inhibition of inflammation in severe plasmodium 
falciparum infection (Kumar, Chopra, Mukherjee, Pottabathini, & Dhull, 2015). 
Excessive production of pro-inflammatory cytokines in neuroinflammation have been 
demonstrated to be involved in causing cognitive dysfunction in CM patients (Kihara, 
Carter, & Newton, 2006; Tapajós et al., 2019). Consequently, this has made inhibition 
of TNFα and IL-6 an attractive target to reduce neuroinflammation in cerebral malaria. 
Observation from the inhibition of pro-inflammatory cytokines and mediators in 
hemozoin activated cells by skimmianine may play a possible role in the treatment of 
CM.  
Furthermore, skimmianine inhibited NO production by reducing the expression of 
iNOS in hemozoin-stimulated BV2 microglia cells. These results suggest that 
skimmianine could inhibit hemozoin-activated neuroinflammation through inhibiting 
the release of NO and iNOS protein. Result in this investigation proposes a new 
mechanism of anti-inflammatory activity of skimmianine in hemozoin-activated cells. 
178 
 
Increase in production of NO has been reported to cause coma in cerebral malaria 
patients, hence suggesting the importance of inhibiting NO and iNOS in order to 
reduce neuroinflammation in CM (Grau & Craig, 2012). The inhibitory effect of 
skimmianine in this study has indicated its possible action in treatment of CM. 
Furthermore, skimmianine suppressed PGE2 production through inhibiting the 
expression of COX-2 enzyme in hemozoin-stimulated BV2 microglia cells. This study 
suggests the inhibitory effect of skimmianine on hemozoin-stimulated 
neuroinflammation through reduction of PGE2 / COX-2 production. Reports have 
shown that increase in the level of COX-2 protein and PGE2 is involved in the 
pathology of murine cerebral malaria (Ball et al., 2004; Xiao, Patterson, Yang, Lal, & 
hygiene, 1999). As a result, these studies suggest the importance of inhibiting PGE2 / 
COX-2 in neuroinflammation and this may indicate the promising role of skimmianine 
in treatment of CM. 
This study has also established that skimmianine reduced the production of pro-IL-1β 
and IL-1β through inhibition of NLRP3 protein and caspase-1activation in hemozoin-
stimulated BV2 microglia cells. These results suggest that skimmianine reduced 
neuroinflammation through NLRP3 pathway in hemozoin-activated BV2 microglia 
cells. Previous studies have shown berberine  to reduce neuroinflammation in BV2 
microglia cells and in experimental cerebral malaria (D. Y. Lu, Tang, Chen, & Wei, 
2010; D. Xiao et al., 2018). The activation of NLRP3 infalmmasome by hemozoin has 
been reported to increase the secretion of IL-1β in neuroinflammation to cause 
neurotoxicity, which has been linked to neurocognitive disorder in CM (Kalantari et al., 
2014; Olivier et al., 2015). Therefore, it is crucial to reduce the activation of NLRP3 
pathway in neuroinflammation. The potential role of alkaloids in the Z. zanthoxyloides 
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extract including skimmianine on neuroinflammation is significant in treatment of 
neuroinflammatory disorder such as cerebral malaria. 
Moreover, skimmianine evidently produced inhibition of hemozoin-induced 
neuroinflammation in BV2 microglia by targeting NF-κB p65 signalling pathway. 
Reports have shown the importance of NF-κB activation in excessive production of 
pro-inflammatory cytokines and mediators, which induces neuroinflammation in CM 
(Punsawad, Maneerat, Chaisri, Nantavisai, & Viriyavejakul, 2013). Therefore, the role 
of skimmianine in inhibition of NF-κB signalling pathway is significant in reducing 
neuroinflammation and may alter the progression of cerebral malaria. Collectively, 
skimmianine has shown a significant inhibitory role on neuroinflammation induced by 
hemozoin in BV2 microglia cells. This may be implicated in therapeutic approach of 








5.1 General discussion 
Neuroinflammation has been shown to play a key role in the pathogenesis of 
neurodegenerative diseases and cerebral malaria (Grau & Craig, 2012; Hora et al., 
2016). Reports have suggested that prolonged process of neuroinflammation may 
lead to neurotoxicity and neuronal damage, which can cause progression of 
neurodegenerative diseases (Balez, Rachelle, Ooi, & Lezanne, 2016). In addition, 
neuroinflammation mediated neurotoxicity has been associated with neurocognitive 
dysfunction which is observed in patients having cerebral malaria, a neurological 
sequelae of malaria (Bangirana et al., 2015). Moreover, studies have reported an 
increase in production of pro-inflammatory cytokines and molecules such as IL-6, 
TNFα and NO in activated microglia cells which may initiate neuroinflammation that is 
detected in neurological complication of plasmodium falciparum infection and in 
neurodegenerative diseases (Schain et al., 2017; Tapajós et al., 2019). 
Several studies have reported the use of medicinal plants in altering the progress of 
neurodegeneration (Shakya, 2016; Tomlinson & Akerele, 2015). The role of 
Zanthoxylum genus has been reported in numerous studies of its potential in reducing 
neuroinflammation and ameliorating cognitive impairment (Barua et al., 2018; Kiraithe, 
N, Nguta, Mbaria, & Kiama, 2016; Saikia et al., 2018). Zanthoxylum zanthoxyloides 
(Z. zanthoxyloides) tree is one of the popular species of Zanthoxylum genus (family- 
Rutaceae) because of its extensive use in traditional medicine (Adesina, 2005; 
Wangensteen et al., 2017). Reports have shown that the different parts of Z. 
zanthoxyloides tree including root and leaves are beneficial in reducing inflammatory 
diseases locally (Patiño et al., 2012). Furthermore, reports have shown the common 
use of Z. zanthoxyloides root as chewing stick in western part of Nigeria for the 
treatment of dental caries because it possess anti-inflammatory activities (Orafidiya et 
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al., 2010). Moreover, the leaves of Z. zanthoxyloides have been shown to be beneficial 
in the treatment of malaria, suggesting its anti-plasmodial activities (Kénou et al., 
2018). These reports indicate the potential role of Z. zanthoxyloides in 
neuroinflammation and neurological complication of severe malaria. Furthermore, 
previous investigation on Z. zanthoxyloides root extract demonstrated the anti-
inflammatory activity of this extract on carrageenan-induced paw inflammation in rats 
(Prempeh & Mensah-Attipoe, 2009). This suggest the anti-inflammatory effect of Z. 
zanthoxyloides extract in peripheral cells.  
In this study, the effect of Z. zanthoxyloides root extract were investigated on 
neuroinflammation in LPS and separately in hemozoin-stimulated BV2 microglia cells. 
Z. zanthoxyloides extract reduced the production of fundamental pro-inflammatory 
cytokines (TNFα, IL-1β and IL-6), NO, PGE2, expression of COX-2 and iNOS protein 
in LPS or hemozoin stimulated BV2 microglia cells. In addition, Z. zanthoxyloides 
extract increased the level of IL-10 (an anti-inflammatory cytokine) secretion in LPS 
and also in hemozoin-stimulated BV2 microglia cells. These results indicate that Z. 
zanthoxyloides extract could attenuate neuroinflammation through its inhibitory effect 
on important interleukins and mediators in BV2 microglia cells. Previous studies on Z. 
zanthoxyloides extract suggested its inhibitory activity on PGE2 concentration in rat 
induced with carrageenan (Prempeh & Mensah-Attipoe, 2008). Furthermore, reports 
on Zanthoxylum acanthopodium (Yanti et al., 2011) and Zanthoxylum armatum (Sati, 
Sati, Raturi, Badoni, & Singh, 2011), which are related species of same genus 
(Zanthoxylum) with Z. zanthoxyloides have evidently reduced the secretion of pro-
inflammatory cytokines and inflammatory mediators (iNOS and COX-2) in animal and 
cell culture studies. These investigations suggest anti-inflammatory activity of species 
of Zanthoxylum in diverse models of inflammation. 
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Sustained activation of microglia cells by inflammatory inducers to secrete pro-
inflammatory mediators and cytokines are of importance in the progression of 
neurodegenerative diseases (Cameron et al., 2010; Sheppard et al., 2019). The 
excessive release of neuroinflammatory factors including TNFα and NO in activated 
microglia cells have been shown to cause neurotoxicity and damage to the 
surrounding neurons (Asiimwe et al., 2016; D. Kim et al., 2018). In addition, elevated 
level of pro-inflammatory cytokines including IL-1β have been linked with 
neurocognitive decline in CM patients (Tapajós et al., 2019). As a result, reduction of 
pro-inflammatory cytokines and mediators by Z. zanthoxyloides extract in this study 
has shown the possible role of this extract in treatment of neurodegenerative diseases 
and cerebral malaria.  
Moreover, Z. zanthoxyloides extract inhibited p-IкB phosphorylation, total IκB 
degradation and phosphorylation of NF-КB p65 in LPS and separately in hemozoin-
stimulated BV2 microglia cells. These results provide new evidence and indicate that 
anti-inflammatory effect of Z. zanthoxyloides on pro-inflammatory cytokines and 
inflammatory mediators may be through the inhibitory action of this extract on NF-κB 
signalling pathway in BV2 microglia cells. Furthermore, Z. zanthoxyloides did not 
inhibit the phosphorylation of IKK in BV2 cells stimulated with LPS. Studies have 
reported that there is cross talking of other kinases including Jun-N-terminal kinase 
and p38 which may interfere with the inhibition of IKK phosphorylation in the upstream 
part of NF-КB signalling pathway (Hoesel & Schmid, 2013; Tian et al., 2015). Also, 
inhibitors of IKK phosphorylation act through the mechanism by competing with ATP 
binding site on IKK or having allosteric effect on IKKα/β (Nadia Lampiasi & Giovanna  
Montana, 2016; Prescott & Cook, 2018). Consequently, Z. zanthoxyloides extract at 
these concentrations (4, 6 and 8 μg/ml) may not be acting through this mechanism to 
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inhibit IKK phosphorylation in LPS stimulated BV2 microglia cells. Previous 
investigation have reported the suppressive effect of Zanthoxylum rhesta (a related 
specie to Z .zanthoxyloides) on expression of COX-2 and iNOS protein through NF-
КB signalling pathway.in LPS-stimulated raw macrophage cells (Thu et al., 2010). This 
finding confirms the current report on the anti-inflammatory effect of Z. zanthoxyloides 
extract, thus explaining the application of this extract in traditional medicine 
Studies have identified the involvement of NF-B transcriptional activity in activated 
microglia cells as it controls the expression of genes including COX-2 and iNOS to 
cause an increase in neuroinflammation (Biswas & Bagchi, 2016; Feng et al., 2017). 
Reports have further shown that neuroinflammation is a crucial factor that contributes 
to the progression of neurodegenerative diseases such as multiple sclerosis and AD 
(Stephenson et al., 2018). Investigations have further revealed the significant role of 
inhibiting activated NF-КB signalling pathway.by drugs to reduce neuroinflammation in 
neurodegenerative diseases (Chen et al., 2016). A different report has further 
demonstrated the effect of activated NF-B in malaria infection to increase the level of 
pro-inflammatory genes leading to neuroinflammation observed in pathology of CM 
(Pais & Penha-Gonçalves, 2018). Therefore, inhibition of activated NF-КB signalling 
pathway by Z. zanthoxyloides extract is essential in reducing neuroinflammation and 
has implication in the treatment of neurodegenerative diseases and cerebral malaria.  
In hemozoin-induced BV2 microglia cells, Z. zanthoxyloides extract reduced the level 
of pro-IL-1β, IL-1β, NLRP3 protein and caspase-1 activity. A previous investigation 
has shown that the anti-inflammatory activity of Zanthoxylum bungeanum extract, (a 
related specie to Z. zanthoxyloides in genus of Zanthoxylum) on activated NLRP3 
inflammasome in mice (Z. Zhang et al., 2017). This indicates the role of Z. 
zanthoxyloides extract on NLRP3 inflammasome pathway. The significant role of 
185 
 
NLRP3 inflammasome activation have made the NLRP3 pathway an attractive target 
in the CNS to regulate the secretion of IL-1β, which is implicated in exacerbation of 
neuroinflammation. More investigations have revealed that the activation of NLRP3 
inflammasome by ligands including hemozoin causes over production of IL-1β leading 
to neuroinflammation and neurotoxicity, which has been associated with 
neurocognitive impairment in CM patients (De Miranda et al., 2015; Pais & Penha-
Gonçalves, 2018). Consequently, inhibition of NLRP3 inflammasome activation by Z. 
zanthoxyloides extract is important reducing the level of IL-1β in neuroinflammation 
and may be beneficial in slowing the progress of cognitive dysfunction in cerebral 
malaria. 
The use of bioassay guided fractionation has been demonstrated to be an important 
strategy in isolating most active fraction and compounds in plant (Weller, 2012). It also 
minimizes the risk of losing the active fraction or compound in plants extract. Based 
on the inhibitory activity of Z. zanthoxyloides extract on neuroinflammation in, it 
became necessary to isolate and identify compound (s) in this extract by bioassay 
guided fractionation that could be responsible for anti-neuroinflammatory effect 
observed in this extract. Four fractions (F1, F2, F3 and F4) were isolated from Z. 
zanthoxyloides extract by solid phase extraction (SPE) technique. Investigations on 
the fractions revealed F3 as the most active fraction due to its significant reduction of 
the levels of TNFα in LPS-activated BV2 microglia cells. Taken together, it is 
suggested that fraction 3 may contain the active constituents responsible for the anti-
neuroinflammatory activity of Z. zanthoxyloides extract.  
Further chemical and pharmacological analyses revealed the bioactive compound is 
4, 7, 8-Trimethoxyfuro [2, 3-b] quinolone, also known as skimmianine. Similar isolation 
of skimmianine has been reported for Z. zanthoxyloides fruit extract (Guetchueng et 
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al., 2018), hence confirming the presence of skimmianine in fraction 3 of 
zanthoxyloides extract in this study. In addition, other studies have also reported the 
isolation of skimmainine from other related species of Zanthoxylum including 
Zanthoxylum buesgenii (Sandjo et al., 2014), Zanthoxylum nitidum (Yang et al., 2012).  
Further investigations on the effects of skimmianine on neuroinflammation showed a 
reduction in the levels of TNFα, IL-6, NO, PGE2, iNOS protein and COX-2 protein in 
BV2 cells activated separately with LPS and synthetic hemozoin. A previous report 
demonstrated that skimmianine inhibited the release of NO in LPS-stimulated BV2 
cells (Yoon et al., 2012). However, this study did not determine the effect of 
skimmianine on the iNOS, which is critical to NO production in inflammation. Moreover, 
studies have shown that berberine, (a related alkaloid to skimmianine in Z. 
zanthoxyloides), inhibits secretion of TNFα, IL-6 and IL-1β in LPS-stimulated BV2 
microglia cells (Z. Zhang, Li, Li, & An, 2016). This may suggest that there are other 
anti-inflammatory alkaloids present in of Z. zanthoxyloides in BV2 cells. The important 
role of increased production of pro-inflammatory factors including TNFα, IL-6, NO in 
CNS inflammation has been reported (Becher & Spath, 2017). Moreover, the 
prolonged exposure of neurons to pro-inflammatory cytokines and mediators have 
been demonstrated to result in neurotoxicity and thus, advancement of 
neurodegeneration (Balez et al., 2016; G. Olmos & J. Lladó, 2014). As a result, the 
anti-neuroinflammatory effect of skimmianine is significant in reducing 
neuroinflammation and suggest its potential role towards treatment of 
neurodegenerative diseases such as AD and also in cerebral malaria. 
Further investigations revealed that, skimmianine reduced the secretion of pro-IL-1β 
and IL-1β cytokine through inhibition of NLRP3 protein expression and caspase-1 
activity in hemozoin-stimulated BV2 microglia cells. Previous investigations have 
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identified the inhibitory role of berberine on activation of NLRP3 inflammasome to 
reduce the secretion of IL-1β in murine macrophage cells (C.-G. Li et al., 2017). In 
addition, therapeutic targeting of activated NLRP3 pathway has been reported to be 
an important strategy in reducing neuroinflammation in cerebral malaria (Sadaf Jahan 
et al., 2017; Kordes, Matuschewski, & Hafalla, 2011) . Reports have further shown an 
association between NLRP3 activation and long term cognitive dysfunction in children 
with cerebral malaria (Pais & Penha-Gonçalves, 2018; Song et al., 2017). Therefore, 
the inhibitory role of skimmianine on secretion of IL-1β in neuroinflammation through 
NLRP3 pathway is essential and may be promising in the treatment of cerebral 
malaria. 
 In neuroinflammation, several studies have established the role of NF-κB signalling 
pathway activation in increasing the expression of genes such as COX-2 and iNOS 
gene (Biswas & Bagchi, 2016; Feng et al., 2017). In addition, reports have further 
demonstrated that inhibition of activated NF-κB is crucial in reducing the level of pro-
inflammatory cytokines and mediators in neuroinflammation, which is involved in the 
pathology of neurodegenerative diseases and cerebral malaria (Nebl, De Veer, & 
Schofield, 2005; Verzola et al., 2017). Skimmianine inhibited the NF-B signalling 
pathway in BV2 cells activated with hemozoin and LPS. Interestingly, similar results 
have been reported for berberine, which suppressed NF-κB activation in BV2 microglia 
cells and in murine primary microglia (Jia et al., 2012; Nam et al., 2010).  
Generally, this study has clearly demonstrated that inhibition of neuroinflammation by 
Z. zanthoxyloides extract may possibly be due to the presence of mixture of 
phytochemical compounds acting in synergy in this extract, which may contribute to 
the activity of Z. zanthoxyloides extract. This study has further established that one of 
such anti-neuroinflammatory compounds is skimmianine. Furthermore, reports have 
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shown other compounds isolated from Z. zanthoxyloides extract to inhibit inflammation 
in vivo and in vitro. Berberine, a compound isolated from Z. zanthoxyloides extract 
was shown to reduce neuroinflammation by activating AMPK in BV2 microglia (Lu, 
Dah‐Yuu, Tang, Chen, & Wei, 2010) and also inhibit NF-κB pathway in macrophage 
cells (H. Zhang et al., 2017). In addition, pellitorine, one of the isolates in Z. 
zanthoxyloides extract was also reported to have anti-inflammatory activity on LPS 
induced- monocytes and in mice (W. Lee et al., 2014). These studies imply that the 
anti-inflammatory activities of other compounds isolated from Z. zanthoxyloides 
extract are significant in different models of inflammation. Therefore, it would be 
interesting to further investigate the anti-neuroinflammatory activity of other 
phytochemical compounds in Z. zanthoxyloides extract. This might provide more 
information on the anti-inflammatory activity of compounds isolated from Z. 
zanthoxyloides extract and identify compounds that act in synergy in the extract to 







Figure 5-1: Isolation of skimmianine from Zanthoxylum zanthoxyloides extract and 
effect of Zanthoxylum zanthoxyloides and skimmianine in BV2 microglia cells 
stimulated with LPS or synthetic hemozoin 
Z.Z: Zanthoxylum zanthoxyloides, SK: Skimmianine, TLR4: Toll like receptor-4, TLR9: Toll like receptor-
9, TLR2: Toll like receptor 2, LPS: Lipopolysaccharide, IL-1β: Interleukin- 1 beta, IL-6: Interleukin-6, IL-
10: Interleukin-10, TNFα: Tumor necrosis factor-alpha, iNOS: Inducible nitric oxide synthase , NO: Nitric 
oxide, PGE2: Prostaglandin E2, COX-2: Cyclooxygenase-2, NLRP3: Nod like receptor protein3, ASC: 
associated speck-like protein containing a caspase activating recruitment domain, DNA: 
Deoxyribonucleic acid, , IκB: Inhibitor of kappa B, IKK: IκB kinase. Figure 5.1 shows that In LPS 
activated microglia cells, Zanthoxylum zanthoxyloides (Z.Z) and skimmianine (SK) targeted IκB/NF-κB 
signalling pathway to reduce production of IL-1β, IL-6, TNFα, NO, PGE2, expression of COX-2 and 
iNOS enzyme. Also, an increase in production of IL-10 was observed on treatment of LPS-stimulated 
BV2 cells with Z. zanthoxyloides extract and skimmianine. Reports have shown that hemozoin activates 
NLRP3 inflammasome to cause excessive secretion of IL-1 β but the role of TLR2 or TLR9 on NLRP3 
pathway remains controversial (Olivier et al., 2015). This figure also shows that Z. zanthoxyloides 
extract and skimmianine inhibited the secretion of IL-1β by reducing the level of pro-IL-1β, caspase-1 
activity and expression of NLRP3 protein. Studies have demonstrated that binding of hemozoin toTLR2 
and TLR9 causes activation of NF-κB signalling pathway (M. Jaramillo et al., 2009; Y. Li et al., 2017). 
In this study, Z. zanthoxyloides extract and skimmianine reduced hemozoin induced neuroinflammation 




5.2  Conclusion 
The outcome of this study has shown the isolation of anti-neuroinflammatory 
skimmianine from Z. zanthoxyloides extract. Results in these findings have further 
demonstrated that Z. zanthoxyloides extract and skimmianine inhibited 
neuroinflammation through NF-κB signalling pathway in BV2 microglia cells stimulated 
with LPS. More investigations revealed that Z. zanthoxyloides extract and isolated 
skimmianine suppressed hemozoin induced neuroinflammation by targeting NF-κB 
and NLRP3 pathway.  
5.3 Recommendations for future studies 
Further investigations are needed to determine the role of Z. zanthoxyloides extract 
and skimmianine.in neuroinflammation. Studies on the effect skimmianine in animal 
models of neurodegenerative diseases such as Alzheimer’s disease. This is an 
important phase in drug development and will further explain the pharmacokinetic 
properties of skimmianine. The role of BBB (blood-brain barrier) in the CNS is a major 
factor to be considered for drugs to act in the CNS. Hence, it is important to investigate 
the permeability of skimmianine across the BBB. Similarly, synthesising an analogue 
of skimmianine is recommended to increase the lipophilicity of skimmianine such as 
addition of a non-polar group to the structure of skimmianine. This may contribute to 
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